

ESOT CONGRESS 2021 – SESSION LIST

SCIENTIFIC PROGRAMME	2
INDUSTRY SATELLITE SYMPOSIA	159

SCIENTIFIC PROGRAMME

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30 Room B - Auditorium	EKITA - Banff 1991 vs. 2021: Balancing between blessing and curse <i>Chair(s): Maarten Naesens - Leuven Belgium</i> <i>Fritz Diekmann - Esplugues de Llobregat Spain</i>
09:00-09:10	<i>The Banff classification: A historical and future perspective</i> <i>Michael Mengel – Alberta Canada</i>
09:10-09:25	<i>The use of the Banff classification for diagnosis of kidney transplant rejection: PROs</i> <i>Jan Ulrich Becker - Cologne Germany</i>
09:25-09:40	<i>The use of the Banff classification for diagnosis of kidney transplant rejection: CONs</i> <i>Marian Clahsen-van Groningen - Rotterdam Netherlands</i>
09:40-09:50	<i>Discussion</i> -
09:50-10:05	<i>The rejection conundrum: the subtypes dilemma: PROs</i> <i>Marion Rabant - Paris France</i>
10:05-10:20	<i>The rejection conundrum: the subtypes dilemma: CONs</i> <i>Aiko De Vries - Amsterdam Netherlands</i>
10:20-10:30	<i>Discussion</i> -

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30
Room J - Blue

ELPAT - Ethics cafe: Prioritization of organs during times of crisis (I)

Chair(s): Dale Gardiner - Nottingham United Kingdom
Hannah Maple - London United Kingdom

Making ethical decisions under time pressure or in difficult circumstances such as those that arose during the COVID-19 pandemic is the daily reality for many organ donation and transplant professionals. In this session we will create a space to discuss dilemma's in organ allocation prioritisation and provide insight into a practical tool to guide this discussion. The aim is to develop skills in ethical analysis and communication among donation and transplant professionals as well as share experiences. The session is designed to be practical and helpful for daily professional life.

09:00-09:05

Introduction

Hannah Maple - London United Kingdom

09:05-09:15

Transplantation in Eurotransplant during COVID-19

Serge Vogelaar - Leiden Netherlands

09:15-09:25

Tension between efficiency and equity in organ allocation during times of crisis

Nadia Primc - Heidelberg Germany

09:25-09:40

Introduction to MORAL Balance tool

Dale Gardiner - Nottingham United Kingdom

09:40-10:05

Round tables 1 - Scenario 1: Analysis of deceased donation dilemmas during COVID-19

Antonia Cronin - London United Kingdom

10:05-10:30

Round tables 1 - Scenario 2: Analysis of deceased donation dilemmas during COVID-19

Antonia Cronin - London United Kingdom

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30
 Room K - Red

ELITA - Marginal donor: How far can we push the limit?

Chair(s): *Ulrich Baumann - Hannover Germany*
Christian Toso - Vésenaz Switzerland

The session will start with the results of a broad ELITA/ELTR-initiated study assessing the impact of COVID-19 on liver transplant candidates and recipients. What should we learn from this pandemic, and how can we get ready for the next one? It will also explore and discuss various frequent clinical situations with marginal donors and recipients. How far can we and should we go? How can we increase our activity and help more patients?

09:00-09:05

Introduction
Wojciech Polak - Rotterdam Netherlands

09:05-09:25

Special release: Impact of COVID-19 on liver transplant candidates and recipients in Europe
Wojciech Polak - Rotterdam Netherlands

09:25-09:40

Marginal donor: What is a (too) marginal DCD donor?
Andrea Schlegel - Florence Italy

09:40-09:55

Marginal donor: What is a (too) marginal graft for a kid?
Silvio Nadalin - Tübingen Germany

09:55-10:10

Marginal donor: Donor with viral infection
Heiner Wedemeyer - Hannover Germany

10:10-10:30

Panel discussion and questions
 -

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30
Room C - Yellow

EPITA - Pancreas Transplantation

Chair(s): Helmut Arbogast - Munich Germany
Joana Ferrer - Barcelona Spain

09:00-09:25

What should we expect from future robotic pancreas transplantation?
Ugo Boggi - Pisa Italy

09:25-09:50

Pancreas transplantation for patients with type 2 diabetes: indications and outcomes
Jon Odorico - Madison United States

09:50-10:20

Impact of COVID-19 on pancreas transplantation: What have we learnt?
Steve White - Newcastle upon Tyne United Kingdom

10:20-10:30

Discussion
-

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30
Room D - Green

EDTCO - New challenges for donation coordinators: The evaluation of donor risk - extending the donor pool

Chair(s): *David Paredes-Zapata - Barcelona Spain
Anne Floden - Alingsås Sweden*

For a donor coordinator it becomes more and more challenging to identify a potential organ donor, because not only the age of the donors is increasing but also comorbidity and infections. In the first part of this symposium we will try to answer questions on how far can we extend donor pool. Is it acceptable for a recipient to accept a marginal organ?

09:00-09:05

Introduction

DP David Paredes-Zapata - Barcelona Spain

09:05-09:20

Patient perspective: Acceptance and informed consent to receive an organ from Extended Criteria Donors

Fiona Loud - Alton United Kingdom

09:20-09:40

Evaluation of risk donors: How much risk can we risk?

Carl-Ludwig Fischer-Fröhlich - Stuttgart Germany

09:40-09:55

Discussion

-

09:55-10:15

Can we still expand the organ donor pool?

Giuseppe Feltrin - Padova Italy

10:15-10:30

Discussion

-

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30

Room E - Orange

ECTTA - The right heart in the center of cardiothoracic transplantation

Chair(s): Cristiano Amarelli - Naples Italy
Robin Vos - Leuven Belgium

This session will highlight the need of knowledge and research on the forgotten ventricle, the lung circulation and their interaction in different clinical settings. We will stress the importance of the right heart for both heart and lung transplantation.

09:00-09:15

Unloading lung and left ventricle during ECMO
Michiel Erasmus - Groningen Netherlands

09:15-09:25

Discussion
-

09:25-09:40

Lung Circulation during lung ex-situ perfusion: Insights
Arne Neyrinck - Leuven Belgium

09:40-09:50

Discussion
-

09:50-10:05

Late onset right ventricular dysfunction after LVAD
Sofia Martin-Suarez - Bologna Italy

10:05-10:30

Plenary discussion and closing remarks
-

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30

Room F - Turquoise
1

VCA - Vascularized Composite Allotransplantation: Now standard of care? (I)

Chair(s): *Henk Giele - Oxford United Kingdom*
Fadi Issa - Oxford United Kingdom

VCA transplantation now appears to have plateaued in numbers worldwide. It is accepted that some injuries are perhaps best treated with VCA transplantation, but it is not clear whether there is consensus. Are patients receiving the treatment they require based on whether they are able to make contact with a VCA transplantation centre? Is there bias towards or against VCA transplantation depending on the institution? Are VCA outcomes now clear and can we provide adequate informed consent to patients? This session explores these important questions that will determine the direction of VCA transplantation, aiming to provide an international perspective on how these programmes are set up and how care is delivered.

09:00-09:05

Introduction

Fadi Issa - Oxford United Kingdom

09:05-09:25

Hand transplantation in the National Health Service, UK: European perspective
Simon Kay - United Kingdom

09:25-09:45

Hand transplantation in the US

Christina Kaufman - Louisville United States

09:45-10:05

Face transplantation & long term results: Should it be routinely offered?
Emmanuel Morelon - Sainte-Foy-les-Lyon France

10:05-10:25

Face transplantation: A historical perspective
Fay Bound Alberti - York United Kingdom

10:25-10:30

Closing remarks and voting

Fadi Issa - Oxford United Kingdom

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30

Room G - Turquoise
 2

BSC & ECTORS - What is new in the translational pipeline?

Chair(s): *Nina Pilat - Vienna Austria*
Maria Kaisar - Oxford United Kingdom

In this symposium we will try to build bridges between problems in clinical routine and newly emerging immunological and therapeutic concepts. In the first part (joint session with ECTORS) we will revisit developments in the field of cell/organ regeneration and organoids. In the second session, we will focus on exploring mechanisms of cell death on a molecular level in marginal organs, ischemia/reperfusion injury, and therapeutic implications in machine perfusion.

09:00-09:20

Super-pancreas
Ekaterine Berishvili - Geneva Switzerland

09:20-09:40

Pancreas atlas
James Shaw - Newcastle upon Tyne United Kingdom

09:40-10:00

Heart regeneration senescence
Gavin Richardson - Newcastle upon Tyne United Kingdom

10:00-10:20

Using organoids to regenerate human organs ex-vivo
Fotis Sampaziotis - Cambridge United Kingdom

10:20-10:30

Discussion and closing
 -

Specialty Update Symposium

Sunday, 29. August 2021

09:00 - 10:30
 Room H - White 1

ETAHP - To be close at a distance: Coping with uncertainty and digital caring encounters (I)

Chair(s): *Coby Annema - Groningen Netherlands*
Marleen van Buren - Rotterdam Netherlands

The main concerns among solid organ recipients is uncertainty regarding graft function and graft survival. This symposium will focus on understanding the fear of graft rejection from a patient perspective and how to approach it as professionals. We will also discuss the use of digital solutions to relieve uncertainty regarding various lifestyle aspects and to empower and support the patients' self-management despite physical distance. There will be a combination of oral presentations of state of the art and interactive round table discussions.

09:00-09:10

Introduction
Anna Forsberg - Lund Sweden

09:10-09:35

Graft rejection: State-of-the-art overview of diagnosis and treatment
MWF Martijn van den Hoogen - Rotterdam Netherlands

09:35-09:50

Fear of graft rejection: State-of-the-art
Anna Forsberg - Lund Sweden

09:50-10:15

Interventions to support patient with fear of graft rejection
Elise Liljekvist - Lund Sweden

10:15-10:30

Discussion
 -

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:00
Room B -
Auditorium

EKITA - Focusing on what really matters: Study endpoints in kidney transplantation

*Chair(s): Robert Langer - Vienna Austria
Marlies Reinders - Rotterdam Netherlands*

11:00-11:05

*ESOT meets EMA
Maarten Naesens - Leuven Belgium*

11:05-11:15

*Rejection as primary endpoint for clinical trials
Candice Roufousse - London United Kingdom*

11:15-11:30

*Kidney function (evolution) as endpoint
Luuk Hilbrands - Nijmegen Netherlands*

11:30-11:45

*Surrogate endpoints for late kidney transplant failure
Rainer Oberbauer - Vienna Austria*

11:45-12:00

*Patient-reported outcomes after kidney transplantation
Allison Tong - Sydney Australia*

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30
Room J - Blue

ELPAT - Ethics cafe: Prioritization of organs during times of crisis (II)

Chair(s): *Hannah Maple - London United Kingdom
Dale Gardiner - Nottingham United Kingdom*

Making ethical decisions under time pressure or in difficult circumstances such as those that arose during the COVID-19 pandemic is the daily reality for many organ donation and transplant professionals. In this session we will create a space to discuss dilemma's in organ allocation prioritisation and provide insight into a practical tool to guide this discussion. The aim is to develop skills in ethical analysis and communication among donation and transplant professionals as well as share experiences. The session is designed to be practical and helpful for daily professional life.

- | | |
|-------------|---|
| 11:00-11:20 | <i>Round tables 2 - Scenario 1: Analysis of living donation dilemmas during COVID-19
Annette Lennerling - Gothenburg Sweden</i> |
| 11:20-11:40 | <i>Round tables 2 - Scenario 2: Analysis of living donation dilemmas during COVID-19
Christina Papachristou - Thessaloniki Greece
Ines Mega – Lisbon Portugal</i> |
| 11:45-12:05 | <i>Round tables 3 - Scenario 1: Heart-to-heart - dilemmas in paediatric heart donation and transplantation
Marion Siebelink - Groningen Netherlands</i> |
| 12:05-12:25 | <i>Round tables 3 - Scenario 2: Heart-to-heart - dilemmas in paediatric heart donation and transplantation
Angie Scales - Bramley United Kingdom</i> |
| 12:25-12:30 | <i>Summary and closing
-</i> |

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30
 Room K - Red

ELITA - Marginal recipient: how far can we push the limit?

Chair(s): *Ulrich Baumann - Hannover Germany*
Christian Toso - Vésenaz Switzerland

The session will start with the results of a broad ELITA/ELTR-initiated study assessing the impact of COVID-19 on liver transplant candidates and recipients. What should we learn from this pandemic, and how can we get ready for the next one? It will also explore and discuss various frequent clinical situations with marginal donors and recipients. How far can we and should we go? How can we increase our activity and help more patients?

11:00-11:15

Marginal recipient: A candidate with ACLF
Luca Belli - Milan Italy

11:15-11:30

Marginal recipient: When is a kid too sick for transplantation?
Valérie Mc Lin - Geneva Switzerland

11:30-11:45

Marginal recipient: A morbidly obese candidate
Giacomo Germani - Padua Italy

11:45-12:00

Marginal recipient: A candidate with advanced cancer
Vincenzo Mazzaferro - Milano Italy

12:00-12:30

Panel discussion and questions

-

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30
Room C - Yellow

EPITA - Islet Transplantation

Chair(s): *Eelco de Koning - Leiden Netherlands
John Casey - Edinburgh United Kingdom*

11:00-11:25

*What donor factors predict successful islet isolation
Julie Kerr-Conte - Lille France*

11:25-11:50

*Manufacturing pseudo human islets for research: What about for clinical
transplantation?
Burcak Yesildag - Schlieren Switzerland*

11:50-12:20

*Where are we with unlimited sources of insulin producing cells: Clinical strategies
to get them to work
Valeria Sordi - Milan Italy*

12:20-12:30

Discussion
-

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30
Room D - Green

EDTCO - New challenges in donation coordination: Determination of brain death and different criteria in the world

Chair(s): *Nichon Jansen - Leiden Netherlands*
Nikola Zgrablic - Pula Croatia

Second part of EDTCO specialty update symposium will focus on questions: Could we reach consensus in a worldwide brain death definition? What is the role of the CD-P-TO and the competent authorities within Europe? Are the definitions in Europe so much different than the rest of the world?

11:00-11:05

Introduction

Nichon Jansen - Leiden Netherlands

11:05-11:20

Controversies and similarities regarding the World Brain Death Project in European countries

Sándor Mihály - Budapest Hungary

11:20-11:40

The evolvement of brain death determination over the years

Nuria Masnou Burralló - Girona Spain

11:40-11:55

Discussion

-

11:55-12:15

Achieving consensus between brain death definition in Europe and USA: Is a worldwide definition possible?

Michael Kuiper - Leeuwarden Netherlands

12:15-12:30

Discussion

-

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30 Room E - Orange	ECTTA - How will machine perfusion change the landscape of cardiothoracic transplantation Chair(s): Andreas Zuckermann - Vienna Austria Arne Neyrinck - Leuven Belgium
11:00-11:07	<i>Debate: hypothermic versus normothermic machine perfusion for heart preservation [hypothermic]</i> <i>Filip Rega - Leuven Belgium</i>
11:07-11:14	<i>Debate: hypothermic versus normothermic machine perfusion for heart preservation [normothermic]</i> <i>Ugolino Livi - Udine Italy</i>
11:14-11:20	Q&A -
11:20-11:27	<i>Debate: machine perfusion is only justified if it changes long term outcome [PROs]</i> <i>James Fildes - Manchester United Kingdom</i>
11:27-11:34	<i>Debate: machine perfusion is only justified if it changes long term outcome [CONS]</i> <i>Jens Gottlieb - Hannover Germany</i>
11:34-11:40	Q&A -
11:40-11:55	<i>From pig to man: The road of new perfusion technologies</i> <i>Johan Nilsson - Lund Sweden</i>
11:55-12:05ex	<i>Taking "ex situ" back to the donor: thoraco-abdominal normothermic regional perfusion</i> <i>Vincent Tchana-Sato - Liege Belgium</i>
12:05-12:15dead	<i>Is my donor really "dead": ethical considerations in thoraco-abdominal regional perfusion</i> <i>Alex Manara - Bristol United Kingdom</i>
12:15-12:30	Discussion -

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30

Room F - Turquoise
1

VCA - Vascularized Composite Allotransplantation: Now standard of care? (II)

Chair(s): Gerald Brandacher - Baltimore United States

VCA transplantation now appears to have plateaued in numbers worldwide. It is accepted that some injuries are perhaps best treated with VCA transplantation, but it is not clear whether there is consensus. Are patients receiving the treatment they require based on whether they are able to make contact with a VCA transplantation centre? Is there bias towards or against VCA transplantation depending on the institution? Are VCA outcomes now clear and can we provide adequate informed consent to patients? This session explores these important questions that will determine the direction of VCA transplantation, aiming to provide an international perspective on how these programmes are set up and how care is delivered.

11:00-11:05

Introduction

Gerald Brandacher - Baltimore United States

11:05-11:25

Immunosuppression: What is the standard of care?

Stefan G. Tullius - Cambridge United States

11:25-11:45

Immunosuppressive strategies that could change the face of the field

Gerald Brandacher - Baltimore United States

11:45-12:05

Understanding the histopathology of rejection

Jean Kanitakis - Lyon France

12:05-12:25

Does vascular rejection matter?

AW Annemarie Weissenbacher - Innsbruck Austria

12:25-12:30

Closing remarks

AW Annemarie Weissenbacher - Innsbruck Austria

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30

Room G - Turquoise
 2

BSC & ECTORS - Exploring the molecular level

Chair(s): *Nina Pilat - Vienna Austria*
Maria Kaisar - Oxford United Kingdom

In this symposium we will try to build bridges between problems in clinical routine and newly emerging immunological and therapeutic concepts. In the first part (joint session with ECTORS) we will revisit developments in the field of cell/organ regeneration and organoids. In the second session, we will focus on exploring mechanisms of cell death on a molecular level in marginal organs, ischemia/reperfusion injury, and therapeutic implications in machine perfusion.

11:00-11:20

The pathological role of ferroptosis
Andreas Linkermann - Dresden Germany

11:20-11:40

Ferroptosis prevention for improving transplantation success
Marcus Conrad - Munich Germany

11:40-12:00

Focusing on the molecular changes: Kidney recondition during machine perfusion
Maria Letizia Lo Faro - Oxford United Kingdom

12:00-12:20

Focusing on the molecular changes: Liver recondition during machine perfusion
Andrea Schlegel - Florence Italy

12:20-12:30

Discussion
 -

Specialty Update Symposium

Sunday, 29. August 2021

11:00 - 12:30
Room H - White 1

ETAHP - To be close at a distance: Coping with uncertainty and digital caring encounters (II)

Chair(s): Coby Annema - Groningen Netherlands
Marleen van Buren - Rotterdam Netherlands

11:00-11:05

Introduction to Interactive session: eHealth solutions

-

11:05-11:30

To be close at a distance: The SMILe project, an eHealth-powered integrated nurse-led model of post-transplant care

Sabina De Geest - Basel Switzerland

11:30-11:55

eHealth intervention to reduce sedentary behaviour

Sofie Compennolle - Ghent Belgium

11:55-12:15

Discussion regarding experiences and opportunities of eHealth solutions in transplant care

-

12:15-12:30

Summary and conclusions

-

Specialty Update Symposium

Sunday, 29. August 2021

12:00 - 12:30

Room B -
Auditorium

EKITA - Immunological risk stratification for kidney transplantation

*Chair(s): Jelena Stojanovic - London United Kingdom
Diederik Kimenai - Rotterdam Netherlands*

12:00-12:15

*Immunological risk stratification in clinical practice
Lucrezia Furian - Padova Italy*

12:15-12:30

*The promise of epitope mismatch analysis: Where do we stand?
Anat Tambur - Chicago United States*

Special Session

Sunday, 29. August 2021

12:30 - 14:00
Room C - Yellow

EU Train Symposium: The digital transformation is now - 2021 Tools

Chair(s): Oriol Bestard - Barcelona Spain
Klemens Budde - Berlin Germany

12:30-12:50

Holistic and integrated biomarkers systems
Olivier Aubert - Paris France

12:50-13:10

Novel integrative web-interface models for report diagnosis and improve clinical decision-making
Pierre Antoine Gourraud - Nantes France

13:10-13:30

Precision diagnostics: World-wide integration of transcriptomics data (ICDOT mutualization and analytics pipeline through a connected model with interoperable interface/servers)
Dina Zielinski - Paris France

13:30-13:50

AI based augmented physician: Disease classification automation virtual biopsy system
Alexandre Loupy - France

Real-life clinical decision making

Sunday, 29. August 2021

14:00 - 15:30

Room B -
Auditorium

A 360-degree view of risk

Chair(s): *Andreas Schnitzbauer - Frankfurt am Main Germany
Raj Thuraisingham - London United Kingdom*

The risk:benefit question is the basis of all decision making in transplantation. In this session, the question of risk will be examined from the perspective of key stakeholders; namely healthcare professionals, patients and the general public. It will also consider how the practice of defensive medicine plays into decision making from an ethical perspective.

14:00-14:05

*STORY 1: risk from medical perspective/defensive medicine
Hannah Maple - London United Kingdom*

14:05-14:20

*Accepting risk: The medical view
Robert Montgomery - New York United States*

14:20-14:25

*STORY 2: patient agency in practice
JC Jillianne Code - Vancouver Canada*

14:25-14:40

*Accepting risk: The patient perspective
Daniel Gallego-Zurro - Valencia Spain*

14:40-14:55

*Communicating risk
Alexandra Freeman - Cambridge United Kingdom*

14:55-15:10

*Strategies to master the risk of being an organ recipient
Pisana Ferrari - Udine Italy*

15:10-15:30

Discussion

-

Real-life clinical decision making

Sunday, 29. August 2021

14:00 - 15:30
Room J - Blue

Liver retransplantation: Extent of the problem in Italy

Chair(s): Salvatore Gruttadauria - Palermo Italy
Matteo Cescon - Bologna Italy

The incidence and the outcome of liver retransplantation, will be reviewed, focusing on: increased operative complexity including longer ischemia times, more difficult postoperative course with more frequent complications, use of more blood products and higher costs. We will discuss, in particular, the indications for liver retransplantation and the best timing to perform such delicate procedure. National and European experiences will be shared on this hot topic.

14:00-14:05

Introduction

-

14:05-14:20

Early and late retransplantation: Definition and epidemiological impact
Enrico Gringeri - Padova Italy

14:20-14:35

Technical problems in late retransplantation
Marco Vivarelli - Ancona Italy

14:35-14:50

Risk of disease recurrence and rejection after retransplantation
Giuseppe Tisone - Rome Italy

14:50-15:05

Prognostic models to identify the best timing for liver retransplantation
Alfonso W. Avolio - Rome Italy

15:05-15:30

Discussion and questions

-

Education Track

Sunday, 29. August 2021

14:00 - 15:30

Room C - Yellow

Setting up a new donation/transplant programme

Chair(s): Yaman Tokat - Istanbul Turkey
Luciano De Carlis - Milan Italy

The DO's and DON'Ts of starting a new transplant programme. What are the key elements to safely starting-up a living transplant programme?

14:00-14:15

Institutional work-up: How to start

Beatriz Dominguez-Gil - Madrid Spain

14:15-14:30

*Donation after circulatory death and heart transplantation
srl Stephen Large - Cambridge United Kingdom*

14:30-14:45

Living donor liver transplant

Markus Boehnert - Rotterdam Netherlands

14:45-15:00

Living donor kidney transplant

Luuk Hilbrands - Nijmegen Netherlands

15:00-15:30

Discussion

-

Education Track

Sunday, 29. August 2021

14:00 - 15:30

Room D - Green

HBV+ and HCV+ donors in heart and lung transplantation

Chair(s): Christian Benden - Zurich Switzerland
Paolo Grossi - Varese Italy

Historically, organs from donors with active or previous hepatitis B or C have not been used due to concern about transmission of infection. The development of effective anti-viral treatment for hepatitis B and C has opened a new pool of potential donors, but careful recipient management is required. This session will explore the benefits of using organs from these donors and strategies to minimise the recipient risk.

14:00-14:05

Introduction

-

14:05-14:20

Donor–recipient matching and immediate management during post-operative care

Francesco Giuseppe De Rosa - Turin Italy

14:20-14:35

Direct-acting anti-virals: Mechanisms, interactions and impact on future epidemiology

Marina Berenguer - Valencia Spain

14:35-14:50

Instructions for working with HBV+ donors and cardiothoracic organ recipients

Audrey Coilly - Villejuif France

14:50-15:05

The impact of using hepatitis C virus nucleic acid test-positive donor hearts on heart transplant waiting list time and transplant rate

Saima Aslam - San Diego United States

15:05-15:30

Discussion

-

Critical Review

Sunday, 29. August 2021

14:00 - 15:30

Room E - Orange

All you want to know about organ perfusion but were afraid to ask

Chair(s): Robert J. Porte - Groningen Netherlands
Andrea Schlegel - Florence Italy

In the world of solid organ transplantation, in situ and ex situ organ perfusion strategies are everywhere; experimental and clinical trials, conferences, webinars, and even guidelines abound. You know that you need to be performing organ perfusion, yet you might not know what organ perfusion actually entails. In this Critical Review session, ESOT Congress 2021 unites a group of experts to explain the 'pearls and pitfalls' of various perfusion modalities and to give a clear and balanced view of these preservation strategies for the 21st century.

14:00-14:15

Should I jump on the machine perfusion bandwagon or get the basics right?
Elmi Müller - Cape Town South Africa

14:15-14:40

Everything that can go wrong, will go wrong. How to deal with it
Christopher Watson - Cambridge United Kingdom
Benno Cardini - Innsbruck Austria

14:40-15:00

How adding a "T" complicated A-NRP...and what to do about it
Alex Manara - Bristol United Kingdom

15:00-15:20

NRP 2.0: Expert consensus on logistics and technique
Amelia Hessheimer - Barcelona Spain

15:20-15:30

Discussion
-

Full Oral Session

Sunday, 29. August 2021

14:00 - 15:30

Room F - Turquoise
1

Kidney transplantation: Beyond histology

Chair(s): Maarten Naesens - Leuven Belgium
Candice Roufosse - London United Kingdom

14:10-14:18

MISSING SELF INDUCED MICROVASCULAR REJECTION OF KIDNEY ALLOGRAFTS: A POPULATION-BASED STUDY
Jasper Callemeyn - Korbeek-Lo Belgium

14:20-14:28

THE EFFECT OF THE DIFFERENT DONOR-DERIVED HLA T-CELL TARGETS ON THE DEVELOPMENT OF T CELL-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION
Aleksandar Senev - Leuven Belgium

14:30-14:38

CRISPR-CAS9 HLA-DELETED GLOMERULAR ENDOTHELIAL CELLS AS A TOOL TO DETECT PATHOGENIC NON-HLA ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS
Baptiste Lamarthée - Leuven Belgium

14:40-14:48

THE BIATHLETE'S DILEMMA : UNRAVELLING THE MOLECULAR MECHANISMS OF THE IMMUNE PRIVILEGE OF GRAFT ENDOTHELIUM DURING TCMR.
Thomas Barba - Lyon France

14:50-14:58

TRANSPLANT GLOMERULOPATHY AFTER KIDNEY TRANSPLANTATION: RISK FACTORS, HISTOPATHOLOGICAL FEATURES AND GRAFT OUTCOME
Aleksandar Senev - Leuven Belgium

15:00-15:08

TERMINAL COMPLEMENT ACTIVATION MAY NOT CONTRIBUTE TO ORGAN DAMAGE IN ANTIBODY-MEDIATED REJECTION
Gesa Tiller - Groningen Netherlands

15:10-15:18

CD56DIM CD16BRIGHT NK CELLS DURING ANTIBODY-MEDIATED REJECTION DISPLAY INCREASED PROLIFERATION, ACTIVATION AND TYPE-1 INFLAMMATORY CYTOTOXIC PROFILES
Elodie Bailly - Paris France

15:20-15:28

SPARSE INTRAGRAFT MOLECULAR CLASSIFIERS FOR ANTIBODY-MEDIATED AND T-CELL MEDIATED KIDNEY TRANSPLANT REJECTION: DEVELOPMENT AND VALIDATION
Jasper Callemeyn - Korbeek-Lo Belgium

Interface Research

Sunday, 29. August 2021

14:00 - 15:30

Room G - Turquoise
2

The start of the clinical regenerative therapy era

Chair(s): Antoine Durrbach - Créteil France
Henri Leuvenink - Donderen Netherlands

Stem cells are considered to be the cornerstone of regenerative medicine. Today there are hundreds of clinical trials investigating the use of stem cells to treat life-threatening conditions such as diabetes and kidney failure. However, these trials bring about various regulatory and ethical conundrums that require resolution.

14:00-14:05

Introduction

-

14:05-14:17

Selection of diabetic patients with hESC-derived β -cells
Bart Keymeulen - Brussels Belgium

14:17-14:29

Selection of kidney transplant patients with mesenchymal stromal cells
Marlies Reinders - Rotterdam Netherlands

14:29-14:44

Panel discussion on patients selection (with ethicist and regulatory officer)
Stefaan van der Spiegel - Brussels Belgium
Sarah Chan – Edinburgh United Kingdom

14:44-14:56

Treatment of diabetic patients with hESC-derived β -cells
Bart Keymeulen - Brussels Belgium

14:56-15:08

Treatment of kidney transplant patients with mesenchymal stromal cells
Marlies Reinders - Rotterdam Netherlands

15:08-15:30

Panel discussion on patients treatment (with ethicist and regulatory officer)
Stefaan van der Spiegel - Brussels Belgium
Sarah Chan – Edinburgh United Kingdom

Brief Oral Session

Sunday, 29. August 2021

14:00 - 15:30

Room H - White 1

What really matters after transplant? Beyond survival: secrets of success

Chair(s): *Marleen van Buren - Rotterdam Netherlands*
Anna Forsberg - Lund Sweden

14:00-14:04

WATERLOW SCORE ON ADMISSION AND POST-SURGERY RISK OF PROLONGED LENGTH OF STAY, EMERGENCY READMISSION AND MORTALITY RISK

Anna Brotherton - Birmingham United Kingdom

14:06-14:10

FRAILITY AND KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Evelien Quint - Groningen Netherlands

14:12-14:16

ASSESSING RISK FACTORS OF NON-ADHERENCE AND POST-TRANSPLANT OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS

Kateryna Maksyutynska - Toronto Canada

14:18-14:22

IMPACT OF THE COVID-19 PANDEMIC ON DAILY LIVES, EMOTIONS AND BEHAVIOURS OF KIDNEY TRANSPLANT RECIPIENTS

Regina van Zanten - Rotterdam Netherlands

14:24-14:28

SOCIAL DISTRESS AND HEALTH-RELATED QUALITY OF LIFE IN SOLID ORGAN TRANSPLANT RECIPIENTS

Noor Al Kaabi - Toronto Canada

14:30-14:34

RENAL TRANSPLANT OUTCOMES IN YOUNG ADULTS BEFORE AND AFTER THE INTRODUCTION OF A YOUNG ADULT SERVICE

Laura Baines - Newcastle upon Tyne United Kingdom

14:36-14:40

SUPPORTING TEENAGE AND YOUNG ADULT TRANSPLANT RECIPIENTS DURING COVID-19 PANDEMIC USING A SOCIAL MEDIA PATIENT GROUP

Daley Cross - Oxford United Kingdom

14:42-14:46

SHORT- AND LONG-TERM PREGNANCY OUTCOMES AFTER ORTHOTOPIC LIVER TRANSPLANTATION IN THE NETHERLANDS

Jildau Meinderts - Groningen Netherlands

14:48-14:52

FATIGUE AMONG HEART RECIPIENTS- A BARRIER TO SELF-EFFICACY?

Matilda Almgren - Lund Sweden

14:54-14:58

SYMPTOM OCCURRENCE AND DISTRESS AFTER HEART TRANSPLANTATION - A NATIONWIDE CROSS-SECTIONAL COHORT STUDY.

Marita Dalvindt - Lund Sweden

- 15:00-15:04 *RECOVERY AND SELF-EFFICACY AFTER HEART TRANSPLANTATION-
IMPORTANT ASPECTS OF SELF-MANAGEMENT*
Matilda Almgren - Lund Sweden
- 15:06-15:10 *THE MEANING OF SURVIVING THREE YEARS AFTER A HEART
TRANSPLANT - A TRANSITION FROM UNCERTAINTY TO ACCEPTANCE
THROUGH ADAPTATION*
Anna Forsberg - Lund Sweden
- 15:12-15:16 *FATIGUE, SELF-EFFICACY AND RECOVERY 1-5 YEARS AFTER LUNG
TRANSPLANTATION*
Annette Lennerling - Gothenburg Sweden
- 15:18-15:22 *ADAPTATION AFTER LUNG TRANSPLANTATION UP TO THREE YEARS
AFTER TRANSPLANTATION.*
Martina Lundmark - Lund Sweden

Plenary

Sunday, 29. August 2021

16:00 - 17:30
 Room A - Silver

Opening Session: Managing inequalities in healthcare and transplantation

Chair(s): *Raj Thuraisingham - London United Kingdom*
Maria Rosa Costanzo - Naperville United States

COVID-19 pandemic proved to be an enormous stress-test for the healthcare system in which difficult choices regarding allocation of limited resources had to be made. Are inequalities more common during stress conditions or during standard conditions? What is driving inequalities in resource allocation and access to resources and how this problem can be managed?

16:00-16:15

Official congress opening

Umberto Cillo - Padova Italy

Luciano Potena – Bologna Italy

Maria Rosa Costanzo - Naperville United States

Raj Thuraisingham - London United Kingdom

16:15-16:35

Genetic diversities as paradigm of inequality management

H A Hannah Valentine - Stanford United States

16:35-17:05

Social justice and health equity

Michael Marmot - London United Kingdom

17:05-17:25

Perspectives of managing inequities in transplantation

Umberto Cillo - Padova Italy

Luciano Potena – Bologna Italy

17:25-17:30

Discussion

-

Critical Review

Monday, 30. August 2021

08:00 - 09:30
Room A - Silver

Clinical guidelines: There is no role for them in the era of global personalised medicine

Chair(s): Johan Nilsson - Lund Sweden
Fiona Loud - Alton United Kingdom

This debate will centre on the utility of guidelines in clinical practice. Do they really ensure equity of care or do they stop clinicians from treating patients as individuals? How do we use them in the era of personalised medicine? Do they prevent innovation? These, and many other topics, will be covered in this session

08:00-08:05

Case 1: Guidelines helpful

-

08:05-08:10

Case 2: Guidelines not helpful

-

08:10-08:25

Guidelines: PROs

Paul Cockwell - United Kingdom

08:25-08:40

Guidelines: CONs

Elmi Müller - Cape Town South Africa

08:40-08:50

Rebuttal

-

08:50-09:10

Discussion and audience voting

-

09:10-09:30

Volume and personalized medicine

Marina Berenguer - Valencia Spain

Real-life clinical decision making

Monday, 30. August 2021

08:00 - 09:30
Room B -
Auditorium

The impact of COVID-19: Lessons learned for future SOT infection management

Chair(s): Robin Vos - Leuven Belgium
Saima Aslam - San Diego United States

The focus of this session is to demonstrate how lessons learned from the COVID-19 pandemic have a profound impact on multidrug resistant organism (MDRO) prevalence and management within transplant institutions. We will discuss whether social distancing measures might have a place in reducing the transmission of MDRO. We also consider whether there are any pathophysiological and or therapeutic insights from the COVID-19 pandemic that might be relevant to more 'traditional' infections. During the pandemic, aggressive screening of both transplant donors and recipients has been successful in avoiding infection transmission; are there any lessons to be learnt that can help reduce infection burden in SOT? We will present a case history, in the format of an MDT meeting, whereby a panel of specialists will discuss clinical issues and present the evidence to support their viewpoints.

08:00-08:05

Case presentation: A heart transplant case in Bologna during first COVID-19 wave
Marco Masetti - Bologna Italy

08:05-08:23

The immunocompromised transplant recipient and SARS-CoV-2 infection
Paolo Grossi - Varese Italy

08:23-08:41

Diagnosis of opportunistic infections during the COVID-19 pandemic
Murat Akova - Ankara Turkey

08:41-08:59

MDRO management: Lessons learned from COVID-19
Jaf Jay Fishman - Boston United States

08:59-09:17

How to organise a safe path in transplant ICU and wards
Maria Cristina Morelli - Bologna Italy

09:17-09:30

Discussion
-

Real-life clinical decision making

Monday, 30. August 2021

08:00 - 09:30
Room J - Blue

Technology advances in transplantation: Real life or dreams?

Chair(s): Ugo Boggi - Pisa Italy
Salvatore Agnes - Rome Italy

08:00-08:05

Introduction

-

08:05-08:17

Machine perfusion and organ reconditioning in the Italian context: Fighting for financial resources

DG Davide Ghinolfi - Pisa Italy

08:17-08:29

Machine perfusion and organ reconditioning in the Spanish context: Fighting for financial resources

Amelia Hessheimer - Barcelona Spain

08:29-08:41

Current status and future of telemedicine in real life transplantation: Italian experience

Franco Citterio - Rome Italy

08:41-08:53

Current status and future of telemedicine in real life transplantation: Swiss experience

Sabina De Geest - Basel Switzerland

08:53-09:05

Telepathology and the Italian transplant net

Albino Eccher - Verona Italy

09:05-09:17

Telepathology and the Italian transplant net: What can we learn?

Alton Farris - Atlanta United States

09:17-09:30

Discussion and questions

-

Full Oral Session

Monday, 30. August 2021

08:00 - 09:30
Room C - Yellow

Should I include my cancer patients in the liver transplant list? From GIST to HCC

Chair(s): *Faouzi Saliba - Villejuif France*
Eytan Mor - Ramat-Gan Israel

- 08:00-08:09 *OUTCOME OF LIVER TRANSPLANTATION FOR NON-HCC MALIGNANCIES – A COLLABORATIVE TRANSPLANT STUDY REPORT*
Philipp Houben - Heidelberg Germany
- 08:11-08:20 *LIVER TRANSPLANTATION SURVIVAL BENEFIT OVER LIVER RESECTION FOR COLORECTAL LIVER METASTASIS IN A SELECTED COHORT OF PATIENTS WITH HIGH TUMOR LOAD*
Jacopo Lanari - Padova Italy
- 08:22-08:31 *DIFFERENT PATTERNS OF RECURRENCE AFTER LIVER RESECTION AND TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORS*
Jorgelina Coppa - Milan Italy
- 08:33-08:42 *LONG TERM OUTCOMES AFTER LIVER TRANSPLANTATION VERSUS RESECTION FOR MILAN-IN NEUROENDOCRINE TUMOR LIVER METASTASES*
Marianna Maspero - Milan Italy
- 08:44-08:53 *UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) LIVER METASTASES AS A NEW INDICATION FOR LIVER TRANSPLANTATION. HAS ITS TIME ARRIVED?*
Felipe Alconchel - Murcia Spain
- 08:55-09:04 *LIVER TRANSPLANTATION FOR UNRESECTABLE PERI-HILAR CHOLANGIOCARCINOMA: AN ITALIAN SURVEY*
Enrico Gringeri - Padova Italy
- 09:06-09:15 *THE BENEFICIAL INTENTION-TO-TREAT SURVIVAL EFFECT OF LIVING DONATION IN PATIENTS WITH HEPATOCELLULAR CANCER WAITING FOR LIVER TRANSPLANT*
Quirino Lai - Rome Italy
- 09:17-09:26 *TUMOR RELATED SURVIVAL AFTER LIVER TRANSPLANTATION OR RESECTION FOR HCC: A COMPETING RISK ANALYSIS WITH AN INTENTION TO TREAT ANALYSIS PERSPECTIVE*
Stefano Di Sandro - Modena Italy

Think Tank

Monday, 30. August 2021

08:00 - 09:30
Room D - Green

Cardiovascular risk in abdominal transplantation

Chair(s): Luciano Potena - Bologna Italy
Amaryllis Van Craenenbroeck - Leuven Belgium

Managing cardiovascular risk in kidney and liver transplantation proves to be a challenge. In this session we will address issues of risk stratification, prevention of cardiovascular complications prior to transplant as well as post-operative management. This Think Tank in its broader scope aims at creating guidelines/recommendations from ESOT on how to manage cardiovascular risk in kidney and liver transplantation.

08:00-08:05

Session introduction
Luciano Potena - Bologna Italy

08:05-08:13

What is the magnitude of post operative cardiac risk?
Ernesto Paoletti - Genova Italy

08:13-08:21

Risk stratification for ischemic heart disease in patients with end-stage kidney disease
Ailish Nimmo - Bristol United Kingdom

08:21-08:29

Risk stratification for ischemic heart disease in patients with end-stage liver disease
Giacomo Germani - Padua Italy

08:29-08:37

Cardiovascular prevention while waiting for transplant
Martin Halle - Munich Germany

08:37-08:45

Cardiovascular prevention post-transplant
Evangelia Koudi - Θεσσαλονίκη Greece

08:45-08:53

Intraoperative monitoring and management in the high risk patient
Steffen Rex - Leuven Belgium

08:53-09:30

Discussion Panel
-

Hands-on Course

Monday, 30. August 2021

08:00 - 09:30

Room E - Orange

Perils and pitfalls in Normothermic Machine Perfusion

Chair(s): *Ina Jochmans - Leuven Belgium*
Sarah Hosgood - Cambridge United Kingdom

This lecture will describe the path from organ selection for perfusion, through to methods of perfusion, organ monitoring and selection for transplantation. Technical details, including logistical/technical difficulties, and pros and cons, will be described by experts.

08:00-08:15

Normothermic kidney perfusion
Sarah Hosgood - Cambridge United Kingdom

08:15-08:30

Normothermic liver perfusion
AW Annemarie Weissenbacher - Innsbruck Austria

08:30-08:40

Discussion
 -

08:40-08:55

Normothermic lung perfusion
SL Sandra Lindstedt - Lund Sweden

08:55-09:10

Normothermic heart perfusion
Simon Messer - Cambridge United Kingdom

09:10-09:25

Discussion
 -

Full Oral Session

Monday, 30. August 2021

08:00 - 09:30

Room F - Turquoise
1

Mitigating donor related risks

Chair(s): Gavin Pettigrew - Cambridge United Kingdom

08:00-08:09

EVOLUTION OF PATIENTS WITH DEVASTATING BRAIN INJURY ADMITTED IN INTENSIVE CARE UNIT FOR INTENSIVE CARE TO FACILITATE ORGAN DONATION

ALICIA PEREZ - MADRID Spain

08:11-08:20

PERCEIVED AND VERIFIED CANCER HISTORY IN POTENTIAL SOLID ORGAN DONORS: AN AUSTRALIAN COHORT STUDY

James Hedley - Sydney Australia

08:22-08:31

KIDNEY TRANSPLANTATION FROM MARGINAL DONORS: AN INCREASED RISK OF URINARY COMPLICATION. STUDY FROM 10279 PATIENTS.

Benoît Mesnard - Nantes France

08:33-08:42

THE ROLE OF THE SURGICAL CARE PRACTITIONER IN ORGAN RETRIEVAL: A SINGLE-CENTRE EXPERIENCE

Francesco Abbadessa - Newcastle Upon Tyne United Kingdom

08:44-08:53

ASSESSMENT OF DONOR-RECIPIENT SIZE MISMATCH BASED ON BODY SURFACE AREA INDEX AND ITS IMPLICATIONS ON OUTCOMES OF DECEASED-DONOR LIVER TRANSPLANTS

Ioannis D. Kostakis - London United Kingdom

08:55-09:04

ASSESSMENT OF HEPATIC STEATOSIS BASED ON NEEDLE BIOPSY IMAGES IN DECEASED DONOR LIVER

Vittorio Cherchi - Udine Italy

09:06-09:15

TISSUE DONATION ACTIVITY OF A THIRD LEVEL HOSPITAL ACCORDING TO THE NEW DEFINITIONS ESTABLISHED BY THE CRITICAL PATHWAY

Christian Suros - Barcelona Spain

09:17-09:26

FACING THE CHALLENGE: TRANSPLANT ACCESS FOR THE HIGHEST SENSITIZED PATIENTS (CPRA=100%). THE SPANISH EXPERIENCE

MO MARIA O VALENTIN - MADRID Spain

Interface Research

Monday, 30. August 2021

08:00 - 09:30
 Room G - Turquoise
 2

Pushing the boundaries of organs before it's too late: Pre-emptive regeneration

Chair(s): *Julie Kerr-Conte - Lille France*
Mehdi Maanaoui - Lille France

Organ and tissue loss due to disease and injury has encouraged the development of therapies that can regenerate tissues and decrease reliance on organ transplantation. We will explore potential therapies that aim to halt degeneration at an early phase. We will also hold a discussion on the therapeutic future of these therapies from a technical, safety, ethical and patient perspective.

08:00-08:15

Mitochondrial transfer to boost organ regeneration
Ariela Benigni - Bergamo Italy

08:15-08:30

Fighting senescence and fibrosis with CAR-T cells
Corina Amor Vegas - New York United States

08:30-08:45

In situ decellularising organs
Alejandro Mayorca - Copenhagen Denmark

08:45-09:00

Cell therapies for lung regeneration
Dan Weiss - Vermont United States

09:00-09:30

Discussion Panel
Christian Jorgensen - Montpellier France
Ariela Benigni - Bergamo Italy
Corina Amor Vegas - New York United States
Alejandro Mayorca - Copenhagen Denmark
Dan Weiss - Vermont United States
Kelly Carden – London United Kingdom

Brief Oral Session

Monday, 30. August 2021

08:00 - 09:30
Room H - White 1

A whistle stop tour of metabolic complications after transplant

Chair(s): -

- 08:00-08:04 *IMPACT OF INHIBITION OF PCSK-9 AMONG RENAL TRANSPLANT RECIPIENTS WITH HIGH CARDIOVASCULAR RISK*
OG Osama Gheith - Mansoura Egypt
- 08:06-08:10 *IMPACT OF FULL CORRECTION OF POST-TRANSPLANT ANEMIA ON CARDIOVASCULAR SYSTEM IN RENAL TRANSPLANT RECIPIENTS RECEIVING ESA: PROSPECTIVE RCT*
Ayman Maher Nagib - Kuwait Kuwait
- 08:12-08:16 *IS ERYTHROCYTOSIS MORE FREQUENT AFTER SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION?: A SINGLE-CENTER EXPERIENCE*
Marina Reis - Vila Nova de Gaia Portugal
- 08:18-08:22 *COMPARING SURVIVAL OUTCOMES FOR KIDNEY TRANSPLANT RECIPIENTS WITH PRE-EXISTING DIABETES VERSUS THOSE WHO DEVELOP POST-TRANSPLANTATION DIABETES*
Azm Hussain - Birmingham United Kingdom
- 08:24-08:28 *OUTCOMES OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES*
Tarek Mahmoud - Kuwait Kuwait
- 08:30-08:34 *HLA ALLELES CW12 AND DQ4 IN KIDNEY TRANSPLANT RECIPIENTS ARE INDEPENDENT RISK FACTORS FOR THE DEVELOPMENT OF POST-TRANSPLANTATION DIABETES*
Azm Hussain - Birmingham United Kingdom
- 08:36-08:40 *SEMAGLUTIDE IS A SAFE AND EFFECTIVE TREATMENT IN PATIENTS AFTER LIVER TRANSPLANTATION WITH POST-TRANSPLANT DIABETES MELLITUS*
Maarten Tushuizen - Leiden Netherlands
- 08:42-08:46 *DETERMINANTS OF THE APPEARANCE OF POST TRANSPLANT DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION*
Maria Smyrli - Athens Greece
- 08:48-08:52 *AMPUTATION AND ULCERATION IN TYPE-1 DIABETIC PATIENTS UNDERGOING SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION: A SYSTEMATIC REVIEW*
Jineel Raythatha - Westmead Australia
- 08:54-08:58 *EVEROLIMUS, GLUCOSE METABOLISM, AND ANTI- VISCERAL OBESITY EFFECT IN KIDNEY TRANSPLANT CANDIDATES*
Mikiko Yoshikawa - Kyoto Japan

- 09:00-09:04 *OUTCOMES OF LIVER TRANSPLANTS FOR NASH FROM A LARGE SINGLE INSTITUTIONAL COHORT*
Aamir Nawaz - London United Kingdom
- 09:06-09:10 *VARIATIONS IN TM6SF2 RS58542926, PCSK9 RS505151 AND PCSK7 RS2277287 WITH THE RISK OF HEPATIC STEATOSIS AFTER LIVER TRANSPLANTATION*
Ahad Eshraghian - Shiraz Iran
- 09:12-09:16 *IMPACT OF ELECTIVE LIGATION OF A PATENT ARTERIOVENOUS FISTULA IN KIDNEY TRANSPLANT RECIPIENTS ON BLOOD PRESSURE AND SERUM LEVELS OF CARDIAC BIOMARKERS*
Gregoire Masson - Liege Belgium
- 09:18-09:22 *POSITIVE IMPACT OF KIDNEY TRANSPLANTATION ON OLFACTORY ABILITY: RESULTS OF A CROSS-SECTIONAL CASE CONTROL STUDY.*
Chiara Caletti - Verona Italy

Brief Oral Session

Monday, 30. August 2021

08:00 - 09:30

Studio - ESOT Live
Studio

Latest news in alloimmunity

Chair(s): Alexandre Loupy - France
Birgit Sawitzki - Berlin Germany

07:59-08:03

IMPACT OF FCGR3A POLYMORPHISMS ON AMR OUTCOME AND IVIG RESPONSE IN KIDNEY TRANSPLANT RECIPIENTS

Alice Koenig - Lyon France

08:05-08:09

THE FCGR3A-158 V/V-GENOTYPE IS ASSOCIATED WITH DECREASED SURVIVAL OF RENAL ALLOGRAFTS WITH CHRONIC-ACTIVE ANTIBODY-MEDIATED REJECTION

Nicolle Litjens - Rotterdam Netherlands

08:11-08:15

PREFORMED T-CELL ALLOIMMUNITY AND HLA EPLET MISMATCH TO GUIDE IMMUNOSUPPRESSION MINIMIZATION WITH TACROLIMUS MONOTHERAPY IN KIDNEY TRANSPLANTATION.

Maria Meneghini - Barcelona Spain

08:17-08:21

HLA EPI TOPE MISMATCHES IN KIDNEY TRANSPLANT RECIPIENTS WITH HISTOLOGICAL ANTIBODY-MEDIATED REJECTION WITH AND WITHOUT HLA DONOR-SPECIFIC ANTIBODIES

Laura Llinàs-Mallol - Barcelona Spain

08:23-08:27

UNSUPERVISED MACHINE LEARNING IDENTIFIES FAST AND SLOW MODULATION OF DSA DYNAMICS FOLLOWING HLA- INCOMPATIBLE TRANSPLANTATION – 5 YEAR OUTCOMES.

Sunil Daga - Leeds United Kingdom

08:29-08:33

MYELOID-DERIVED SUPPRESSOR CELLS IN KIDNEY TRANSPLANT RECIPIENTS AND THE EFFECT OF MAINTENANCE IMMUNOTHERAPY MARIA IGLESIAS ESCUDERO - SANTANDER Spain

08:35-08:39

CLINICAL VALUE OF THE USE OF COMPLETE HIGH RESOLUTION HLA TYPING FOR THE DEFINITION OF DNDSA AFTER KIDNEY TRANSPLANTATION

Maria Meneghini - Barcelona Spain

08:41-08:45

DONOR-SPECIFIC ELISPOT ASSAY FOR PREDICTING ACUTE REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Suwasin Udomkarnjananun - Rotterdam Netherlands

08:47-08:51

HLA AND NON-HLA ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH A HISTOLOGICAL PICTURE OF ANTIBODY-MEDIATED REJECTION
Laura Llinàs-Mallol - Barcelona Spain

08:53-08:57

DEVELOPMENT OF DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AND ABMR IN RENAL TRANSPLANT PATIENTS DEPENDS ON CYP3A5 GENOTYPE

Justa Friebus-Kardash - Essen Germany

- 08:59-09:03 *EVOLUTION OF HUMORAL LESIONS ON CONTROL BIOPSY STRATIFIES THE RISK FOR RENAL GRAFT LOSS AFTER ANTIBODY-MEDIATED REJECTION TREATMENT*
Antonin Bouchet - Lyon France
- 09:05-09:09 *CHALLENGING EARLY CHRONIC-ACTIVE ANTIBODY-MEDIATED REJECTION AFTER SUCCESSFUL DESENSITIZATION FOR CDC-CROSSMATCH-POSITIVE KIDNEY TRANSPLANTATION.*
Annelies de Weerd - Rotterdam Netherlands
- 09:11-09:15 *TEMRA CD8 T CELLS FROM KIDNEY TRANSPLANT RECIPIENTS EXHIBIT ENHANCED PURINERGIC P2X4 RECEPTOR-DEPENDENT PROINFLAMMATORY AND MIGRATORY RESPONSES*
Nicolas Degauque - Nantes France
- 09:17-09:21 *GRANZYME B POSITIVE B CELLS ENRICH REGULATORY T CELL COMPARTMENT AND INDUCE INHIBITION OF EFFECTOR CD4+ CD25- T CELL RESPONSE.*
Nicolas Sailliet - Nantes France

Plenary

Monday, 30. August 2021

10:00 - 11:30
 Room A - Silver

The end of Kaplan-Meier: New endpoints in transplantation

Chair(s): Anna Forsberg - Lund Sweden
 Thierry Berney - Geneva Switzerland

In the current era of transplantation and the excellent outcomes that have been achieved, metrics such as patient and graft survival are increasingly becoming obsolete. This, combined with the emergence of precision medicine and the importance of demonstrating value, means that the time is right to completely rethink what success looks like for transplantation in the 21st century.

10:00-10:10

Introduction

-

10:10-10:25

Big data analysis in definition of medical endpoints
 Euan Ashley - United States

10:25-10:40

Fine-tuning endpoints in specific transplant settings
 Alexandre Loupy - France

10:40-10:55

Novel endpoints for tailoring therapeutic interventions
 Maarten Naesens - Leuven Belgium

10:55-11:10

An education of [real] survival analysis: Learning it's about life, not failure
 JC Jillianne Code - Vancouver Canada

11:10-11:30

Discussion

-

State of the Art

Monday, 30. August 2021

11:45 - 13:15
Room A - Silver

Immunosuppression novelties at a glance

Chair(s): *Paolo De Simone - Pisa Italy*
Fauzi Saliba - Villejuif France

Transplant immunosuppression should be as personalised as possible to minimize the risk of excessive treatment, which can lead to an increased risk of infections and malignancies. Although personalised drugs remain a challenge for the future, the pharmacogenetic approach in drug development should be continued. Do international guidelines exist for managing therapy?

11:45-12:00

CD40 blockade
Gilles Blancho - Nantes France

12:00-12:15

Should we trust guidelines on immunosuppression? A multiorgan perspective
Stefano Fagioli - Bergamo Italy

12:15-12:30

Antibody immunotherapy in SOT: Past, present and future
Stefan Schaub - Basel Switzerland

12:30-12:45

Pharmacogenetics of immunosuppressant drugs
Kiran Khush - Stanford United States

12:45-13:15

Discussion
-

State of the Art

Monday, 30. August 2021

11:45 - 13:15

Room D - Green

Measuring the value of organ donation programmes

Chair(s): Ugo Boggi - Pisa Italy
Paolo Muiesan - Florence Italy

Demonstrating value is of paramount importance with the rising global cost of healthcare. In order to do so, healthcare systems need to be able set their priorities and monitor and measure their outcomes. In this session, these themes will be discussed by key representatives of healthcare organisations in Europe.

11:45-12:03

Performance in Spanish donation programs
Beatriz Dominguez-Gil - Madrid Spain

12:03-12:21

Key performance indicators in donation programs in Croatia
Mirela Basic - Zagreb Croatia

12:21-12:39

Swedish approach to donation performance evaluation
Carl Jorns - Stockholm Sweden

12:39-12:57

An unified European perspective?
Marta López Fraga - Council of Europe France

12:57-13:15

Discussion
-

State of the Art

Monday, 30. August 2021

11:45 - 13:15

Room E - Orange

Transplant organs of the future

Chair(s): *Sandra Lindstedt - Lund Sweden*
Martin Hoogduijn - Rotterdam Netherlands

The ongoing development of biological and engineering techniques will lead to the availability of novel types of organs for transplantation. In this session, four such potential state-of-the-art organ transplants will be presented

11:45-12:10

Xenotransplantation
Julia Radan - Munich Germany

12:10-12:35

Interspecies organ generation using cell competitive niche
Hiroimitsu Nakauchi - Stanford United States

12:35-13:00

Organoids
Nuria Montserrat - Barcelona Spain

13:00-13:15

Discussion
-

Education Track

Monday, 30. August 2021

11:45 - 13:15

Room F - Turquoise
1

Yes we can! How to start a DCD programme

Chair(s): Gabriel Oniscu - Edinburgh United Kingdom
Chloe Balleste - Barcelona Spain

Ensuring success in donation after circulatory death (DCD) programmes depends on multiple aspects. We will explore how to involve stakeholders and obtain their buy-in, as well as legal and professional challenges and how to overcome them. We will also discuss the more practical issues of setting-up logistics, policies, SOPs, and tasks. Additionally, we will also take a look at facing challenging scenarios, from both a clinical and surgical perspective.

11:45-12:03

Know thy enemy
DP David Paredes-Zapata - Barcelona Spain

12:03-12:21

Do your ground work
C. A. Corinne Antoine - Saint Denis France

12:21-12:39

Roll your sleeves up
Riccardo De Carlis - Milan Italy

12:39-13:15

Discussion and interactive case
-

Full Oral Session

Monday, 30. August 2021

- 11:45 - 13:15
Room G - Turquoise
2
- Paediatric kidney transplant technique and post-OP management: Good seed makes good fruit**
Chair(s): Stephen D Marks - London United Kingdom
- 11:45-11:54
THE IMPACT OF DONOR AND RECIPIENT SIZE IN PAEDIATRIC RENAL TRANSPLANTATION
Ioannis D. Kostakis - London United Kingdom
- 11:56-12:05
UK CONSENSUS ON SURGICAL TECHNIQUES IN PAEDIATRIC RENAL TRANSPLANT
John Fallon - Bristol United Kingdom
- 12:07-12:16
IMPACT OF VASCULAR ANOMALIES ON SURGICAL COMPLICATIONS AND OUTCOME IN PEDIATRIC KIDNEY TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER ANALYSIS.
Gionata Spagnoletti - Rome Italy
- 12:18-12:27
FINAL HEIGHT OF CHILDREN OVER 12 YEARS INITIATED ON A STEROID MINIMISATION IMMUNOSUPPRESSIVE REGIMEN FOLLOWING KIDNEY TRANSPLANTATION
Demetria Theodorou - Manchester United Kingdom
- 12:29-12:38
IMPACT OF DONOR HUMAN LEUKOCYTE ANTIGEN SPECIFIC ANTIBODIES DETECTED IN PEDIATRIC KIDNEY TRANSPLANT PATIENTS WITH STABLE OR DECLINED GRAFT FUNCTION
Asimina Fylaktou - Thessaloniki Greece
- 12:40-12:49
ROLE OF NON-DONOR SPECIFIC ANTIBODIES IN PEDIATRIC KIDNEY TRANSPLANTATION
MARIA SANGERMANO - Padua Italy
- 12:51-13:00
STANDARDISATION OF IMMUNOSUPPRESSIVE AND ANTI-INFECTIVE DRUG REGIMENS IN UK PAEDIATRIC RENAL TRANSPLANTATION: THE HARMONISATION PROGRAMME
Stephen D Marks - London United Kingdom
- 13:02-13:11
KIDNEY TRANSPLANTED CHILDREN NOT RESPONDING TO ANTI-REJECTION TREATMENT: HOW TO IMPROVE THE OUTCOME
Irene Alberici - Padua Italy

Full Oral Session

Monday, 30. August 2021

11:45 - 13:15
Room H - White 1

From donor selection to outcome perfection in lung transplantation: The path to paradise begins in hell

Chair(s): *Wiebke Sommer - Heidelberg Germany*
Lorenzo Rosso - Milan Italy

Abstract sessions will be announced in June 2021.

- 11:45-11:54 *LONG-TERM OUTCOME AFTER LUNG TRANSPLANTATION FROM DONATION AFTER EUTHANASIA EQUALS DONATION FROM CONTROLLED CIRCULATORY-DEAD AND BRAIN-DEAD DONORS*
Cedric Vanluyten - Leuven Belgium
- 11:56-12:05 *THE FIRST SPANISH EXPERIENCE USING THE LUNG ALLOCATION SCORE: FIVE YEARS' EXPERIENCE OF A SINGLE CENTER, LAS AS A PROTECTIVE FACTOR FOR WAITLIST DEATHS*
Irene Bello - Barcelona Spain
- 12:07-12:16 *LUNG TRANSPLANT FOR PULMONARY FIBROSIS; SMALLER DONOR LUNGS IMPACT SURVIVAL*
Gillian Hardman - Bristol United Kingdom
- 12:18-12:27 *LUNG TRANSPLANT FOR LATE REFRACTORY ARDS (LR-ARDS) : PRIMARY EXPERIENCE IN FOCH HOSPITAL*
Guillaume Tachon - suresnes France
- 12:29-12:38 *DONORS FROM DONATION AFTER CARDIAC DEATH ARE A RISK FACTOR FOR BRONCHIAL COMPLICATIONS AFTER LUNG TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY*
Irene Bello - Barcelona Spain
- 12:40-12:49 *CLUSTER ANALYSIS IDENTIFIES DISTINCT PROFILES OF TRANSBRONCHIAL BIOPSIES IN LUNG TRANSPLANT RECIPIENTS ASSOCIATED WITH ALLOGRAFT SURVIVAL*
Antoine Roux - Suresnes France
- 12:51-13:00 *DONOR LYMPHOCYTES IN PERIPHERAL BLOOD OF PATIENTS AFTER LUNG TRANSPLANTATION COMPRISE HIGH FREQUENCIES OF KIR-POSITIVE T AND NK CELL SUBSETS*
Jenny Kuehne - Hannover Germany
- 13:02-13:11 *MIR-339 AND GALECTIN-3: DIAGNOSTIC VALUE IN PATIENTS WITH AIRWAY OBSTRUCTION AFTER LUNG TRANSPLANTATION*
Olga Gichkun - Moscow Russian Federation

Focus Group Session

Monday, 30. August 2021

11:45 - 13:15
Room I - White 2

Does organ perfusion buy us time?

Chair(s): *Andrea Schlegel - Florence Italy*
Daniele Dondossola - Pontirolo Nuovo, Bergamo Italy

- 11:45-11:52 *METABOLISM-REGULATED SUB-NORMOTHERMIC CULTURE SYSTEM OF HUMAN KIDNEYS RETAINS EX VIVO VIABILITY FOR 4 DAYS*
Franca Wijtas - Leiden Netherlands
- 12:00-12:07 *FEASIBILITY OF PROLONGED NORMOTHERMIC MACHINE PERFUSION OF DISCARDED DECEASED DONOR KIDNEYS TO BETTER ASSESS AND ENHANCE ORGAN UTILISATION*
Asel Arykbaeva - Leiden Netherlands
- 12:15-12:22 *OBSERVATIONS ON 24-HOUR EX SITU NORMOTHERMIC LIVER PERFUSION*
Amelia Hessheimer - Barcelona Spain
- 12:30-12:37 *IMPROVEMENT OF A RAT MODEL OF PROLONGED LIVER NORMOTHERMIC MACHINE PERFUSION*
Caterina Lonati - Milan Italy
- 12:45-12:52 *SUCCESSFUL EX-VIVO RECONDITIONING OF KIDNEYS RETRIEVED 4.5 HOURS AFTER CIRCULATORY DEATH*
Deepti Antony - Gothenburg Sweden
- 13:00-13:07 *A CLINICAL COMPARISON OF TWO DIFFERENT OXYGEN CARRIERS FOR COMBINED HYPOTHERMIC AND NORMOTHERMIC MACHINE PERFUSION OF HIGH-RISK DONOR LIVERS*
Otto B. van Leeuwen - Groningen Netherlands

Focus Group Session

Monday, 30. August 2021

11:45 - 13:15
Z1 - Edu Zone |
Room

Precision in monitoring

Chair(s): Umberto Baccarani - Udine Italy
Acar Tuzuner - Ankara Turkey

- 11:45-11:52 *BILE LACTATE AS A MARKER OF BALLOONING AND POTENTIAL CRITERIA FOR CHOOSING A PRESERVATION STRATEGY OF LIVER GRAFTS.*
Aliaksei Shcherba - Minsk Belarus
- 12:00-12:07 *TISSUE VIABILITY AND MITOCHONDRIAL RESPIRATION DURING STATIC COLD STORAGE PREDICTS LIVER TRANSPLANTATION OUTCOME*
Andras T. Meszaros - Innsbruck Austria
- 12:15-12:22 *DYNAMIC FORECASTING OF PATIENT-SPECIFIC KIDNEY TRANSPLANT FUNCTION WITH A SEQUENCE-TO-SEQUENCE DEEP-LEARNING MODEL*
Elisabet Van Loon - Leuven Belgium
- 12:30-12:37 *MONITORING OF ANTIVIRAL IMMUNE RESPONSE AS AN INDICATOR OF IMMUNOSUPPRESSION INTENSITY AND OUTCOME AFTER KIDNEY TRANSPLANTATION: THE VIRENO STUDY*
Veronica Di Cristanziano - Cologne Germany
- 12:45-12:52 *LUMINAL ACTIVATION OF COMPLEMENT WITH APICAL DEPOSITION OF C3DG AND C5B-9 IN THE PROXIMAL TUBULES IN KIDNEY TRANSPLANT RECIPIENTS*
Gustaf Isaksson - Odense C Denmark
- 13:00-13:07 *THE UPTAKE OF THE PET RADIOTRACER 18-FLUORODEOXYGLUCOSE BY THE RENAL ALLOGRAFT CORRELATES WITH THE ACUTE BANFF SCORES OF CORTEX INFLAMMATION*
Laurent Weekers - Liege Belgium

Full Oral Session

Monday, 30. August 2021

14:45 - 16:15
Room A - Silver

ESOT Leonardo Da Vinci Transplant Research Innovation Award

Chair(s): *Umberto Cillo - Padova Italy*
Luciano Potena - Bologna Italy

- 14:45-14:54 *IL-21 DRIVEN EXPANSION AND REPROGRAMMING OF T-BET EXPRESSING B CELLS DURING ANTIBODY-MEDIATED REJECTION OF KIDNEY TRANSPLANTS*
Kevin Louis - Paris France
- 14:56-15:05 *SPECIFIC ELIMINATION OF ANTI-HLA ANTIBODY-PRODUCING B CELLS IN AN IN VIVO MOUSE MODEL BY USING CHIMERIC HLA ANTIBODY RECEPTOR (CHAR) T CELLS*
Sergi Betriu Méndez - Barcelona Spain
- 15:07-15:16 *ENHANCED DELIVERY OF NANOMEDICINE TO KIDNEY GRAFT ENDOTHELIAL CELLS DURING EX VIVO PERFUSION*
Claire ALBERT - New Haven United States
- 15:18-15:27 *EXTRACELLULAR VESICLES FROM HUMAN LIVER STEM CELLS REDUCE INJURY IN A MODEL OF NORMOTHERMIC PERFUSION OF RAT ISCHEMIC LIVERS*
Nicola De Stefano - Chiaverano Italy
- 15:29-15:38 *PERIPHERAL BLOOD INFLAMMATORY CHEMOKINES UNCOVER ALLO-IMMUNE INFLAMMATION IN THE ABSENCE OF HISTOLOGICAL LESIONS*
Elisabet Van Loon - Leuven Belgium
- 15:40-15:49 *SCREENING FOR SARS-COV-2 NEUTRALIZING ANTIBODIES IN CIRRHOTIC PATIENTS WAITING FOR LIVER TRANSPLANTATION: IMPACT ON DONOR POOL EXPANSION*
Margherita Saracco - Turin Italy
- 15:51-16:00 *DYNAMIC PREDICTION OF KIDNEY-GRAFT SURVIVAL WITH ARTIFICIAL INTELLIGENCE:AN INTERNATIONAL STUDY OF DEEP COHORTS OF KIDNEY RECIPIENTS*
Marc Raynaud - Paris France
- 16:02-16:11 *REGULAR PHYSICAL ACTIVITY IN THE PREVENTION OF POST-TRANSPLANT DIABETES MELLITUS AND ASSOCIATED METABOLIC CONDITIONS IN KIDNEY TRANSPLANT RECIPIENTS*
Karol Graňák - Martin Slovakia

Real-life clinical decision making

Monday, 30. August 2021

14:45 - 16:15

Room D - Green

Risky donors for risky recipients: What can we do to get this right?

Chair(s): Allan Rasmussen - Copenhagen Denmark
David Paredes-Zapata - Barcelona Spain

The risk:benefit question is the basis of all decision making in transplantation. In this session, the question of risk will be examined from the clinical perspective. Real-life decisions will be discussed, focusing on how the question of risk plays out in day-to-day clinical practice. This is designed to be an interactive session with audience participation.

14:45-14:50

STORY 1: Liver

Roberto Mereu - Clichy France

14:50-15:05

Potential liver donors with infections and/or scarring: A risk worth taking and for which recipients?

Francois Durand - Clichy France

15:05-15:10

STORY 2: Kidney

Caterina Di Bella - Padua Italy

15:10-15:25

Potential kidney donors with a history of malignancy: A risk worth taking and for which recipients?

Lucrezia Furian - Padova Italy

15:25-15:30

STORY 3: Lung

Irene Bello - Barcelona Spain

15:30-15:45

Potential heart donors on ECMO: A risk worth taking and for which recipients?

Johan Nilsson - Lund Sweden

15:45-16:15

Discussion

-

Think Tank

Monday, 30. August 2021

14:45 - 16:15

Room E - Orange

Precision transplantation: Where do we stand?

*Chair(s): Christine Falk - Hannover Germany
 Rainer Oberbauer - Vienna Austria*

Precision medicine in transplantation is an important goal but, to date, treatment (immunosuppression, etc.) is still not adjusted to sex and individual patient physiology. So while we have some of the tools needed to achieve precision medicine, we need to make more intense efforts to evolve towards more individualised patient treatment in order to optimise outcomes.

14:45-15:00

*Precision for what: How can we define clinical endpoints?
 Maarten Naesens - Leuven Belgium*

15:00-15:15

*Biomarkers and biotargets
 Umberto Maggiore - Parma Italy*

15:15-15:30

*Precision medicine: The sex and gender aspects
 Ruth Sapir-Pichhadze - Montreal Canada*

15:30-15:45

*How much regulation do we need in precision transplantation?
 -*

15:45-16:15

*Discussion
 -*

Education Track

Monday, 30. August 2021

14:45 - 16:15

Room F - Turquoise
1

Social and ethical aspects of clinical regeneration

Chair(s): *Dominique Martin - Geelong Australia*
Martin Hoogduijn - Rotterdam Netherlands

This joint session with the Regenerative Medicine domain will examine the ethical arguments around regenerative medicine. It will look at the current state-of-play and the future possibilities from both the professional and public perspective and will also address the important topic of sustainability and equity.

14:45-15:00

The ethical aspect of regenerative medicine: An overview
Timothy Caulfield - Edmonton Canada

15:00-15:15

Regenerative medicine: The current state of play
Ton Rabelink - Leiden Netherlands

15:15-15:30

Human brain organoids to model neurodevelopment and disease
Silvia Velasco - Cambridge United States

15:30-15:45

The patient wish list
Holly Loughton - Manchester United Kingdom

15:45-16:00

Funding of regenerative medicine: implications for access and sustainability
TBA

16:00-16:15

Discussion
-

Focus Group Session

Monday, 30. August 2021

14:45 - 16:15
 Room G - Turquoise
 2

Clinical Cases: Donors, Zebras and COVID: challenges in infection management

Chair(s): Oriol Bestard - Barcelona Spain
 Nina Pilat - Vienna Austria

- 14:45-14:52 *LETERMOVIR TREATMENT FOR RESISTANT/REFRACTORY CYTOMEGALOVIRUS INFECTION IN KIDNEY AND PANCREAS TRANSPLANTATION*
FO Fernanda Ortiz - Espoo Finland
- 15:00-15:07 *DISEASE COURSE AND TREATMENT OF SARS-COV-2 INFECTION IN AN ISOLATED INTESTINAL TRANSPLANT RECIPIENT.*
Mathias Clarysse - Leuven Belgium
- 15:15-15:22 *COVID-19 ASSOCIATED NEPHROPATHY IN A KIDNEY TRANSPLANT RECIPIENT AND HIGH RISK APOL1 VARIANT DONOR*
Camille Roger - Lille France
- 15:30-15:37 *ORGAN DONOR WITH RT-PCR POSITIVE FOR SARS-COV-2, IS IT ALWAYS NO?*
José Moya Sánchez - MURCIA Spain
- 15:45-15:52 *ORGAN DONATION IN KSA: COVID-19 PANDEMIC*
Besher Al-Attar - riyadh Saudi Arabia
- 16:00-16:07 *BILATERAL PNEUMONIA IN A KIDNEY TRANSPLANT RECIPIENT THE COVID-19 ERA- SOMETIMES IT'S A ZEBRA*
Bojana Šimunov - Zagreb Croatia

Brief Oral Session

Monday, 30. August 2021

14:45 - 16:15
Room H - White 1

Outcome improvements in liver transplant: Going the extra mile

Chair(s): Wojciech Polak - Rotterdam Netherlands
Renato Romagnoli - Turin Italy

- 14:45-14:49 ASSOCIATION OF PROCUREMENT TIME WITH SHORT- AND LONG-TERM OUTCOMES AFTER LIVER TRANSPLANTATION
Verner Eerola - Helsinki Finland
- 14:51-14:55 HEPATITIS B OCCULT INFECTION IN DECEASED LIVER DONORS: LONG TERM POST TRANSPLANT CLINICAL EVALUATION.
Davide Cussa - Savigliano Italy
- 14:57-15:01 PROPOSAL AND VALIDATION OF A LIVER GRAFT DISCARD SCORE FOR LIVER TRANSPLANTATION: A MULTICENTRE ITALIAN STUDY
fabio melandro - Pisa Italy
- 15:03-15:07 EXTENDED CRITERIA DONORS IN LIVER TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Francesco Giovinazzo - Rome Italy
- 15:09-15:13 DONATION AFTER CIRCULATORY DEATH LIVERS CAN BE SAFELY USED FOR TRANSPLANTATION IN PATIENTS WITH PRE-EXISTING PORTAL VEIN THROMBOSIS
Willemijn van der Plas - Groningen Netherlands
- 15:15-15:19 RISK FACTORS ASSOCIATED WITH HISTOLOGICAL INJURY TO THE DEEP PERIBILIARY GLANDS AND PERIBILIARY VASCULAR PLEXUS PRIOR TO LIVER TRANSPLANTATION
Willemijn van der Plas - Groningen Netherlands
- 15:21-15:25 INDICATIONS AND WAITING LIST PRIORITY FOR DECEASED DONOR LIVER TRANSPLANTATION IN HIV/HCV CO-INFECTED PATIENTS IN JAPAN.
Susumu Eguchi - Nagasaki Japan
- 15:27-15:31 RECENT TRENDS AND INTENTION-TO-TREAT SURVIVAL OF LIVER TRANSPLANTATION FOR NONALCOHOLIC STEATOHEPATITIS:AN ITALIAN LIVER TRANSPLANT REGISTRY STUDY
Chiara Di Renzo - Padova Italy
- 15:33-15:37 OUTCOMES OF DONORS WITH BMI \geq 30 FOR LIVING DONOR LIVER TRANSPLANTATION
Oya Andacoglu - Istanbul Turkey
- 15:39-15:43 PERFORMANCE OF ARTIFICIAL INTELLIGENCE IN PREDICTING SURVIVAL FOLLOWING LIVER TRANSPLANTATION: STUDY USING DATA FROM THE KOREAN TRANSPLANT REGISTRY
Young-dong Yu - Seoul Korea, Rep. of South

- 15:45-15:49 *UPDATE ON WAITLIST MORTALITY OF YOUNG PATIENTS WITH BILIARY ATRESIA - RESULTS FROM THE EUROTRANSPLANT DATABASE*
Heda Esmati - Groningen Netherlands
- 15:51-15:55 *LIVER TRANSPLANTATION (LT) IN HIGH-MELD (≥ 30) PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF): SINGLE-CENTER EXPERIENCE WITH 90 CASES*
Andrea Della Penna - Tübingen Germany
- 15:57-16:01 *EVOLUTION OF INDICATION IN LIVER TRANSPLANTATION IN ITALY: THE CNT REGISTRY STUDY; ECALITA STUDY. ON BEHALF OF ECALITA STUDY GROUP*
Tommaso Maria Manzia - Rome Italy
- 16:03-16:07 *IMPACT EXTENDED LIVING DONOR CRITERIA FOCUSING ON DONOR SAFETY IN LIVING DONOR LIVER TRANSPLANTATION*
JOODONG KIM - Daegu Korea, Rep. of South

Focus Group Session

Monday, 30. August 2021

14:45 - 16:15
 Room I - White 2

Clinical Cases: Alloimmunity

Chair(s): Gianluigi Zaza - Verona Italy

- 14:45-14:52 *THE OUTCOME OF PLASMA CELL-RICH ACUTE REJECTION IN KIDNEY TRANSPLANTATION, IS IT REALLY POOR?*
Tarek Mahmoud - Kuwait Kuwait
- 15:00-15:07 *SUCCESSFUL SECONDARY TRANSPLANTATION AFTER PLASMAPHERESSES FOR SUSPECTED ANTI-ENDOTHELIAL CELL ANTIBODIES*
Rosa Lammerts - Groningen Netherlands
- 15:15-15:22 *HYPERACUTE HUMORAL NON-HLA ALLOGRAFT REJECTION AND PROTEIN S DEFICIENCY DISEASE, CASE REPORT AND REVIEW.*
Luis Garcia Covarrubias - MEXICO CITY Mexico
- 15:30-15:37 *ALLOIMMUNE CELLULAR AND HUMORAL MONITORING IN A KIDNEY TRANSPLANT RECIPIENT THAT PRESENTS AN ACUTE LEUKEMIA TREATED WITH BLINATUMOMAB*
Paula Anton Pampols - Barcelona Spain
- 15:45-15:52 *GRAFT-VERSUS-HOST-DISEASE AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION WITH SEVERE GASTROINTESTINAL AFFECTION TREATED WITH VEDOLIZUMAB*
Juulia Rähkä - Helsinki Finland
- 16:00-16:07 *TRANSPLANTING A TRANSPLANTED KIDNEY- A SAFE STRATEGY IN TIMES OF ORGAN SHORTAGE?*
Hristos Karakizlis - Giessen Germany

Brief Oral Session

Monday, 30. August 2021

14:45 - 16:15

Studio - ESOT Live
Studio

Addressing risk factors in kidney transplantation

Chair(s): Jacopo Romagnoli - Rome Italy
Jelena Stojanovic - London United Kingdom

14:45-14:49

HLA-DQ DISPARITIES AND KIDNEY TRANSPLANT OUTCOME
Aleksandar Senev - Leuven Belgium

14:51-14:55

KIDNEY RECIPIENTS CHARACTERISTICS QUESTIONED THE
DISCRIMINATIVE CAPACITIES OF KIDNEY DONOR RISK INDEX: AN
EXTERNAL VALIDATION FROM A FRENCH COHORT
Anne-Hélène QUERARD - LA ROCHE SUR YON France

14:57-15:01

DONOR FACTORS -FOR KIDNEYS ACCEPTED FOR TRANSPLANTATION-
MARGINALLY IMPACT TRANSPLANT OUTCOMES. CONCLUSIONS FROM
NATIONWIDE PAIRED OUTCOME ANALYSES
Jan Lindeman - Leiden Netherlands

15:03-15:07

IMPACT OF ASIAN AND BLACK DONOR AND RECIPIENT ETHNICITY ON
THE OUTCOMES AFTER DECEASED DONOR KIDNEY TRANSPLANTATION
IN THE UNITED KINGDOM
Abdul Rahman Hakeem - Leeds United Kingdom

15:09-15:13

PREDICTING NUCLEAR RENOGRAPHY BASED SPLIT RENAL FUNCTION IN
LIVING DONOR TRANSPLANTATION WITH CT BASED MEASURED SPLIT
RENAL VOLUMES
Bahattin Ozkul - Istanbul Turkey

15:15-15:19

EPITOPE DISTRIBUTION AND FEASIBILITY OF PIRCHE-II T-CELL
MATCHING FOR RENAL TRANSPLANTATION IN CANADA
Karen R Sherwood - Vancouver Canada

15:21-15:25

ITALIAN NATIONAL KIDNEY ALLOCATION ALGORITHM
(INKAA): APPLICATION AND FIRST RESULTS
Andrea Ricci - Rome Italy

15:27-15:31

THE IMPACT OF COLD ISCHAEMIA TIME ON OUTCOMES OF LIVING
DONOR KIDNEY TRANSPLANTATION IN THE UK LIVING KIDNEY SHARING
SCHEME
Stijn van de Laar - London United Kingdom

15:33-15:37

CLOSING THE GAP: EXAMINING WAIT LIST OUTCOMES FOR THE MOST
HIGHLY SENSITIZED CANDIDATES IN THE USA ACROSS REGIONS
Miriam Manook - Durham United States

15:39-15:43

THE REMUZZI SCORE IS A SAFE DECISION-MAKING TOOL AND UTILIZES
MORE KIDNEYS FOR TRANSPLANT COMPARED TO DONOR EGFR
AW Annemarie Weissenbacher - Innsbruck Austria

- 15:45-15:49 *LONG-TERM EVOLUTION OF KIDNEY GRAFT DONATION PROCEDURES IN UNCONTROLLED DONORS AFTER CARDIAC DEATH IN THE COMMUNITY OF MADRID*
ALONSO MATEOS-RODRIGUEZ - MADRID Spain
- 15:51-15:55 *MODIFIED FRAILTY INDEX (MFI-11): A SIMPLE TOOL TO ACCESS FRAILTY IN OLDER KIDNEY TRANSPLANT WAITING LIST POPULATION*
Mariana Sousa - Almada Portugal
- 15:57-16:01 *COMPARING OUTCOMES IN RIGHT VERSUS LEFT KIDNEY TRANSPLANTATION; A SYSTEMATIC REVIEW AND META-ANALYSIS*
Caitlin Carolan - Cramlington United Kingdom
- 16:03-16:07 *ARE UNSPECIFIED KIDNEY DONORS TREATED DIFFERENTLY TO SPECIFIED KIDNEY DONORS? VIEWS OF UK TRANSPLANT PROFESSIONALS*
Mira Zuchowski - London United Kingdom

Focus Group Session

Monday, 30. August 2021

14:45 - 16:15
 Z1 - Edu Zone |
 Room

Outcome optimisation in paediatric organ transplantation: All roads lead to...Milan

Chair(s): -

14:45-14:55

UK DECEASED DONATION AND TRANSPLANT ACTIVITY IN PAEDIATRICS FOR 2019 – 2020

Chloe Brown - Bristol United Kingdom

15:03-15:13

THE END STAGE RENAL DISEASE (ESRD) IN ANORECTAL MALFORMATION (ARM) PATIENTS: RISK FACTORS AND OUTCOME.

Miriam Duci - Padova Italy

15:21-15:31

PREEMPTIVE KIDNEY TRANSPLANTATION VERSUS NON-PREEMPTIVE KIDNEY TRANSPLANTATION IN CHILDREN: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Reshma Rana Magar - Kidlington, Oxfordshire United Kingdom

15:39-15:49

DOES EXTRAPERITONEAL APPROACH INCREASE THE RISK OF COMPLICATIONS AFTER KIDNEY TRANSPLANT IN LOW-WEIGHT CHILDREN? EXPERIENCE FROM A SINGLE INSTITUTION

Filippo Ghidini - Padua Italy

15:57-16:07

PEDIATRIC LIVER TRANSPLANTATION WITH DCD GRAFTS: SINGLE CENTER EXPERIENCE

Annalisa Dolcet - London United Kingdom

Hands-on Course

Monday, 30. August 2021

16:45 - 18:15
Z2 - Edu Zone |
Hands-on

Machine perfusion lab 2.0. - Wet Lab (Course 1)

Chair(s): -

12 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow steps of organ perfusion of kidney, liver and lung.

Additional registration to this session is required. Please register via congress website: <https://www.esotcongress.org/registrations>

Focus Group Session

Monday, 30. August 2021

16:45 - 18:15
Room K - Red

Available technologies in kidney transplantation: Make good use of it, if you want to win the race

Chair(s): *Annemarie Weissenbacher - Innsbruck Austria*

- 16:45-16:52 *ROBOT-ASSISTED SURGERY AS A MINIMALLY INVASIVE APPROACH FOR KIDNEY TRANSPLANTATION RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSES*
Julia Slagter - Rotterdam Netherlands
- 17:00-17:07 *ROBOTIC VS. LAPAROSCOPIC DONOR NEPHRECTOMY: A RETROSPECTIVE BI-CENTRIC COMPARISON OF SURGICAL OUTCOMES FROM TWO HIGH VOLUME CENTERS*
Alessandro Giacomoni - Milano Italy
- 17:15-17:22 *INDICATIONS FOR AND TECHNIQUES OF NATIVE NEPHRECTOMY IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE*
Usman Haroon - London United Kingdom
- 17:30-17:37 *A LARGE SERIES OF LAPAROSCOPIC NEPHRECTOMIES FOR POLYCYSTIC KIDNEYS PRE, POST AND SIMULTANEOUS WITH KIDNEY TRANSPLANTATION: ANALYSIS OF OUTCOME.*
Marianna Di Bello - Padua Italy
- 17:45-17:52 *ROBOT ASSISTED KIDNEY TRANSPLANTATION: A SAFE APPROACH FOR COMPLEX LIVING TRANSPLANT SITUATIONS.*
Carlos Couceiro - Barcelona Spain
- 18:00-18:07 *FULL ROBOTIC DONOR NEPHRECTOMY FOR LIVING DONOR KIDNEY TRANSPLANT*
Stefano Di Sandro - Modena Italy

Full Oral Session

Monday, 30. August 2021

16:45 - 18:15
Room C - Yellow

Is there room for improvement in donation?

Chair(s): Nichon Jansen - Leiden Netherlands
Paolo Rigotti - Padova Italy

- 16:45-16:54 *IMPACT OF THE CHANGE IN ORGAN DONATION LAW IN ENGLAND ON DONATION RATES IN THE MULTICULTURAL AND ETHNICALLY DIVERSE CITY OF LONDON*
Lucy Dames - London United Kingdom
- 16:56-17:05 *OPT OUT LEGISLATION IN THE UK – PRELIMINARY DATA*
Sue Madden - Bristol United Kingdom
- 17:07-17:16 *DISPARITIES IN THE USE OF DONATION AFTER CARDIAC DEATH LIVER ALLOGRAFTS FROM DONORS OVER 60 YEARS OF AGE IN THE UNITED STATES VS. THE UNITED KINGDOM.*
EG Emmanouil Giorgakis - Little Rock United States
- 17:18-17:27 *PRIORITIZING DONOR HEPATECTOMY DURING COMBINED LUNG AND LIVER PROCUREMENT IN DCD DONORS IS SAFE AND FEASIBLE: A SINGLE CENTRE EXPERIENCE*
Joris Blondeel - Leuven Belgium
- 17:29-17:38 *COMPUTERISED INTEGRATION OF ALTERNATIVE LIVING DONOR KIDNEY TRANSPLANTATION PROGRAMS: FIRST PROMISING RESULTS FOR DIFFICULT-TO-MATCH PATIENTS*
M Marry de Klerk - Rotterdam Netherlands
- 17:40-17:49 *ALTRUISTIC KIDNEY DONATIONS: OPTIMIZING UTILITY AND BENEFICENCE*
Muhammad Yahya Jan - Indianapolis United States
- 17:51-18:00 *MEASURING THE GAINS OF THE PARTICIPATION OF COMPATIBLE PAIRS TO KIDNEY EXCHANGE PROGRAMS AT A LOCAL LEVEL.*
Caterina Di Bella - Padua Italy
- 18:02-18:11 *OUTCOMES IN CADAVERIC UTERUS TRANSPLANTATION*
Cristiano Quintini - Cleveland United States

Full Oral Session

Monday, 30. August 2021

16:45 - 18:15
Room D - Green

Abdominal transplantation: Bittersweet interactions

Chair(s): Valeria Sordi - Milan Italy
Thierry Berney - Geneva Switzerland

- 16:45-16:54 *BETA-CELL DEATH, RATHER THAN INSULIN RESISTANCE, DRIVES HYPERGLYCAEMIA IN ORGAN DONORS.*
Iestyn Shapey -
- 16:56-17:05 *PERIOPERATIVE THROMBOINFLAMMATORY MARKERS DIFFER IN PANCREAS TRANSPLANT ALONE AND SIMULTANEOUS PANCREAS-KIDNEY RECIPIENTS AND PREDICT GRAFT THROMBOSIS*
Kristina Rydenfelt - Oslo Norway
- 17:07-17:16 *DIFFERENTIALLY METHYLATED CELL FREE DNA MONITORING IN PANCREAS TRANSPLANT RECIPIENTS WITH FUNCTIONING GRAFT*
Maria José Ramírez-Bajo - Barcelona Spain
- 17:18-17:27 *COMPARABLE OUTCOMES FOR CIRCULATORY DEATH AND BRAIN-STEM DEATH PANCREAS TRANSPLANTATION IRRESPECTIVE OF THE USE OF NORMOTHERMIC REGIONAL PERFUSION*
James Richards - Edinburgh United Kingdom
- 17:29-17:38 *UTILITY OF DONOR-DERIVED CELL-FREE DNA IN PANCREAS-KIDNEY TRANSPLANTATION*
Pedro Ventura-Aguiar - Barcelona Spain
- 17:40-17:49 *EFFICACY AND SAFETY OF PANCREAS TRANSPLANT ALONE (PTA) IN SUBJECTS WITH TYPE 1 DIABETES (T1D): 15 YEAR ACTUAL FOLLOW-UP*
Walter Baronti - Pisa Italy
- 17:51-18:00 *PRELIMINARY ITALIAN EXPERIENCE OF COMBINED LIVER TRANSPLANTATION AND SLEEVE GASTRECTOMY*
Tommaso M. Manzia - Rome Italy
- 18:02-18:11 *LIVER INCLUSION IN INTESTINAL TRANSPLANTATION: SINGLE-CENTER EXPERIENCE*
Mathias Clarysse - Leuven Belgium

Full Oral Session

Monday, 30. August 2021

16:45 - 18:15
Room E - Orange

Optimising outcomes after heart transplantation: From a little spark may burst a flame

Chair(s): Lori West - Edmonton Canada
Stephan Ensminger - Lübeck Germany

- 16:45-16:54 *SHORT-TERM INTERLEUKIN-6 BLOCKADE PREVENTS ALLOGRAFT REJECTION UNDER COSTIMULATION BLOCKADE IN MURINE CARDIAC TRANSPLANTATION*
Moritz Muckenhuber - Vienna Austria
- 16:56-17:05 *CD34+ CELL THERAPY IS ASSOCIATED WITH BENEFICIAL CLINICAL OUTCOMES IN ADVANCED CHRONIC HEART FAILURE PATIENTS LISTED FOR HEART TRANSPLANTATION*
Gregor Poglajen - Ljubljana Slovenia
- 17:07-17:16 *SURVIVAL AFTER HEART TRANSPLANT VS. SIMULTANEOUS HEART KIDNEY TRANSPLANT BY DEGREES OF RENAL DYSFUNCTION AT TRANSPLANTATION IN THE UNITED STATES*
Samy Riad - Minneapolis United States
- 17:18-17:27 *THE EXPRESSION LEVELS OF CIRCULATING MIR-101 AND MIR-27 ASSOCIATE WITH HEART TRANSPLANT ACUTE REJECTION*
Olga Gichkun - Moscow Russian Federation
- 17:29-17:38 *REAL WORLD DATA OF EVEROLIMUS WITH OR WITHOUT CALCINEURIN-INHIBITORS ON LONGTERM OUTCOME AFTER HEART TRANSPLANTATION*
Markus J. Barten - Hamburg Germany
- 17:40-17:49 *CLUSTERING ANALYSIS IDENTIFIES DISTINCT PROFILES OF HEART TRANSPLANT RECIPIENTS ASSOCIATED WITH PATIENT SURVIVAL*
Guillaume BONNET - Paris France
- 17:51-18:00 *LONG TERM FOLLOW-UP OF CARDIAC TRANSPLANTATION WITH SELECTED ORGANS BY PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY*
Sofía Martin-Suarez - Bologna Italy
- 18:02-18:11 *DONOR-DERIVED CELL-FREE DNA FOR THE DETECTION OF HEART ALLOGRAFT INJURY: IMPACT OF REJECTION SEVERITY AND TIMING OF THE LIQUID BIOPSY*
Jeroen Verhoeven - Rotterdam Netherlands

Full Oral Session

Monday, 30. August 2021

16:45 - 18:15

Room F - Turquoise
1

Predictive models and tools in transplantation: Looking into the crystal ball

Chair(s): Elmi Müller - Cape Town South Africa

16:45-16:54

COMPUTER BASED, VS HUMAN BASED ASSESSMENT OF KIDNEY ALLOGRAFT FAILURE PREDICTION AND STRATIFICATION (HUMAN VS IBOX TRIAL)

Gillian Divard - Paris France

16:56-17:05

MULTIDIMENSIONAL PROGNOSTICATION TOOL FOR KIDNEY TRANSPLANT PATIENT SURVIVAL : THE MORTALITY MBOX

Charlotte Debiais-Deschamps - Paris France

17:07-17:16

MORTALITY AFTER EMERGENCY SURGERY COMPARING KIDNEY TRANSPLANT OR DIALYSIS PATIENTS VERSUS THE GENERAL POPULATION: A NATIONAL COHORT STUDY

Benjamin Anderson - Birmingham United Kingdom

17:18-17:27

ARE SURVIVAL BENEFITS OF KIDNEY TRANSPLANTATION VERSUS REMAINING ON THE WAITING LIST VALID FOR ALL KIDNEY FAILURE PATIENTS IN THE CONTEMPORARY ERA?

Daoud Chaudhry - Birmingham United Kingdom

17:29-17:38

TRENDS OF RENAL FAILURE AFTER NONRENAL SOLID ORGAN TRANSPLANT: A COMPETING RISK ANALYSIS OF THE SRTR

Samy Riad - Minneapolis United States

17:40-17:49

MEDICATION ADHERENCE AND FEAR OF REJECTION AFTER CONVERSION FROM DUAL TO MONOTHERAPY: A RANDOMIZED CONTROLLED TRIAL

Regina van Zanten - Rotterdam Netherlands

17:51-18:00

THE ASSOCIATION OF TRAJECTORIES OF DEPRESSION AND ANXIETY ON OUTCOMES AT THE LONG TERM AFTER LIVER TRANSPLANTATION

Coby Annema - Groningen Netherlands

18:02-18:11

I-DTI: A SECOND OPINION PLATFORM BETWEEN HEALTHCARE PROFESSIONALS RELATED TO ORGAN DONATION AND TRANSPLANTATION

Estephan Arredondo - Barcelona Spain

Full Oral Session

Monday, 30. August 2021

16:45 - 18:15

Room G - Turquoise
2

Immunological mechanisms of organ rejection

Chair(s): Katja Kotsch - Berlin Germany
Marion Rabant - Paris France

16:45-16:54

DEFECTIVE T REGULATORY CELL RESPONSES IN KIDNEY TRANSPLANT RECIPIENTS DEVELOPING ANTIBODY-MEDIATED REJECTION
Kevin Louis - Paris France

16:56-17:05

CD21-CD27+ ACTIVATED MEMORY B CELLS ARE A DELETERIOUS SOURCE OF PLASMA CELLS AND DONOR SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS
Kevin Louis - Paris France

17:07-17:16

ACUTE ANTIBODY MEDIATED REJECTION IN MICE IS ACCOMPANIED BY ELEVATED BASOPHIL LEVELS AND THE DEVELOPMENT OF IGE+ CD23+ B CELLS
Anna Marianne Weijler - Vienna Austria

17:18-17:27

CYTOMEGALOVIRUS SPECIFIC POLYFUNCTIONAL T-CELL RESPONSES EXPRESSING CD107A ASSOCIATED WITH CONTROL OF CMV REACTIVATION AFTER LIVER TRANSPLANTATION
Angela Carvalho-Gomes - Valencia Spain

17:29-17:38

IL-10 SIGNALING IN T CELLS IS ESSENTIAL FOR TRANSPLANT TOLERANCE INDUCTION
Giorgio Raimondi - Baltimore United States

17:40-17:49

ROLE OF ALLOREACTIVE CD8+ T CELLS IN TREG MEDIATED SKIN GRAFT SURVIVAL
Romy Steiner - Vienna Austria

17:51-18:00

INVESTIGATING THE ALLOIMMUNE BACKGROUND OF THE HISTOLOGICAL CHANGES SUGGESTIVE OF ANTIBODY-MEDIATED INJURY IN THE ABSENCE OF HLA-DSA ANTIBODIES
Aleksandar Senev - Leuven Belgium

18:02-18:11

RECIPIENT SEX AND ESTRADIOL LEVELS AFFECT TRANSPLANT OUTCOMES IN AN AGE-SPECIFIC FASHION
Jasper Iske - Boston United States

Brief Oral Session

Monday, 30. August 2021

16:45 - 18:15
Room H - White 1

COVID-19 and else: overcoming the pandemic

Chair(s): *Maria Irene Bellini - Rome Italy*
Sushma Shankar - Oxford United Kingdom

- 16:45-16:49 *CXCR3+ CIRCULATORY FOLLICULAR HELPER T LYMPHOCYTES COULD HELP IN COVID-19 RESOLUTION IN KIDNEY TRANSPLANT RECIPIENTS*
Patricia Suárez Fernández - Madrid Spain
- 16:51-16:55 *INCREASING DIAGNOSTIC ACCURACY IN RENAL TRANSPLANT PATIENT WITH ACUTE COVID-19 AND GRAFT FAILURE BY T CELL ANALYSIS IN PERIPHERAL BLOOD AND BIOPSY*
Ulrik Stervbo - Herne Germany
- 16:57-17:01 *DETECTION OF PRE-EXISTING SARS-COV-2-REACTIVE T CELLS IN UNEXPOSED RENAL TRANSPLANT PATIENTS*
Arturo Blázquez Navarro - Berlin Germany
- 17:03-17:07 *COVID-19 SEVERITY INFLUENCES ANTI-SARS-COV2 ANTIBODIES TITER IN KIDNEY TRANSPLANT RECIPIENTS*
Francisco Gonçalves - Porto Portugal
- 17:09-17:13 *OUTCOMES OF KIDNEY TRANSPLANTATION AT THE EPICENTRE OF THE COVID-19 PANDEMIC: THE EXPERIENCE OF THE OSPEDALE MAGGIORE POLICLINICO*
Evaldo Favi - Milan Italy
- 17:15-17:19 *IMPACT OF SARS-COV-2 INFECTION IN WAITING LIST FOR LIVER TRANSPLANTATION*
Anna Sessa - Créteil France
- 17:21-17:25 *LIVER TRANSPLANTATION IN PATIENTS WITH LIVER CIRRHOSIS RECOVERED FROM COVID-19 INFECTION*
Ahad Eshraghian - Shiraz Iran
- 17:27-17:31 *SARS-COV-2 INFECTION IN KIDNEY TRANSPLANT RECIPIENTS: ONE YEAR LATER. WHAT HAVE WE LEARNT?*
Joana Tavares - Porto Portugal
- 17:33-17:37 *LIVER TRANSPLANT RECIPIENTS WITH SARS-COV-2 INFECTION: RESULTS FROM AN ITALIAN MULTICENTER COHORT*
Chiara Mazzarelli - Milan Italy
- 17:39-17:43 *COVID-19 MANAGEMENT IN PATIENTS AFTER HEART TRANSPLANTATION*
Maria Simonenko - Saint-Petersburg Russian Federation

- 17:45-17:49 *COVID-19 IN DECEASED RENAL TRANSPLANT RECIPIENTS*
Mariana Sousa - Almada Portugal
- 17:51-17:55 *EPIDEMIOLOGY AND CLINICAL RELEVANCE OF ACUTE KIDNEY INJURY IN*
COVID-19 KIDNEY TRANSPLANT RECIPIENTS
Gabriele Guglielmetti - Novara Italy
- 17:57-18:01 *INFLUENZA VACCINATION IN SOLID ORGAN TRANSPLANT RECIPIENTS: A*
NATIONWIDE POPULATION-BASED COHORT STUDY
SD Susanne Dam Nielsen - Copenhagen Denmark
- 18:03-18:07 *KIDNEY TRANSPLANT PATIENTS ARE ABLE TO GENERATE AND MOUNT*
VARICELLA ZOSTER-REACTIVE T CELL AND HUMORAL IMMUNITY
FOLLOWING VARICELLA ZOSTER VACCINATION
Toralf Roch - Berlin Germany

Focus Group Session

Monday, 30. August 2021

16:45 - 18:15
 Room I - White 2

Biomarkers: What's circulating?

Chair(s): *Marta Crespo - Barcelona Spain*
Umberto Maggiore - Parma Italy

- 16:45-16:52 *IMPACT OF DELAYED GRAFT FUNCTION ON BASELINE DONOR DERIVED CELL-FREE DNA (DD-CFDNA) IN KIDNEY TRANSPLANT RECIPIENTS*
Bhavna Chopra - Pittsburgh United States
- 17:00-17:07 *COMPARING METHODS FOR DONOR-DERIVED CELL-FREE DNA QUANTIFICATION IN PLASMA AND URINE FROM KIDNEY AND LIVER TRANSPLANT RECIPIENTS*
Nicholas Kueng - Bern Switzerland
- 17:15-17:22 *PITFALLS IN THE DETECTION OF DONOR-DERIVED CELL-FREE DNA IN TRANSPLANT RECIPIENTS*
Jeroen Verhoeven - Rotterdam Netherlands
- 17:30-17:37 *CIRCULATING ENDOTHELIAL CELL LEVELS TRANSIENTLY INCREASE IN PERIPHERAL BLOOD AFTER KIDNEY TRANSPLANTATION*
H. Hector Tejeda Mora - Rotterdam Netherlands
- 17:45-17:52 *PERIPHERAL BLOOD TRANSCRIPTOMICS DEMONSTRATE GREAT POTENTIAL IN UNRAVELING PATHOPHYSIOLOGICAL PATHWAYS OF KIDNEY ALLOGRAFT PATHOLOGY*
Elisabet Van Loon - Leuven Belgium
- 18:00-18:07 *DIFFERENTIALLY EXPRESSED TISSUE MICRORNAS DISTINGUISH SPECIFIC DISEASE PHENOTYPES FOLLOWING KIDNEY TRANSPLANTATION*
Špela Borštnar - Ljubljana Slovenia

Brief Oral Session

Monday, 30. August 2021

16:45 - 18:15

Studio - ESOT Live
Studio

IRI mechanism with an eye on treatment

Chair(s): *Henri Leuvenink - Donders Netherlands
Amelia Hessheimer - Barcelona Spain*

16:45-16:49

*CORRELATION BETWEEN COLD ISCHEMIA TIME AND
THROMBOCYTOPENIA AFTER LIVER TRANSPLANTATION
Marco Maria Pascale - Rome Italy*

16:51-16:55

*DANGER SIGNALS IN ORGAN PRESERVATION SOLUTION AFTER COLD
ISCHEMIA IN LIVER TRANSPLANTATION: ACTIVATION OF MACROPHAGES
AND ENDOTHELIAL CELLS
Alberto Baroja-Mazo - Murcia Spain*

16:57-17:01

*ROLE OF ACETYLCHOLINE IN LIVER GRAFTS FROM BRAIN DEAD
DONORS WITH HEALTHY AND MARGINAL LIVERS WITH SIMPLE
STEATOSIS OR NON-ALCOHOLIC STEATOHEPATITIS
Marc Micó Carnero - Barcelona Spain*

17:03-17:07

*PERSISTENT BILIARY HYPOXIA AND LACK OF REGENERATION ARE KEY
MECHANISMS IN THE PATHOGENESIS OF NON-ANASTOMOTIC
STRICTURES AFTER LIVER TRANSPLANTATION
Iris de Jong - Groningen Netherlands*

17:09-17:13

*ANG-3777 TREATMENT ATTENUATES ISCHEMIA-REPERFUSION-INDUCED
RENAL INJURY IN RAT AND DOG MODELS
Prakash Narayan - Uniondale United States*

17:15-17:19

*INFLUENCE OF THE ANESTHETIC METHOD ON THE OUTCOME OF A
RODENT MODEL OF INTESTINAL ISCHEMIA-REPERFUSION INJURY
Mathias Clarysse - Leuven Belgium*

17:21-17:25

*CLINICALLY APPLICABLE INTRALUMINAL PRESERVATION OF HUMAN
SMALL BOWEL DOES NOT REDUCE HISTOLOGICAL DAMAGE COMPARED
TO STANDARD VASCULAR FLUSH
A.M.S. Anne Marye de Jong - Groningen Netherlands*

17:27-17:31

*CALCIUM CARBONATE NANOPARTICLES IN AN EX VIVO RAT INTESTINAL
PERFUSION MODEL: PREVENTION OF ISCHEMIC INJURY IN COLON AND
SMALL INTESTINE
Michele Finotti - Padova Italy*

17:33-17:37

*L-ARGININE PREVENTS ISCHEMIC INJURY IN EXPLANTED RAT
INTESTINAL REGIONS IN AN EX VIVO PERFUSION MODE
Michele Finotti - Padova Italy*

17:39-17:43

*ATTENUATION OF INTESTINAL ISCHEMIA-REPERFUSION INJURY IN A
RODENT MODEL BY INTRAVENOUS ADMINISTRATION OF POLYETHYLENE
GLYCOL
Mathias Clarysse - Leuven Belgium*

- 17:45-17:49 *IN VIVO PHOSPHORYLATION OF C-MET BY ANG-3777, A HEPATOCYTE GROWTH FACTOR MIMETIC*
LATHA PAKA - San Francisco United States
- 17:51-17:55 *OXYGENATED VERSUS NON-OXYGENATED FLUSH OUT AND STORAGE OF DCD PORCINE LIVERS*
Isabel Brüggewirth - Groningen Netherlands
- 17:57-18:01 *THE IRRADIATION-INDUCED RENAL ISCHEMIC PRECONDITIONING IS BLUNTED BY THE ORAL ADMINISTRATION OF THE ANTI-ANGIOGENIC AGENT, SUNITINIB*
Badr Khbouz - Liège Belgium
- 18:03-18:07 *ILOPROST INFUSION ACCELERATES THE RECOVERY OF RENAL FUNCTION IN PATIENTS EXPERIENCING IRI-RELATED DELAYED GRAFT FUNCTION AFTER KIDNEY TRANSPLANT*
Antonella Troiano - Bologna Italy

Focus Group Session

Monday, 30. August 2021

16:45 - 18:15
Z1 - Edu Zone |
Room

Regeneration for transplantation

Chair(s): Roos Masereeuw - Netherlands
Dan Weiss - Vermont United States

- 16:45-16:52 IDENTIFICATION OF PREDICTIVE MARKERS FOR THE GENERATION OF WELL-DIFFERENTIATED IPSC-DERIVED KIDNEY ORGANIDS
Zhaoyu Du - Rotterdam Netherlands
- 17:00-17:07 PRE-VASCULARIZED ORGANOID GENERATED FROM DECELLULARIZED HUMAN PLACENTA SUPPORT PANCREATIC TISSUES IN TYPE-1 DIABETES TREATMENT
Kevin Bellofatto - Geneva Switzerland
- 17:15-17:22 PORTAL VENOUS REPOPULATION OF DECELLULARISED RAT LIVER SCAFFOLDS WITH SYNGENEIC BONE MARROW STEM CELLS
Mekhola Hoff - Cambridge United Kingdom
- 17:30-17:37 THE MATRIX RELOADED: USING INTRAHEPATIC CHOLANGIOCYTE ORGANIDS AND DECELLULARIZED HUMAN LIVER EXTRACELLULAR MATRIX TO CREATE FUNCTIONAL LIVER TISSUE
Jorke Willemse - Rotterdam Netherlands
- 17:45-17:52 PERFUSION-DECELLULARIZATION OF VASCULARIZED BONE MATRIX: APPLICATION TO THE PORCINE FORELIMB
Guillaume Rougier - Brussels Belgium
- 18:00-18:07 ANTI-FIBROTIC EFFECTS OF MEMBRANE PARTICLES FROM MESENCHYMAL STROMAL CELLS IN A RENAL ISCHEMIA REPERFUSION INJURY MOUSE MODEL
Ana Merino - Rotterdam Netherlands

Education Track

Tuesday, 31. August 2021

08:00 - 09:30
 Room A - Silver

Organ transplantation in a big data world: Lost in precision?

Chair(s): *Rainer Oberbauer - Vienna Austria*
Marta Crespo - Barcelona Spain

Big data in precision medicine involves large cohorts and OMICS technologies. If we are to achieve artificial intelligence, we require advanced education in terms of bioinformatics and computational biology and, in the future, even more experts in both transplant medicine and bioinformatics.

08:00-08:20

The biology of OMICS in transplantation
Gianluigi Zaza - Verona Italy

08:20-08:40

Computational biology: Special exercises for transplantation
Thomas Mueller - Erlenbach Switzerland

08:40-09:00

Big data: The interface between biostatistics, pathology and clinics
Michael Mengel -

09:00-09:20

Application for transplantation: Practical and clinical perspectives
Dorry Segev - Baltimore United States

09:20-09:30

Discussion
 -

Full Oral Session

Tuesday, 31. August 2021

08:00 - 09:30

Room B -
Auditorium

COVID-19 in donors and recipients: Surfing the waves of pandemic

Chair(s): *Saima Aslam - San Diego United States*

08:00-08:09

IMPACT OF THE COVID-19 PANDEMIC ON WORLDWIDE ORGAN DONATION AND TRANSPLANTATION

Olivier Aubert - Paris France

08:11-08:20

MAINTENANCE OF A DECEASED-DONOR KIDNEY TRANSPLANTATION PROGRAM DURING PANDEMIC SARS-COV-2

Richard Dumbill - Oxford United Kingdom

08:22-08:31

SAFE USE OF SARS-COV-2 POSITIVE DONORS IN LIVER TRANSPLANTATION

Davide Cussa - Turin Italy

08:33-08:42

IS IT SAFE TO RECEIVE KIDNEYS FROM DECEASED KIDNEY DONORS WHO TESTED POSITIVE FOR COVID-19 INFECTION?

Hatem Ali - Coventry United Kingdom

08:44-08:53

A NATIONAL RESPONSE TO COVID PRIORITISING LIVER TRANSPLANT RECIPIENTS WITH THE HIGHEST NEED PROVIDED EXCELLENT OUTCOMES IN THE UK

Steven Masson - Newcastle United Kingdom

08:55-09:04

COVID-19 IN LIVER TRANSPLANT CANDIDATES: WAIT-LIST OUTCOMES AND POST-TRANSPLANT COURSE

Giovanni Perricone - Milan Italy

09:06-09:15

PANCREAS TRANSPLANTATION IN THE TIME OF COVID. A SINGLE CENTRE'S EXPERIENCE

Ann Etohan Ogbemudia - Oxford United Kingdom

09:17-09:26

A CASE SERIES OF PAEDIATRIC KIDNEY TRANSPLANTS DURING THE ONGOING COVID-19 PANDEMIC

Sergio Assia-Zamora - London United Kingdom

Real-life clinical decision making

Tuesday, 31. August 2021

08:00 - 09:30
Room C - Yellow

The 'complexity team'

Chair(s): Giandomenico Biancofiore - Pisa Italy
Martin Oliverius - Prague Czech Republic

Close collaboration within a multidisciplinary team during each step of a transplant is of fundamental importance. Anaesthetists and surgeons often find themselves sharing difficult decisions during surgical procedures and post-transplant management in order to achieve the best possible outcome for the patient.

08:00-08:05 *Clinical Case: Anesthesia for combined liver-thoracic transplantation*
Marieke Groenewold - Groningen Netherlands

08:05-08:20 *Anesthesia for combined liver-thoracic transplantation*
K.M.E.M. Koen Reytjens - Groningen Netherlands

08:20-08:25 *Clinical Case: Perioperative coagulation management*
Sabrina Stern - Essen Germany

08:25-08:40 *Perioperative coagulation management at point-of-care*
Fuat Saner - Essen Germany

08:40-08:45 *Clinical Case: Acute chronic liver failure*
Ecaterina Scarlatescu - Bucharest Romania

08:45-09:00 *Acute chronic liver failure: A critical care perspective*
Dana Tomescu - Bucharest Romania

09:00-09:30 *Discussion*
-

Education Track

Tuesday, 31. August 2021

08:00 - 09:30
Room D - Green

Children are not small adults: The conundrum of scarce evidence

Chair(s): Michele Colledan - Bergamo Italy
Christian Benden - Zurich Switzerland

Frequently in paediatric solid organ transplantation, patient management is extrapolated from adult practice. However, children are not just small adults as the surgical approach is challenging, and effects of immunosuppressive therapy in the developing immune system of children needs to be considered. Paediatric experts in the field will tackle topics such as graft size matching and early post-operative management, and they will critically review long-term outcomes. Furthermore, the role of resilience in transition among adolescent transplant patients is addressed within this Joint Session with the International Paediatric Transplant Association (IPTA)

08:00-08:15 *Resilience in healthcare transitions among adolescent SOT recipients*
MI Mignon McCulloch - Cape Town South Africa

08:15-08:22 *How to deal with size-matching (kidney)*
J Jelena Stojanovic - London United Kingdom

08:22-08:29 *How to deal with size-matching (liver)*
Barbara Wildhaber - Geneva Switzerland

08:29-08:36 *How to deal with size-matching (heart)*
Martin Schweiger - Zurich Switzerland

08:36-08:43 *Early post-operative management (kidney)*
J Jelena Stojanovic - London United Kingdom

08:43-08:50 *Early post-operative management (liver)*
Barbara Wildhaber - Geneva Switzerland

08:50-08:57 *Early post-operative management (heart)*
Martin Schweiger - Zurich Switzerland

08:57-09:04 *Long-term outcome data (kidney)*
J Jelena Stojanovic - London United Kingdom

09:04-09:11	<i>Long-term outcome data (liver)</i> <i>Barbara Wildhaber - Geneva Switzerland</i>
09:11-09:18	<i>Long-term outcome data (heart)</i> <i>Martin Schweiger - Zurich Switzerland</i>
09:18-09:30	<i>Discussion</i> -

Education Track

Tuesday, 31. August 2021

08:00 - 09:30

Room E - Orange

Bioartificial organs (BAO)

Chair(s): Gerardo Catapano - Rende Italy
Dimitrios Stamatialis - Enschede Netherlands

Developing bioartificial organs has the potential to transform the lives of patients with organ failure while obviating the need for organ donors. However, the technology is associated with numerous challenges in terms of biological, bioengineering and transplantation-related issues.

08:00-08:20

Cell biology: opportunities and challenges for developing bioartificial kidney
Roos Masereeuw - Netherlands

08:20-08:40

Engineering: opportunities and challenges for developing bioartificial liver
Gerardo Catapano - Rende Italy

08:40-09:00

Bioartificial pancreas
Dimitrios Stamatialis - Enschede Netherlands

09:00-09:20

Pancreas and liver on a chip
Cecile Legallais - Compiègne France

09:20-09:30

Discussion
-

Focus Group Session

Tuesday, 31. August 2021

08:00 - 09:30

Room F - Turquoise
1

Ethical and legal aspects of donation and transplantation

Chair(s): *Antonia Cronin - London United Kingdom
David Paredes-Zapata - Barcelona Spain*

08:00-08:07

*ETHICS SUPPORT FOR PAEDIATRIC CARDIAC DCD
Joe Brierley - LONDON United Kingdom*

08:15-08:22

*ARE WE READY TO START WITH THE PEDIATRIC DONATION AFTER
CARDIOCIRCULATORY DETERMINATION OF DEATH IN ITALY? A SINGLE-
CENTRE SURVEY ON PICU ATTITUDE
Cristina Giugni - firenze Italy*

08:30-08:37

*INEQUITABLE ACCESS TO TRANSPLANTS: PERSONS WITH IMPAIRED
DECISION-MAKING CAPACITY
Rebecca Thom - London United Kingdom*

08:45-08:52

*FRIEND OR FOE: LAW, REGULATION AND THE PSYCHOSOCIAL
ASSESSMENT OF LIVING KIDNEY DONORS
Bonnie Venter - Bristol United Kingdom*

09:00-09:07

*FAMILY'S LEGAL ROLE IN DECEASED ORGAN PROCUREMENT. AN
EUROPEAN AND COMPARATIVE LAW STUDY
Marina Morla - León Spain*

09:15-09:22

*WITHDRAWING LIFE SUSTAINING TREATMENT AND ORGAN DONATION
OF BRAIN DEATH PATIENTS
Seungrye Jeong - Seoul Korea, Rep. of South*

Think Tank

Tuesday, 31. August 2021

08:00 - 09:30
Room G - Turquoise
2

Ethical conduct of clinical research in donation and transplantation during end-of-life care

Chair(s): *Dominique Martin - Geelong Australia
Brendan Parent - New York United States*

Ethical concerns about the conduct of human research during end of life care have long been recognized as a potential deterrent or barrier to the conduct of valuable research. In this session, which is a part of a broader Think Tank, we will explore findings from a recent review of ethical challenges and considerations in the conduct of research relating to organ donation and transplantation during the end-of-life period. We will discuss clinician perspectives of ethical barriers to innovative research, the limitations of existing guidelines, and the potential role of new ethical guidance tools to support the ethical development of vital research around the world.

08:00-08:05

*Introduction: Ethical challenges of innovative research in donation and transplantation during end-of-life care
Dominique Martin - Geelong Australia*

08:05-08:15

*Key ethical considerations in research
Anne Dalle Ave - Lausanne Switzerland*

08:15-08:25

*Ethical barriers to innovative research in transplantation: Surgeon's perspective
Jayme Locke - Birmingham United States*

08:25-08:35

*Ethical barriers to innovative research in donation: Intensivist's perspective
Frank Van Haren - Sydney Australia*

08:35-08:50

*Limitations of current ethical frameworks for research
Brendan Parent - New York United States*

08:50-09:30

Panel discussion with all speakers: How might ethical guidance be helpful in addressing barriers to innovative research during the end of life period?

Brief Oral Session

Tuesday, 31. August 2021

08:00 - 09:30
Room H - White 1

Pot Pouri of cardiothoracic transplantation: Follow your own star

Chair(s): Massimo Boffini - Torino Italy
Ivan Knežević - Portorose Slovenia

- 08:00-08:04 ANASTOMOSIS TIME IS AN INDEPENDENT RISK FACTOR FOR PRIMARY GRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY
Christelle M. Vandervelde - Leuven Belgium
- 08:06-08:10 FEASIBILITY OF SURVEILLANCE AFTER LUNG TRANSPLANTATION USING MULTIVOLUME MRI INSTEAD OF IONIZING RADIATION TECHNIQUES IN CYSTIC FIBROSIS PATIENTS
Alessandro Palleschi - Milan Italy
- 08:12-08:16 CHRONIC KIDNEY DISEASE: A FREQUENT COMPLICATION IN PATIENTS WITH LUNG TRANSPLANT
Marisa Serrano Salazar - Madrid Spain
- 08:18-08:22 COMPARATIVE ANALYSIS OF SURVIVAL OF PATIENTS WITH CONGENITAL HEART DISEASE TRANSPLANTED FROM HEART OR HEART-LUNG
Víctor Donoso Trenado - Valencia Spain
- 08:24-08:28 CURRENT STATUS AND DEVELOPMENT OF CARDIOPULMONARY TRANSPLANTATION IN SPAIN
Raquel López-Vilella - VALENCIA Spain
- 08:30-08:34 IS HEART TRANSPLANTATION A VALUABLE OPTION IN PATIENTS WITH SYSTEMIC RARE DISEASES?
Concetta Di Nora - Udine Italy
- 08:36-08:40 SINGLE CENTER ASSESSMENT OF CARDIAC TRANSPLANTATION RESULTS COMPARING URGENT VERSUS ELECTIVE REGIMEN
Mariafrancesca Fiorentino - Bologna Italy
- 08:42-08:46 WAITLIST OUTCOMES AFTER THE IMPLEMENTATION OF A NEW ALLOCATION SYSTEM FOR URGENT HEART TRANSPLANTATION IN ITALY
Alessandra Oliveti - Rome Italy
- 08:48-08:52 LIFE OF AN HEART FAILURE AND HEART TRANSPLANT CENTER IN THE COVID ERA : NEVER GIVE IN TO FEAR, USE TELEMEDICINE.
Marco Masetti - Bologna Italy
- 08:54-08:58 MYOCARDIAL SCAR BURDEN CORRELATES WITH CHANGES IN LEFT VENTRICULAR DIASTOLIC FUNCTION AND NT-PROBNP SERUM LEVELS IN HEART TRANSPLANT RECIPIENTS
Gregor Poglajen - Ljubljana Slovenia

- 09:00-09:04 *DECREASED CIRCULATING CD34+ CELL COUNT IS ASSOCIATED WITH CORONARY ALLOGRAFT VASCULOPATHY IN HEART TRANSPLANT RECIPIENTS*
Gregor Poglajen - Ljubljana Slovenia
- 09:06-09:10 *MONITORING LYMPHOCYTE SUBPOPULATIONS IN PERIPHERAL BLOOD IN HEART TRANSPLANT RECIPIENTS. A NEW TOOL TO DETECT CAV?*
Clara Simón Ramón - Barcelona Spain
- 09:12-09:16 *RISK FACTORS AND OUTCOMES OF ACUTE KIDNEY INJURY AFTER HEART TRANSPLANT*
Nicolina Conti - Bologna Italy
- 09:18-09:22 *THE RISK OF SKIN CANCER DOES NOT CORRELATE WITH VITAMIN D SERUM LEVELS IN HEART TRANSPLANT RECIPIENTS*
Gregor Poglajen - Ljubljana Slovenia

Focus Group Session

Tuesday, 31. August 2021

08:00 - 09:30
Room I - White 2

Clinical Cases: Surgical issues in kidney transplantation

Chair(s): Franco Citterio - Rome Italy
Robert Minnee - Rotterdam Netherlands

- 08:00-08:07 *BENCH SURGERY AND KIDNEY AUTO-TRANSPLANTATION IN RESCUE OF GERM-CELL RESIDUAL MASS. 3D MODELS UTILITY IN SURGICAL PLANNING*
VICTORIA GOMEZ - MADRID Spain
- 08:15-08:22 *THE USE OF 3D AUGMENTED REALITY DURING ROBOT-ASSISTED LIVING DONOR NEPHRECTOMY (RALDN): A CASE REPORT TECHNICAL OVERVIEW*
Riccardo Schiavina - Bologna Italy
- 08:30-08:37 *AN ALTERNATIVE WAY OF LAPAROSCOPIC PERITONEAL FENESTRATION BY USING A SECOND LAPAROSCOPE AND TRANSILLUMINATION TO MANAGE POST-TRANSPLANT LYMPHOCELES*
Vasileios Tatsis - Ioannina Greece
- 08:45-08:52 *BENCH THROMBOLYSIS AND "AUTO-TRANSPLANTATION" AS A RESCUE TREATMENT FOR VENOUS THROMBOSIS AFTER LIVING-DONOR KIDNEY TRANSPLANTATION*
Filippo Ghidini - Padua Italy
- 09:00-09:07 *THE USE OF EX VIVO NORMOTHERMIC PERFUSION TO REDUCE COLD ISCHAEMIC TIME IN A CASE OF DUAL KIDNEY TRANSPLANT FROM A DONOR OF ADVANCED AGE*
Robert Pearson - Glasgow United Kingdom
- 09:15-09:22 *FIBROMUSCULAR DYSPLASIA IN LIVING RENAL DONORS STILL A CHALLENGE TO KIDNEY TRANSPLANTATION: CASE REPORT AND REVIEW OF THE LITTERATURE*
RM ROSTAND EMMANUEL NGUEFOUET MOMO - Verona Italy

Brief Oral Session

Tuesday, 31. August 2021

08:00 - 09:30

Studio - ESOT Live
Studio

Organ perfusion, a platform to preserve, predict, and protect

Chair(s): Sarah Hosgood - Cambridge United Kingdom
Constantino Fondevila - Madrid Spain

08:00-08:05

MAGNETIC RESONANCE IMAGING TO ASSESS RENAL FLOW
DISTRIBUTION DURING EX VIVO NORMOTHERMIC MACHINE PERFUSION
Rianne Schutter - Groningen Netherlands

08:07-08:12

DONATION AFTER CIRCULATORY DEATH (DCD) STRATEGY IN ITALY: THE
BARRIER OF A PROLONGED NO-TOUCH PERIOD CAN BE OVERCOME
Lucia Masiero - Rome Italy

08:14-08:19

NORMOTHERMIC LIQUID VENTILATION ATTENUATES INFLAMMATION
FROM ISCHEMIA-REPERFUSION INJURY IN AN EX VIVO RAT MODEL
Helena M. Linge - Magdeburg Germany

08:21-08:26

NORMOTHERMIC MACHINE PERFUSION FACILITATES DELIVERY OF RNA
INTERFERENCE THERAPEUTICS IN DONOR KIDNEYS
Emily Thompson - Newcastle-Upon-Tyne United Kingdom

08:28-08:33

TREATING CIRCULATORY DEATH DONOR KIDNEYS WITH ANTI-FIBROTIC
DRUGS USING EX VIVO PRECISION CUT KIDNEY SLICES
Leonie van Leeuwen - Groningen Netherlands

08:35-08:40

COMPLEMENT IS ACTIVATED DURING NORMOTHERMIC MACHINE
PERFUSION OF PORCINE AND DISCARDED HUMAN KIDNEYS
Leonie Venema - Zuidwolde Netherlands

08:42-08:47

NORMOTHERMIC REGIONAL PERFUSION VERSUS RAPID RECOVERY IN
CONTROLLED DONATION AFTER CIRCULATORY DEATH KIDNEY
TRANSPLANTATION
MARIA PADILLA - MADRID Spain

08:49-08:54

IMMUNE CELL PROFILING AND ASSESSMENT OF INFLAMMATORY
CYTOKINE LEVELS IN THE PERFUSATE DURING NORMOTHERMIC
MACHINE PERFUSION OF HUMAN LIVER ALLOGRAFTS
Margot Fodor - Innsbruck Austria

08:56-09:01

EXPLORING THE RELEASE OF EXTRACELLULAR VESICLES IN
PERFUSATE AND BILE AS AN ADDITIONAL TOOL TO UNRAVEL
MECHANISMS OF FUNCTION OF LIVER NMP.
Nicholas Gilbo - Leuven Belgium

09:03-09:08

METABOLIC AND IMMUNOLOGICAL ALTERATIONS IN NORMOTHERMIC
MACHINE PERFUSION OF THE LIVER AS COMPARED TO STATIC COLD
STORAGE
Maria Letizia Lo Faro - Oxford United Kingdom

- 09:10-09:15 *MICROVASCULAR OBSTRUCTIONS IN PORTAL BILE DUCT CAPILLARIES
AND HEPATIC SINUSOIDS DURING NORMOTHERMIC MACHINE
PERFUSION OF MARGINAL HUMAN LIVERS*
 Samuel Tingle - Newcastle-Upon-Tyne United Kingdom
- 09:17-09:22 *RE-WRITING THE DEFINITION OF HIGH-RISK AND FUTILE DCD LIVER
TRANSPLANTATION WITH NRP*
 Ahmed E Sherif - Edinburgh United Kingdom

Plenary

Tuesday, 31. August 2021

10:00 - 11:30
Room A - Silver

Re-deploying resources in the era of SARS-CoV-2

Chair(s): Massimo Cardillo - Rome Italy
Vassilios Papalois - London United Kingdom

What lessons can the transplant community learn from the ongoing COVID-19 pandemic so that we might prepare for the future? How can we continue to provide transplant activities at a time when healthcare systems are stretched to their limits? Furthermore, how can we use these learnings to help inform government policy and decision-making processes?

10:00-10:10

Introduction

-

10:10-10:25

Facing crisis: The need for a modelling approach
Glenn Bonney - Singapore Singapore

10:25-10:40

Lessons learned from the management of the emergency: How to move forward the normality
Massimo Puoti - Milan Italy

10:40-10:55

Safety and efficacy of vaccination in the transplant population
Dorry Segev - Baltimore United States

10:55-11:10

EU centrality in reshaping and relaunching the health system
Stefaan van der Spiegel - Brussels Belgium

11:10-11:30

Discussion

-

State of the Art

Tuesday, 31. August 2021

11:45 - 13:15

Room B -
Auditorium

Living donation in liver transplantation: Re-emerging?

Chair(s): *Stefan Schneeberger - Innsbruck Austria*
Salvatore Gruttadauria - Palermo Italy

Living donation in liver transplantation is a story of medical achievement, cultural and social discrepancies, technical raffinesse and permanent ethical dilemma. The key question here is: can and should the 'Asian experience' – which is a result of high volume programmes with a profound dedication to detail, in systems with clear role definitions, well equipped with personnel, and thoughtful patient selection – be adopted by Europe and the US on a broader scale?

11:45-11:50

Introduction

-

11:50-12:05

Achievements and limitations in living donor liver transplantation
SG Lee - Korea, Rep. of South

12:05-12:20

Risk minimisation in living donor living donation
Nancy Kwan Man - Hong Kong China

12:20-12:35

Living donation in westernised countries – too little too late?
Elizabeth Pomfret - Aurora United States

12:35-12:50

Is there a future for living donor living donation in Europe?
Raymond Reding - Brussels Belgium

12:50-13:15

Discussion

-

State of the Art

Tuesday, 31. August 2021

11:45 - 13:15
Room C - Yellow

Achieving 'person-centred' not 'patient-centred' care in the era of telemedicine

Chair(s): *Annette Lennerling - Gothenburg Sweden
Frank Dor - London United Kingdom*

The concept of 'patient-centred care' is now well established. However this session will explore the important emerging theme of 'person-centred care' and will examine how it differs from 'patient-centred' care from the perspective of health professionals and transplant recipients. We will explore how new technologies are enabling this process.

11:45-12:03

*Being there or being with: The challenge of telemedicine and digital encounters
Angeliki Gkouziouta - Kallithea Greece*

12:03-12:21

*Ready for prime time: The art and science of person-centred care
Anna Forsberg - Lund Sweden*

12:21-12:39

*It takes two to tango: The importance of partnership
Fiona Loud - Alton United Kingdom*

12:39-12:57

*Who is going to serve as 'patient data manager'?
Jessica Morley - Oxford United Kingdom*

12:57-13:15

Discussion
-

Critical Review

Tuesday, 31. August 2021

11:45 - 13:15
Room D - Green

Weighing up tumour biology aggressiveness in clinical decisions for SOT candidates

Chair(s): *Maria Reig - Spain*
Vincenzo Mazzaferro - Milano Italy

In the era of biomolecular stratification of cancer-related aggressiveness and prognosis, this session will critically discuss some essential topics: (a) the relevance of evidence gained from research in scoring systems/biomarkers/molecular signatures and how the evidence supports decision making when considering adding a patient to the transplant waiting list (or whether organs from donors with malignancies can be used); (b) pushing the limits: cancer as an indication for transplantation (HCC, CCA, CRLM); (c) current strategies for the safe management of immunosuppression in SOT recipients with cancer; (d) safety of immunotherapy and chemotherapy in SOT recipients with cancer

11:45-12:05 *Biological stratification of previous tumour history: Liquid biopsy, biomarkers, and molecular signature*

Karim Halazun - New York United States

12:05-12:25 *Biological prediction in liver transplant oncology: A spotlight on CRLM and other tumours*

RA René Adam - Paris France

12:25-12:45 *Should immunosuppressive therapy be stopped or modified after a cancer diagnosis in the transplant patients?*

Edward K. Geissler - Wenzelbach Germany

12:45-13:05 *Chemotherapy and immunotherapy: Which drugs can be safely used in SOT?*

Umberto Maggiore - Parma Italy

13:05-13:15 *Discussion*

-

State of the Art

Tuesday, 31. August 2021

11:45 - 13:15

Room E - Orange

Immune repertoires: Prototypes for precision transplantation

Chair(s): *Elke Eggenhofer - Ihrlersstein Germany*
Antoine Roux - Suresnes France

The repertoires of specific T and B cells are still the centre of alloreactivity in SOT. The repertoires in blood represent only a small fraction of the circulating repertoire – and some organs, such as the liver and lung, have their own tissue-resident immune compartment. In these organs, a local chimerism may generate a special microenvironment that impinges on alloreactivity and rejection. Beyond the blood, immune repertoires are now also defined from biopsy tissue – and provide novel insights into the local chimerism – at least for some organs.

11:45-12:05

Signatures and specificity of lymphocytes in the human kidney
Katja Kotsch - Berlin Germany

12:05-12:20

Immune repertoires: The T&B puzzle
Gavin Pettigrew - Cambridge United Kingdom

12:20-12:35

The missing self repertoire
Olivier Thaunat - Lyon France

12:35-12:50

Tolerance approaches
Nina Pilat - Vienna Austria

12:50-13:15

Discussion
 -

Full Oral Session

Tuesday, 31. August 2021

11:45 - 13:15

Room G - Turquoise
2

Tackling solid organ injury via drugs or cells

Chair(s): Maria Kaisar - Oxford United Kingdom

11:45-11:54

THE GENETIC DELETION OF THE DUAL SPECIFICITY PHOSPHATASE 3 (DUSP3) ATTENUATES KIDNEY DAMAGE FOLLOWING ISCHEMIA/REPERFUSION IN MOUSE

Badr Khbouz - Liège Belgium

11:56-12:05

H2S ENRICHED FLUSH-OUT IN DBD AND NON-DBD PORCINE KIDNEYS
Hanno Maassen - Groningen Netherlands

12:07-12:16

PATTERNS AND INHIBITION OF CELL DEATH DURING STATIC COLD STORAGE OF HUMAN KIDNEYS

Jenna DiRito - New Haven United States

12:18-12:27

COMBINED DRUGS APPROACH TO PREVENT ISCHEMIA-REPERFUSION INJURY DURING TRANSPLANTATION OF LIVERS (CAPITL): RESULTS OF A RANDOMIZED CONTROLLED TRIAL

Nicolas Meurisse - Liege Belgium

12:29-12:38

DONOR SIMVASTATIN TREATMENT IS SAFE AND IMPROVES OUTCOMES AFTER LIVER TRANSPLANTATION: A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL.

Duilio Pagano - Palermo Italy

12:40-12:49

MODIFIED IMMUNE CELL (MIC) INFUSION IN KIDNEY TRANSPLANTATION
Christian Morath - Heidelberg Germany

12:51-13:00

CHARACTERISATION OF DISTINCT GRAFT INFILTRATES FOLLOWING REGULATORY T CELL THERAPY IN KIDNEY TRANSPLANT RECIPIENTS

Matthew Brook - Oxford United Kingdom

13:02-13:11

LONG TERM FOLLOW-UP OF LIVER TRANSPLANT RECIPIENTS AFTER ALLOGENEIC MESENCHYMAL STROMAL CELL INFUSION

Morgan Vandermeulen - Liege Belgium

Focus Group Session

Tuesday, 31. August 2021

11:45 - 13:15
 Room H - White 1

Navigating follow-up after heart transplantation: My course is set for an uncharted sea

Chair(s): Stephen Pettit - Cambridge United Kingdom
 Hannah Valantine - Stanford United States

- 11:45-11:52 *MULTICENTER ITALIAN STUDY ON DURABLE RADIAL MECHANICALLY ASSISTED CIRCULATORY SUPPORT (MIRAMACS): ENCOURAGING LONG-TERM OUTCOMES*
Antonio Loforte - Bologna Italy
- 12:00-12:07 *DEVELOPMENT AND VALIDATION OF SPECIFIC POST-HEART TRANSPLANT RISK SCORES ACCORDING TO THE CIRCULATORY SUPPORT STATUS AT TRANSPLANT*
Guillaume Coutance - Paris France
- 12:15-12:22 *CORE SIGNATURE OF REJECTION-SPECIFIC CYTOKINES AND CHEMOKINES IN HEART BIOPSIES AFTER TRANSPLANTATION*
Lena Radomsky - Hannover Germany
- 12:30-12:37 *ECHOCARDIOGRAPHIC ASSESSMENT OF THE LEFT ATRIUM FOR CATEGORIZATION OF LEFT VENTRICULAR DIASTOLIC FUNCTION IN HEART TRANSPLANT RECIPIENTS*
Tímea Teszák - Budapest Hungary
- 12:45-12:52 *CARDIAC COMPUTED TOMOGRAPHY ANGIOGRAPHY FOR THE SCREENING OF CARDIAC ALLOGRAFT VASCULOPATHY, TWO YEARS OF EXPERIENCE*
Stefan Roest - Rotterdam Netherlands
- 13:00-13:07 *SUDDEN CARDIAC DEATH AFTER HEART TRANSPLANTATION: A POPULATION BASED STUDY*
Guillaume BONNET - Paris France

Focus Group Session

Tuesday, 31. August 2021

11:45 - 13:15
Room I - White 2

Hot issues in living kidney donation

Chair(s): Marta Crespo - Barcelona Spain

- 11:45-11:52 *DONATING A KIDNEY TO A STRANGER: ARE HEALTHCARE PROFESSIONALS FACILITATING THE JOURNEY? RESULTS FROM THE BOUND STUDY*
Hannah Maple - London United Kingdom
- 12:00-12:07 *HOW GOOD IS A LIVING DONOR? THE EFFECT OF DONOR DEMOGRAPHICS ON POST KIDNEY TRANSPLANT OUTCOMES*
Maria Irene Bellini - Rome Italy
- 12:15-12:22 *IMPACT OF MEASURED VERSUS ESTIMATED GFR ON LIVING KIDNEY DONOR SELECTION: A MULTICENTER COHORT STUDY*
Jessica van der Weijden - Groningen Netherlands
- 12:30-12:37 *PREDICTION OF RENAL OUTCOMES IN LIVING KIDNEY DONORS USING CROSS-VALIDATED LOGISTIC REGRESSION*
Florian Westphal - Muenster Germany
- 12:45-12:52 *CHANGES IN KIDNEY FUNCTION AFTER LIVING DONOR NEPHRECTOMY: A TWO-DECADE SINGLE CENTER EXPERIENCE*
Bb Barbara Buscemi - Palermo Italy
- 13:00-13:07 *A DYNAMIC MARKOV MODEL TO ASSESS THE COST-EFFECTIVENESS OF THE KIDNEY TEAM AT HOME INTERVENTION IN THE NETHERLANDS*
Steef Redeker - Voorschoten Netherlands

Brief Oral Session

Tuesday, 31. August 2021

11:45 - 13:15

Studio - ESOT Live
Studio

Clinical aspects of kidney rejection

Chair(s): *Andrea Collini - Siena Italy*
Ina Jochmans - Leuven Belgium

11:45-11:49

INCIDENCE AND PREDICTORS OF FAILED KIDNEY ALLOGRAFT INTOLERANCE SYNDROME

Carolina Ormonde - Ponta Delgada Portugal

11:51-11:55

TRANSPLANTECTOMY VERSUS NON-TRANSPLANTECTOMY AFTER FAILED KIDNEY TRANSPLANT. A SYSTEMATIC REVIEW AND META-ANALYSIS.

Paschalis Gavriilidis - Coventry United Kingdom

11:57-12:01

ASSOCIATION BETWEEN DECEASED DONOR ACUTE KIDNEY INJURY ASSESSED BY BASELINE SERUM CREATININE BACK-ESTIMATION AND GRAFT SURVIVAL

Rémi Lenain - Lille France

12:03-12:07

CLINICAL AND IMMUNOLOGICAL FOLLOW-UP OF VERY LONG-TERM KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS

Amaury Dujardin - Nantes France

12:09-12:13

DEEP-LEARNING BASED PREDICTION OF CLINICAL ENDPOINTS IN RENAL PRE-IMPLANTATION BIOPSIES USING SLIDE-LEVEL LABELS

Ka Ho Tam - Oxford United Kingdom

12:15-12:19

MOLECULAR AND CELLULAR MECHANISMS OF LIPOCALIN-2 MEDIATED RENOPROTECTION IN KIDNEY TRANSPLANTATION

Anna Pfefferkorn - Berlin Germany

12:21-12:25

REVISITING THE CHANGES IN THE BANFF CLASSIFICATION FOR ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION

Jasper Callemeyn - Korbeek-Lo Belgium

12:27-12:31

INTERSTITIAL FIBROSIS IN PREIMPLANTATION KIDNEY BIOPSIES OF EXTENDED CRITERIA DONORS PREDICTS LONG-TERM GRAFT SURVIVAL.

Elisabetta Bussalino -

12:33-12:37

THREE-MONTH GRAFT FUNCTION OF KIDNEYS RETRIEVED 4.5 HOURS AFTER CIRCULATORY DEATH

Deepti Antony - Gothenburg Sweden

12:39-12:43

ENDOTHELIAL TO MYOFIBROBLAST TRANSITION (ENMT) AND CAPILLARY VEGF LOSS ENHANCES THE DEVELOPMENT OF INTERSTITIAL FIBROSIS AND GLOMERULOSCLEROSIS

Binnaz Handan Ozdemir - Ankara Turkey

- 12:45-12:49 *AGGRAVATION OF FIBRIN DEPOSITION AND MICROTHROMBUS
FORMATION WITHIN THE GRAFT DURING KIDNEY TRANSPLANTATION*
Tamar van den Berg - Groningen Netherlands
- 12:51-12:55 *HYPERLEPTINAEMIA AND LOW VALUES OF INTERLEUKIN 10 AS RISK
FACTORS FOR GRAFT REJECTION IN PROTOCOL BIOPSY AFTER KIDNEY
TRANSPLANTATION*
Ivana Dedinská - Příbovce Slovakia
- 12:57-13:01 *POST-TRANSPLANTATION EARLY BLOOD TRANSFUSION AND KIDNEY
ALLOGRAFT OUTCOMES: A SINGLE-CENTER OBSERVATIONAL STUDY*
Mehdi Maanaoui - Lille France

State of the Art

Tuesday, 31. August 2021

14:45 - 16:15
Room B -
Auditorium

Breaking scepticism in AI-aided clinical management

Chair(s): Oriol Bestard - Barcelona Spain

Artificial intelligence (AI) is poised to transform healthcare. Key ethical issues include accountability and transparency of decisions made by AI-based systems, the potential for group harm resulting from algorithmic bias, and the professional roles and integrity of physicians. Machine learning classifiers can be effectively applied for more accurate clinical prediction and data management, optimising principles of justice, efficiency and equity, such as genetics and imaging in transplants, especially in cases where subjectivity is common.

14:45-15:00

Systems medicine: Approach for developing novel therapeutic strategies
Patrick Aloy - Barcelona Spain

15:00-15:15

Application of Artificial Intelligence techniques for donor-receipient matching
Tommy Ivanics - Toronto Canada

15:15-15:30

Using Artificial Intelligence for diagnostics in transplantation.
Alexandre Loupy - France

15:30-15:45

Personalized survival predictions
Simon Knight - Oxford United Kingdom

15:45-16:15

Discussion
-

Full Oral Session

Tuesday, 31. August 2021

14:45 - 16:15
Room K - Red

Reducing the threat of infectious and cardiovascular disease after transplantation

Chair(s): Menna Clatworthy - Cambridge United Kingdom
Paolo Grossi - Varese Italy

- 14:45-14:54 MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AFTER KIDNEY TRANSPLANTATION: A POPULATION-COHORT ANALYSIS OF ENGLISH TRANSPLANT CENTRES
Benjamin Anderson - Birmingham United Kingdom
- 14:56-15:05 IMPACT OF EVEROLIMUS-TACROLIMUS COMBINATION ON CARDIOVASCULAR PARAMETERS EVALUATED BY CARDIAC-MRI. RESULTS FROM A PILOT RANDOMIZED CLINICAL TRIAL
Edoardo Melilli - Barcelona Spain
- 15:07-15:16 PHASE 3 OPEN-LABEL STUDY OF MARIBAVIR FOR REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS: SUBGROUP ANALYSES BY ORGAN TYPE
Nassim Kamar - Saubens France
- 15:18-15:27 SURVEILLANCE AND TREATMENT OF HUMAN HERPESVIRUS 8 IN TRANSPLANT RECIPIENTS: A STRICT PROTOCOL TO BRING MORTALITY TOWARD ZERO
alessandra mularoni - Palermo Italy
- 15:29-15:38 MTOR INHIBITORS PREVENT CMV INFECTION THROUGH THE RESTORATION OF FUNCTIONAL AB AND $\Gamma\Delta$ T CELLS IN KIDNEY TRANSPLANTATION
hannah kaminski - Bordeaux France
- 15:40-15:49 PRECISION MEDICINE IN TRANSPLANTATION: MAGNITUDE, DURATION, AND IMPACT OF CMV VIREMIA ON GRAFT AND MORTALITY OUTCOMES
Paul A Keown - Vancouver Canada
- 15:51-16:00 POST-HOC ANALYSIS OF THE CAVIAR STUDY: DO SHORT-TERM BENEFITS OF LIFESTYLE INTERVENTION TRANSLATE TO LONG-TERM BEHAVIOUR CHANGE AT 3-YEARS?
Joanne Driscoll - Birmingham United Kingdom
- 16:02-16:11 BARIATRIC SURGERY COMPROMISES MACROPHAGE DRIVEN ALLOIMMUNITY IN OBESE TRANSPLANT RECIPIENTS
Jasper Iske - Boston United States

Think Tank

Tuesday, 31. August 2021

14:45 - 16:15
Room C - Yellow

Consensus process on how to measure value in liver transplantation: Which methodology and which endpoints? The start up

Chair(s): *Umberto Cillo - Padova Italy*
Mario Strazzabosco - Hamden United States

Current healthcare systems are still diffusely linked to a pay per procedure methodology. Such an approach is associated to a high risk to reduce the efficiency of the systems to achieve their value based goals. That is particularly relevant in the context of limited resource environments as in transplantation. The concept of 'value-based healthcare' (VBHC) has been recently proposed with the ambition to maximise outcomes achieved per resources spent. The implementation of VBHC is particularly relevant in organ transplantation, which represents a costly procedure offered to a minority of highly selected patients with end-stage organ disease. However, there is no agreed definition of what value means (for whom) in the health context in general and in particular in the transplantation area (e.g. survival, quality adjusted life years etc.)

14:45-14:53

Why agreeing on value endpoints matters
Umberto Cillo - Padova Italy

14:53-15:01

Value-based care, a compass to guide healthcare decisions in liver transplantation
Mario Strazzabosco - Hamden United States

15:01-15:09

Understand and measure shared health needs of patients
Anna Forsberg - Lund Sweden

15:09-15:17

Measuring organ donation: mission impossible?
Nichon Jansen - Leiden Netherlands

15:17-15:27

Models and metrics to evaluate organ transplantation – the UK experience
James Neuberger - Winchcombe United Kingdom

15:27-15:37

Guiding metrics for European healthcare systems
Beatriz Dominguez-Gil - Madrid Spain

15:37-15:47

A proposed framework to improve value in liver transplantation
Marco Carbone - Monza Italy

15:47-16:15

Discussion Panel

Marco Carbone - Monza Italy

Umberto Cillo - Padova Italy

Beatriz Dominguez-Gil - Madrid Spain

Anna Forsberg – Lund Sweden

Contantino Fondevila – Madrid Spain

Nichon Jansen - Leiden Netherlands

James Neuberger - Winchcombe United Kingdom

Wojciech Polak – Rotterdam Netherlands

Mario Strazzabosco - Hamden United States

State of the Art

Tuesday, 31. August 2021

14:45 - 16:15
Room D - Green

Cell-based therapies: From CARs to TRUCKs

Chair(s): *Birgit Sawitzki - Berlin Germany*
Martin Hoogduijn - Rotterdam Netherlands

Beyond the naturally developing repertoires of T and B cells, specificity can be achieved artificially by chimeric antigen receptors (CARs) transduced into different cell types (Treg, effector T cells, NK cells, and myeloid cells). The manipulation of immune responses towards tolerance would be the ultimate goal for organ transplantation. CARs have been developed for targeting haematological malignancies, but their potential was extended towards SOT, and the addition of cytokines pushes them further towards TRUCKs (T-cells redirected for universal cytokine killing)

14:45-15:03

Which REGs do you want?
Carla Baan - Rotterdam Netherlands

15:03-15:21

CAR therapies in SOT: How precise do they have to be?
Megan Levings - Vancouver Canada

15:21-15:39

Adaptive cell therapy approaches: Call for specificity
Alberto Sanchez-Fueyo - London United Kingdom

15:39-15:57

Therapeutic chimerism for kidney transplantation
Thomas Wekerle - Vienna Austria

15:57-16:15

Discussion
-

State of the Art

Tuesday, 31. August 2021

14:45 - 16:15
Room E - Orange

Cost-effectiveness and sustainability of abdominal machine perfusion: The elephant in the room

Chair(s): *Lucrezia Furian - Padova Italy*
Gabriel Oniscu - Edinburgh United Kingdom

Machine perfusion helps transplant professionals to evaluate donor organs, facilitate organ preservation and increase organ availability. However, this comes at a significant financial cost. The time has come to have an open discussion about the cost effectiveness and utility of the variety of approaches currently available with the aim of producing guidance for the whole transplant community.

14:45-15:05

Localised versus centralised model of service in machine perfusion: an economic evaluation
Luke Vale - Newcastle upon Tyne United Kingdom

15:05-15:25

How to establish whether a perfusion laboratory is a valid regional resource: Extending the benefit of modern therapies
Henri Leuvenink - Donderen Netherlands

15:25-15:45

National recommendations for perfusion machine use
C. A. Corinne Antoine - Saint Denis France

15:45-16:05

RCTs versus registries and endpoints versus benchmarks: The future of clinical research in organ perfusion
Paulo Martins - Worcester United States

16:05-16:15

Discussion
-

Focus Group Session

Tuesday, 31. August 2021

14:45 - 16:15

Room F - Turquoise
 1

Psychosocial aspects of transplantation

Chair(s): Hannah Maple - London United Kingdom
 Allison Tong - Sydney Australia

14:45-14:52

POSTTRAUMATIC GROWTH IN LIVER TRANSPLANT RECIPIENTS: RESULT
 OF A PROSPECTIVE COHORT STUDY

Coby Annema - Groningen Netherlands

15:00-15:07

VIEWS AND EXPERIENCES OF PATIENTS AWAITING A TRANSPLANT AND
 OF TRANSPLANTED PATIENTS: A NATIONAL SURVEY TO UNDERSTAND
 THEIR NEEDS

Lia Bellis - Rome Italy

15:15-15:22

PSYCHOLOGICAL FACTORS ASSOCIATED WITH MEDICATION
 NONADHERENCE IN KIDNEY TRANSPLANT PATIENTS

Rosie Heape - London United Kingdom

15:30-15:37

PSYCHOLOGICAL EVALUATION OF DIALYSIS PATIENTS AND KIDNEY
 TRANSPLANT RECIPIENTS DURING COVID-19

Sanem Cimen - Ankara Turkey

15:45-15:52

PSYCHOLOGICAL MORBIDITY AMONG LONG-TERM KIDNEY TRANSPLANT
 RECIPIENTS: A SINGLE CENTRE STUDY

Arcan Altinar - London United Kingdom

16:00-16:07

PSYCHOLOGICAL MORBIDITY ACROSS THREE KIDNEY TRANSPLANT
 PATIENT GROUPS: A SINGLE CENTRE COMPARATIVE STUDY

Antonia Cronin - London United Kingdom

Focus Group Session

Tuesday, 31. August 2021

<p>14:45 - 16:15 Room G - Turquoise 2</p>	<p>Improving techniques in liver transplantation: Chef's rules for better outcome <i>Chair(s): Amelia Hessheimer - Barcelona Spain</i> <i>Massimo Rossi - Rome Italy</i></p>
<p>14:45-14:52</p>	<p><i>RESULTS OF NON-ANATOMICAL REDUCTION COMPARED TO STANDARD LEFT LATERAL SECTION IN PEDIATRIC LIVER TRANSPLANTATION</i> <i>Aliaksei Shcherba - Minsk Belarus</i></p>
<p>15:00-15:07</p>	<p><i>BILIARY RECONSTRUCTION USING HIGH BILIARY RADICAL IS SAFE OPTION FOR MULTIPLE GRAFT BILE DUCT IN RIGHT LOBE LIVING DONOR LIVER TRANSPLANTATION</i> <i>JOODONG KIM - Daegu Korea, Rep. of South</i></p>
<p>15:15-15:22</p>	<p><i>RE-THINKING OF T-TUBE USE AT WHOLE LIVER TRANSPLANTATION: AN ANALYSIS ON THE RISK OF DELAYED GRAFT FUNCTION</i> <i>Riccardo Pravisani - Udine Italy</i></p>
<p>15:30-15:37</p>	<p><i>POST-LIVER TRANSPLANT INFERIOR VENA CAVA STENOSIS IN A LARGE VOLUME UK CENTRE.</i> <i>Fanourios Georgiades - Cambridge United Kingdom</i></p>
<p>15:45-15:52</p>	<p><i>PRE-LIVER TRANSPLANT MANAGEMENT OF NON-NEOPLASTIC PORTAL VEIN THROMBOSIS: A LONG TERM MONOCENTRIC EXPERIENCE</i> <i>Davide Cussa - Savigliano Italy</i></p>
<p>16:00-16:07</p>	<p><i>PHYSIOLOGICAL RECONSTRUCTIONS IN LIVER TRANSPLANTATION WITH NON-TUMORAL EXTENDED PORTAL VEIN THROMBOSIS: RESULTS AT TWO LARGE VOLUME CENTRES</i> <i>Domenico Pinelli - Villongo (Bergamo) Italy</i></p>

Brief Oral Session

Tuesday, 31. August 2021

14:45 - 16:15
Room H - White 1

De novo cancer in transplant patients: knowledge is power

Chair(s): Annemarie Weissenbacher - Innsbruck Austria
Jacopo Romagnoli - Rome Italy

- 14:45-14:49 *MALIGNANCIES BEFORE AND AFTER HEART TRANSPLANTATION – A SINGLE-CENTRE LONG-TERM OUTCOME STUDY*
Caroline Stenman - Gothenburg Sweden
- 14:51-14:55 *CANCER TRANSMISSIONS AND NON-TRANSMISSIONS FROM SOLID ORGAN TRANSPLANTATION: AN AUSTRALIAN COHORT STUDY*
James Hedley - Sydney Australia
- 14:57-15:01 *SURVIVAL WITH TABELCLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER SOLID ORGAN TRANSPLANT*
S Prockop - New York, NY United States
- 15:03-15:07 *DONOR-TRANSMITTED CANCERS: THE SPANISH EXPERIENCE*
Beatriz Dominguez-Gil - Madrid Spain
- 15:09-15:13 *SERIOUS ADVERSE EVENTS (SAE) AND SERIOUS ADVERSE REACTIONS (SAR) REPORTING IN GERMANY FROM 2016-2020: ANALYSIS OF DONOR-TRANSMITTED MALIGNANCY.*
Klaus Böhler - Frankfurt Germany
- 15:15-15:19 *HETEROGENEOUS INFLUENCE OF DIFFERENT FORMS OF POST-TRANSPLANT DE NOVO CANCER ON SURVIVAL OF KIDNEY GRAFTS – A COLLABORATIVE TRANSPLANT STUDY REPORT*
Christian Unterrainer - Heidelberg Germany
- 15:21-15:25 *POST-TRANSPLANT MALIGNANCIES AFTER PANCREAS TRANSPLANTATION: INCIDENCE AND IMPLICATIONS ON LONG-TERM OUTCOME FROM A SINGLE-CENTER PERSPECTIVE*
FJK Felix Julius Krendl - Innsbruck Austria
- 15:27-15:31 *T AND B CELL ABUNDANCE ARE STRONGLY REDUCED IN THE IMMUNE MICROENVIRONMENT OF POST-TRANSPLANT MALIGNANCIES*
Simon Schran - Cologne Germany
- 15:33-15:37 *IMPACT OF CANCER ON THE RISK OF DEATH AMONG ITALIAN KIDNEY TRANSPLANT RECIPIENTS WITH A FUNCTIONING GRAFT: ITALIAN TRANSPLANT & CANCER COHORT STUDY*
Pierluca Piselli - ROMA Italy
- 15:39-15:43: *MANAGEMENT OF THE KIDNEY TRANSPLANT PATIENT WITH CANCER”: REPORT FROM A CONSENSUS CONFERENCE.*
Gionata Spagnoletti - Rome Italy

- 15:45-15:49 *RETROSPECTIVE STUDY OF NEOPLASM TRANSMISSION FROM ORGAN DONOR TO RECIPIENT*
Helena Martí Grífol - Barcelona Spain
- 15:51-15:55 *POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN KIDNEY TRANSPLANT RECIPIENTS: A SINGLE CENTER STUDY*
STATHIS TSIAKAS - ATHENS Greece
- 15:57-16:01 *DISTINCT IMPACT OF POSTTRANSPLANT MALIGNANCIES AND MORTALITY IN DIFFERENT IMMUNOSUPPRESSIVE THERAPY PROTOCOLS BASED- PERIODS IN A LONG-TERM FOLLOW-UP*
Ignacio Revuelta - Barcelona Spain
- 16:03-16:07 *PREVALENCE AND CLINICAL SIGNIFICANCE OF PANCREATIC CYSTIC LESIONS IN IMMUNOSUPPRESSED PATIENTS WITH SOLID ORGAN TRANSPLANTATION*
Young-dong Yu - Seoul Korea, Rep. of South

Focus Group Session

Tuesday, 31. August 2021

14:45 - 16:15
Room I - White 2

Recipient challenges in liver transplantation: May the force be with you

Chair(s): Fabrizio Di Benedetto - Modena Italy
Christophe Duvoux - Chatenay Malabry France

- 14:45-14:52 *EFFECT OF PRE-TRANSPLANT SARCOPENIA ON THE ESTIMATION OF STANDARD LIVER VOLUME IN LIVING-DONOR LIVER TRANSPLANT CANDIDATES*
Riccardo Pravisani - Udine Italy
- 15:00-15:07 *A PROSPECTIVE ANALYSIS OF CLINICAL FRAILTY ASSESSMENT AND TELOMERE LENGTH IN A NATIONAL COHORT OF LIVER TRANSPLANT CANDIDATES*
Sinead Cremen - Dublin Ireland
- 15:15-15:22 *FAST-TRACK LIVER TRANSPLANTATION: 100 MONTHS OF A FULL-FLEDGED ERAS PROTOCOL*
Gonzalo Rodríguez-Laiz - Alicante Spain
- 15:30-15:37 *ARE WE READY FOR BARIATRIC SURGERY IN A LIVER TRANSPLANT PROGRAM? A META-ANALYSIS*
Victor López-López - Murcia Spain
- 15:45-15:52 *RISKS FACTORS FOR CHRONIC RENAL DYSFUNCTION IN LIVER TRANSPLANTED PATIENTS WITH DONOR AFTER CIRCULATORY DEATH: GENEVA SINGLE CENTER EXPERIENCE*
Daina Sapovalova - Geneva Switzerland
- 16:00-16:07 *THE IMPACT OF HEPATIS-C VIRUS DIRECT ACTING AGENTS IN LIVER TRANSPLANTATION USING VERY OLD DONOR GRAFTS: A SINGLE CENTER ANALYSIS*
fabio melandro - Pisa Italy

Brief Oral Session

Tuesday, 31. August 2021

- 14:45 - 16:15**
Studio - ESOT Live
Studio
- Strategies to improve quality and duration of life after kidney and liver transplantation**
Chair(s): Silvio Nadalin - Tübingen Germany
- 14:45-14:49 *MAXIMIZE THE USE OF ARTIFICIAL INTELLIGENCE IN ORGAN DONATION AND TRANSPLANTATION MANAGEMENT TO IMPROVE EFFICACY AND SAFETY*
Wenshi Jiang - Shenzhen China
- 14:51-14:55 *OUTPATIENT URETERIC STENT REMOVAL FROM KIDNEY TRANSPLANT RECIPIENTS USING ISIRIS IS FEASIBLE, SAFE AND COST-EFFECTIVE*
Fanourios Georgiades - Cambridge United Kingdom
- 14:57-15:01 *MULTILINEAR EGFR PROGRESSION PATTERN IS ASSOCIATED WITH GRAFT FAILURE IN KIDNEY TRANSPLANT RECIPIENTS*
Ruth Rahamimov - Petach Tikva Israel
- 15:03-15:07 *PERSPECTIVES OF AUTOLOGOUS BLOOD TRANSFUSION AS A TOOL FOR PREVENTING IMMUNIZATION DURING NATIVE KIDNEY NEPHRECTOMY IN WAITING LIST CANDIDATES*
Magdalena Jankowska - Gdansk Poland
- 15:09-15:13 *QUALITY OF LIFE AFTER LIVER TRANSPLANTATION, A CROSS-SECTIONAL SINGLE CENTRE STUDY.*
MV Mathias Vidgren - Stockholm Sweden
- 15:15-15:19 *QUALITY OF LIFE AND FATIGUE IN DE NOVO LIVER TRANSPLANT RECIPIENTS; 24-MONTH RESULTS FROM A MULTI-CENTER OPEN LABEL, RANDOMIZED CONTROLLED STUDY*
Midas Mulder - Rotterdam Netherlands
- 15:21-15:25 *COMPARING RENAL FUNCTION IN LT RECIPIENTS WITH LOW-DOSE TACROLIMUS AND SIROLIMUS VERSUS NORMAL-DOSE TACROLIMUS, A MULTICENTER RCT; 24-MONTH RESULTS*
Midas Mulder - Rotterdam Netherlands
- 15:27-15:31 *CLIF-C ACLF SCORE DOES NOT PREDICT SURVIVAL AFTER LIVER TRANSPLANTATION IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE*
Joris Blondeel - Leuven Belgium
- 15:33-15:37 *LIVER TRANSPLANTATION IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE: A SINGLE CENTRE EXPERIENCE*
Joris Blondeel - Leuven Belgium
- 15:39-15:43 *VARIOUS SELECTION CRITERIA FOR PRETRANSPLANT MYOSTEATOSIS AND THEIR VALUE IN THE ASSESSMENT OF SHORT- AND LONG-TERM OUTCOMES FOLLOWING OLT*
Zoltan Czigany - Aachen Germany

- 15:45-15:49 *ULTRA-LONG-TERM OUTCOME AND ITS DETERMINANTS AFTER LIVER TRANSPLANTATION IN ADULTS*
Laura Boer - Groningen Netherlands
- 15:51-15:55 *THERAPEUTIC ANTICOAGULATION IN PREVENTION OF RECURRENT PORTAL VEIN THROMBOSIS AFTER LIVER TRANSPLANTATION: UTILITY OR FUTILITY?*
Michel Rayar - Rennes France
- 15:57-16:01 *A PHOTOGRAPH OF PATIENTS APPROACHING LIVER TRANSPLANTATION: ASSESSMENT OF THE PSYCHOLOGICAL OUTCOME PREDICTORS*
Marco Valente - Bologna Italy
- 16:03-16:07 *AN ECONOMIC EVALUATION OF THE COST OF COMPLICATIONS FOLLOWING LIVER TRANSPLANTATION IN THE UK NATIONAL HEALTH SYSTEM*
Dimitri A. Raptis - London United Kingdom

Hands-on Course

Tuesday, 31. August 2021

16:45 - 18:15
Z2 - Edu Zone |
Hands-on

Machine perfusion lab 2.0. - Wet Lab (Course 2)

Chair(s): -

12 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow steps of organ perfusion of kidney, liver and lung.

Additional registration to this session is required. Please register via congress website: <https://www.esotcongress.org/registrations>

Full Oral Session

Tuesday, 31. August 2021

16:45 - 18:15
Room A - Silver

Organ perfusion, current and future outcomes

Chair(s): Christopher Watson - Cambridge United Kingdom
Ina Jochmans - Leuven Belgium

- 16:45-16:54 *NORMOTHERMIC REGIONAL PERFUSION OR NORMOTHERMIC MACHINE PERFUSION IN LIVER TRANSPLANTATION FROM DONATION AFTER CIRCULATORY DEATH*
Kayvan Mohkam - Lyon France
- 16:56-17:05 *ADMINISTRATION OF GALINISERTIB DURING NORMOTHERMIC MACHINE PERFUSION POTENTIALLY PROTECTS DONATION AFTER CIRCULATORY DEATH DONOR KIDNEYS*
Leonie van Leeuwen - Groningen Netherlands
- 17:07-17:16 *GRAFT UTILIZATION AFTER NORMOTHERMIC REGIONAL PERFUSION IN CONTROLLED DONATION AFTER CIRCULATORY DEATH - 5-YEAR EXPERIENCE FROM FRANCE*
Xavier Muller - Lyon France
- 17:18-17:27 *HYPOTHERMIC OXYGENATED MACHINE PERFUSION (HOPE) IN LIVER TRANSPLANTATION FOR EXPANDED CRITERIA DONOR GRAFT: SINGLE CENTER EXPERIENCE*
Luca Perin - Padova Italy
- 17:29-17:38 *A RANDOMIZED CONTROLLED TRIAL OF DUAL HYPOTHERMIC OXYGENATED MACHINE PERFUSION IN DONATION AFTER CIRCULATORY DEATH LIVER TRANSPLANTATION*
Rianne van Rijn - Groningen Netherlands
- 17:40-17:49 *VIABILITY TESTING DURING EX VIVO NORMOTHERMIC MACHINE PERFUSION OF THE PORCINE LIVER BY ANALYSIS OF MITOCHONDRIAL RESPIRATION*
Julia Hofmann - Innsbruck Austria
- 17:51-18:00 *DISCARDED LIVERS TRANSPLANTED AFTER NORMOTHERMIC PERFUSION: A NEW FRONTIER TO REDUCE WAITLIST MORTALITY*
Cristiano Quintini - Cleveland United States
- 18:02-18:11 *SELECTIVE USE OF EX-SITU MACHINE PERFUSION AFTER NORMOTHERMIC REGIONAL PERFUSION IN LIVER TRANSPLANTATION FROM DONATION AFTER CIRCULATORY DEATH*
Stefania Camagni - Carate Brianza Italy

Full Oral Session

Tuesday, 31. August 2021

16:45 - 18:15

Room B -
Auditorium

Frontiers in kidney immunosuppression

Chair(s): Menna Clatworthy - Cambridge United Kingdom
Klemens Budde - Berlin Germany

16:45-16:54

IMMUNE RESPONSES FOLLOWING TOCILIZUMAB THERAPY TO
DESENSITIZE HLA-SENSITIZED KIDNEY-TRANSPLANT CANDIDATES
TJ Thomas Jouve - Grenoble France

16:56-17:05

TOCILIZUMAB AS FIRST-LINE THERAPY FOR CHRONIC/ACTIVE ANTIBODY
MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENT: 12 MONTHS
MONOCENTRIC EXPERIENCE
Marco Busutti - Bologna Italy

17:07-17:16

CLINICAL TRANSLATION OF CD40-CD154 PATHWAY CO-STIMULATION
BLOCKADE IN SOLID ORGAN TRANSPLANTATION
James Rush -

17:18-17:27

IMPAIRED FLU-SPECIFIC MEMORY B CELL RESPONSE AFTER INFLUENZA
VACCINATION IN BELATACEPT-TREATED KIDNEY TRANSPLANT
RECIPIENTS
Vincent Pernin - Montpellier France

17:29-17:38

BRINGING A PHARMACOKINETIC POPULATION MODEL INCLUDING
PHARMACOGENETICS INTO CLINICAL PRACTICE TO OPTIMIZE
TACROLIMUS DOSAGE IN RENAL TRANSPLANTATION
Nuria Lloberas - BARCELONA Spain

17:40-17:49

TOCILIZUMAB EVALUATION IN DESENSITIZATION BEFORE KIDNEY
TRANSPLANTATION AS AN ADD-ON TO APHERESIS: THE TETRA STUDY
TJ Thomas Jouve - Grenoble France

17:51-18:00

OUTCOMES OF RABBIT ANTI-THYMOCYTE GLOBULIN VERSUS IL-
2 RA INDUCTION THERAPIES IN 2DR MISMATCH RENAL TRANSPLANT
RECIPIENTS
Hatem Ali - Coventry United Kingdom

18:02-18:11

HAEMATOLOGICAL AUTOIMMUNE DISORDERS FOLLOWING
ALEMTUZUMAB INDUCTION FOR KIDNEY TRANSPLANT
sarah Gleeson - London United Kingdom

Special Session

Tuesday, 31. August 2021

16:45 - 17:45
Room J - Blue

Science Slam Symposium

Chair(s): Gabriel Oniscu - Edinburgh United Kingdom
Susanne Behlke - Staines-Upon-Thames United Kingdom

16:45-16:50	Session introduction -
16:50-16:56	IMMUNOLOGIC AND FUNCTIONAL PREDICTORS OF ECP RESPONSE IN HEART TRANSPLANTATION (HTX) CA Cristiano Amarelli - Naples Italy
16:56-17:02	ECP TREATMENT OF CHRONIC HUMORAL REJECTION IN CARDIAC TRANSPLANTATION: EXPLORING IMMUNOMODULATION BY EXOSOMES Johanne Hjort Baatrup - Aarhus N Denmark
17:02-17:08	THE INFLUENCE OF ECP INDUCTION THERAPY ON CIRCULATING AND TISSUE BIOMARKERS AFTER HEART TRANSPLANTATION Johannes Goekler - Vienna Austria
17:08-17:14	SCANDINAVIAN REGISTRY FOR EXTRA CORPORAL PHOTOPHERESIS IN LUNG TRANSPLANTATION Michael Perch - Copenhagen Denmark
17:14-17:30	ECP Immunomodulation Award in SOT: questions from jury members Christian Benden - Zurich Switzerland Nina Pilat - Vienna Austria Luciano Potena - Bologna Italy Raj Thuraisingham - London United Kingdom Andreas Zuckermann - Vienna Austria
17:30-17:45	Winner announcement and award ceremony -

Real-life clinical decision making

Tuesday, 31. August 2021

16:45 - 18:15
Room C - Yellow

Do cholangiocarcinoma and colorectal metastases really enter into the picture?

Chair(s): *Umberto Cillo - Padova Italy*
Solange Peters - Switzerland

Thanks to the increase in the donor pool and recent therapeutic advances, liver transplantation has been cautiously extended to patients with other primary or secondary liver neoplasms: colorectal liver metastases and cholangiocarcinoma are among the most relevant new indications. Current results are promising but we must, however, avoid compromising patients awaiting liver transplantation for chronic liver disease.

16:45-16:52

Clinical case presentation: Colorectal liver metastases
Carlo Sposito - Milan Italy

16:52-17:07

Selecting candidates and donors for liver transplantation in colorectal liver metastases
Pal-Dag Line - Asker Norway

17:07-17:14

Clinical case presentation: Cholangiocarcinoma
Quirino Lai - Rome Italy

17:14-17:29

Intrahepatic cholangiocarcinoma
Gonzalo Sapisochin - Toronto Canada

17:29-17:44

Perihilar cholangiocarcinoma
Eric Vibert - Paris France

17:44-17:59

Chemotherapy strategy in transplant oncology
Christophe Tournigand - Paris France

17:59-18:13

Discussion
-

Real-life clinical decision making

Tuesday, 31. August 2021

16:45 - 18:15
Room D - Green

Strategies for mechanical support in acute heart and lung failure: Bridge over troubled waters

Chair(s): Stephen Pettit - Cambridge United Kingdom
Mauro Rinaldi - Torino Italy

Many devices are available to support the circulation or gas exchange, and these can be used as a bridge to transplantation in patients with advanced heart or lung failure. These devices are complex, have significant adverse event rates and are not appropriate in every patient. This session will explore the types of device that are available and use clinical cases to demonstrate when their use may be beneficial.

16:45-16:50

Case part 1: mechanical support in acute heart and lung failure
David Schibilsky - Freiburg Germany

16:50-17:05

Extracorporeal life support protocols: Use of portable ECMO for out-of-hospital cardiac arrest
Wiebke Sommer - Heidelberg Germany

17:05-17:10

Case part 2: mechanical support in acute heart and lung failure
David Schibilsky - Freiburg Germany

17:10-17:25

Venoarterial versus venovenous extracorporeal membrane oxygenation
Arne Neyrinck - Leuven Belgium

17:25-17:30

Case part 3: mechanical support in acute heart and lung failure
David Schibilsky - Freiburg Germany

17:30-17:45

Short-term mechanical circulatory support in cardiogenic shock
Emer Joyce - Dublin Ireland

17:45-18:15

Discussion
-

Focus Group Session

Tuesday, 31. August 2021

- 16:45 - 18:15**
Room E - Orange
- Managing the difficult paediatric liver recipients: All is well that ends well**
*Chair(s): Marco Spada - Rome Italy
Barbara Wildhaber - Geneva Switzerland*
- 16:45-16:52 **MANAGEMENT OF CONGENITAL PORTOSYSTEMIC SHUNTS**
Lilia Martinez de la Maza - Stockholm Sweden
- 17:00-17:07 **HEPATOPORTOENTEROSTOMY VERSUS PRIMARY LIVER
TRANSPLANTATION FOR BILIARY ATRESIA**
Dor Yoeli - Aurora United States
- 17:15-17:22 **THE ROLE OF VASCULAR ADHESION PROTEIN-1 IN THE PATHOGENESIS
OF CHRONIC ALLOGRAFT HEPATITIS AFTER PAEDIATRIC LIVER
TRANSPLANTATION**
Steffen Hartleif - Tübingen Germany
- 17:30-17:37 **VEIN OUTFLOW OBSTRUCTION AFTER LEFT LATERAL SEGMENTS
TRANSPLANT: EXPERIENCE AT A LARGE PEDIATRIC TRANSPLANTATION
CENTER.**
Domenico Pinelli - Villongo (Bergamo) Italy
- 17:45-17:52 **LIVER TRANSPLANTATION FOR LANGERHANS CELL HISTIOCYTOSIS : A
PROTOCOL BASED APPROACH**
Jagadeesh Menon - Chennai India
- 18:00-18:07 **COMPARISON OF CYSTATIN C, CREATININE AND IOHEXOL CLEARANCE
IN PEDIATRIC LIVER TRANSPLANTATION - A RETROSPECTIVE COHORT
STUDY**
Emil Bluhme - Stockholm Sweden

Real-life clinical decision making

Tuesday, 31. August 2021

16:45 - 18:15
Room F - Turquoise
1

Transplanting high-risk patients: Navigating safely between risk factors and comorbidities

Chair(s): Jacopo Romagnoli - Rome Italy

Standard recipients are becoming a rare breed as we continue to deal with an overwhelming wave of high-risk patients (cardiopathy, advanced age, diabetics, hyper immunity, retransplants, etc.). In this session will give you the fundamentals to help in making the most appropriate choice for the safety of your patients.

16:45-16:50

Introduction

-

16:50-17:00

Case presentation: Clinically high-risk kidney recipient

Giuseppe Giuffrida - Manchester United Kingdom

Giovanni Amoroso – Amsterdam Netherlands

Nicoletta Fossati – London United Kingdom

17:00-17:25

Case discussion with multidisciplinary panel

Giuseppe Giuffrida - Manchester United Kingdom

17:25-17:35

Case presentation: Immunologically high-risk kidney recipient

Letizia Zeni - Brescia Italy

17:35-18:00

Case discussion with multidisciplinary panel

Giorgina Barbara Piccoli - Torino Italy

Emanuele Cozzi – Padova Italy

Giuseppe Grandaliano – Rome Italy

18:00-18:15

Closing remarks and audience voting

-

Full Oral Session

Tuesday, 31. August 2021

16:45 - 18:15

Room G - Turquoise
2

Molecular predictors of outcomes

Chair(s): Christine Falk - Hannover Germany
Sarah Hosgood - Cambridge United Kingdom

16:45-16:54

PROTEOMIC ANALYSIS OF MACHINE PERFUSION SOLUTION FROM BRAIN DEAD DONOR KIDNEYS REVEALS THAT COMPLEMENT ACTIVATION IS ASSOCIATED WITH 1-YEAR OUTCOME

Nora Spraakman - Groningen Netherlands

16:56-17:05

OPERATIONAL TOLERANCE-RELATED GENES ALLOW NON-INVASIVE DETECTION OF SUBCLINICAL REJECTION AT ONE YEAR AFTER RENAL TRANSPLANTATION

Richard Danger - Nantes France

17:07-17:16

URINE PROTEOME PROFILING TO IDENTIFY THE MOLECULAR SIGNATURE OF PRIMARY NON FUNCTION PRIOR TO TRANSPLANT IN DECEASED DONOR KIDNEYS

Sadr Shaheed - Oxford United Kingdom

17:18-17:27

AGE-RELATED PROTEOMIC DIFFERENCES IN DECEASED DONOR KIDNEYS ASSOCIATE WITH 12-MONTH POSTTRANSPLANTATION OUTCOME

Philip Charles - Oxford United Kingdom

17:29-17:38

DEVELOPMENT AND VALIDATION OF AN INTEGRATIVE DD-CFDNA SYSTEM TO PREDICT ALLOGRAFT REJECTION : A POPULATION BASED STUDY

Olivier Aubert - Paris France

17:40-17:49

SUBOPTIMAL RECIPIENT OUTCOMES CORRELATE TO INCREASED INFLAMMATORY MARKERS IN DECEASED AFTER BRAIN DEATH DONORS

Rebecca Vaughan - Bristol United Kingdom

17:51-18:00

PROTEOMIC ANALYSIS OF URINARY EXTRACELLULAR VESICLES REVEALS SPECIFIC BK VIRUS-RELATED BIOLOGICAL FINGERPRINTS.

Gianluigi Zaza - Verona Italy

18:02-18:11

NOVEL AVENUE OF ALLOGRAFT MONITORING: DIRECT MEASUREMENT OF DONOR-SPECIFIC EXTRACELLULAR VESICLES IN HUMAN PLASMA SAMPLES

Wouter Woud - Rotterdam Netherlands

Brief Oral Session

Tuesday, 31. August 2021

16:45 - 18:15
Room H - White 1

Pancreas and islets transplantation at 360°

Chair(s): Antonio Secchi - Milan Italy
Volkert Huurman - Leiden Netherlands

- 16:45-16:49 *THE EFFECT OF DONOR DIABETES-ASSOCIATED GENOTYPES ON OUTCOMES AFTER PANCREAS TRANSPLANTATION.*
Charles Sneddon - Oxford United Kingdom
- 16:51-16:55 *PANCREAS TRANSPLANTATION FROM DONORS DECLARED DEATH BY CIRCULATORY CRITERIA: INITIAL EXPERIENCE IN SPAIN.*
Joana Ferrer - Barcelona Spain
- 16:57-17:01 *METABOLIC OUTCOMES OF PANCREAS TRANSPLANT ALONE FROM DONATION AFTER CIRCULATORY DEATH DONORS - THE UK REGISTRY ANALYSIS*
Jeevan Gopal - London United Kingdom
- 17:03-17:07 *HUMAN AMNIOTIC EPITHELIAL CELLS PROTECT PANCREATIC ISLETS AGAINST PRO-INFLAMMATORY CYTOKINES*
Fanny LEBRETON - Geneva Switzerland
- 17:09-17:13 *OUTCOMES OF SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTS FROM DONATION AFTER CIRCULATORY DEATH DONORS IN THE UK: A NATIONAL REGISTRY ANALYSIS*
Nikolaos Karydis - London United Kingdom
- 17:15-17:19 *DEVELOPMENT OF EX VIVO NORMOTHERMIC PERFUSION AS AN INNOVATIVE METHOD TO ASSESS PANCREASES AFTER PRESERVATION*
Ann Etohan Ogbemudia - Oxford United Kingdom
- 17:21-17:25 *THE EUROPEAN P-PASS AND US PDRI SCORES ARE ASSOCIATED WITH INCREASED RISK OF PANCREAS GRAFT REJECTION*
Ky-Leigh Ang - Cardiff United Kingdom
- 17:27-17:31 *IMPROVED PANCREATIC GRAFTS SURVIVAL WITH OPERATING PROTOCOL AMENDMENTS.*
Paweł Skrzypek - Warsaw Poland
- 17:33-17:37 *POST-TRANSPLANT INFLAMMATION IS LOCALISED TO THE PANCREAS GRAFT AND ASSOCIATED WITH EARLY GRAFT THROMBOSIS*
Kristina Rydenfelt - Oslo Norway
- 17:39-17:43 *COMPARISON OF DRB1 AND DQB1 ALLELE FREQUENCIES AND PRE-TRANSPLANT ANTI-HLA ANTIBODIES IN PATIENTS WAITING FOR PANCREAS VS. KIDNEY TRANSPLANT*
Fabio Vistoli - Pisa Italy

- 17:45-17:49 *TEN YEARS OF SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATIONS
- SINGLE CENTRE NATIONWIDE EXPERIENCE
Kaisa Ahopelto - Helsinki Finland*
- 17:51-17:55 *PANCREAS GRAFT SALVAGE AFTER DUODENAL LEAK - FOLEY OR
FOLLY? OUTCOMES FROM OVER 1000 PANCREAS TRANSPLANTS
Fungai Dengu - Oxford United Kingdom*
- 17:57-18:01 *FIRST POSTOPERATIVE DAY PLASMA AMYLASE CAN BE USED TO
DETECT PATIENTS AT RISK OF COMPLICATIONS AFTER SIMULTANEOUS
PANCREAS-KIDNEY TRANSPLANTATION
Akseli Bonsdorff - Helsinki Finland*
- 18:03-18:07 *ISLETS LOADED IN HYDROGEL DERIVED FROM HUMAN AMNIOTIC
MEMBRANE REVERSE DIABETES IN IMMUNODEFICIENT MICE
Kevin Bellofatto - Geneva Switzerland*

Focus Group Session

Tuesday, 31. August 2021

16:45 - 18:15
Room I - White 2

T- and B-Cell response to SARS-Cov2 in SOT

Chair(s): Dorry Segev - Baltimore United States
Emanuele Cozzi - Padua Italy

- 16:45-16:52 SARS-COV-2 REACTIVE CELLULAR AND HUMORAL IMMUNITY IN TRANSPLANT POPULATION IS SIMILAR TO THE GENERAL POPULATION DESPITE IMMUNOSUPPRESSION
Constantin Thieme - Berlin Germany
- 17:00-17:07 LONG TERM IMMUNITY TO SARS-COV-2 AMONG SOLID ORGAN TRANSPLANT RECIPIENTS
Alexandre Fava - Barcelona Spain
- 17:15-17:22 SARS-COV-2-SPECIFIC SEROLOGICAL AND FUNCTIONAL T-CELL IMMUNE RESPONSES DURING ACUTE COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS
Alexandre Fava - Barcelona Spain
- 17:30-17:37 TRANSPLANT PATIENTS ARE ABLE TO GENERATE SARS-COV-2 CROSS-REACTIVE MEMORY B AND TFH CELLS DESPITE IMMUNOSUPPRESSION
Krystallenia Paniskaki - Essen Germany
- 17:45-17:52 SYSTEMATIC SCREENING FOR SARS-COV-2 S1/S2 ANTIBODIES HELPS TO BETTER ASSESS THE REAL INCIDENCE OF COVID-19 IN KIDNEY TRANSPLANT RECIPIENTS
Louis Firket - Liege Belgium
- 18:00-18:07 COMPARISON OF THE IMMUNE RESPONSES OF RENAL TRANSPLANT RECIPIENTS AFTER COVID-19 VERSUS SARS-COV2 VACCINATION
Xavier Charmetant - Lyon France

Brief Oral Session

Tuesday, 31. August 2021

16:45 - 18:15

Studio - ESOT Live
Studio

Genetic and immune factors regulating alloreactivity

Chair(s): Maria Kaisar - Oxford United Kingdom

16:45-16:49

BLOCKADE OF THE IL-21 PATHWAY: A NEW PERSPECTIVE FOR THE TREATMENT OF T AND B CELL MEDIATED ALLOGENEIC RESPONSES AFTER TRANSPLANTATION

Carla Baan - Rotterdam Netherlands

16:51-16:55

PROLIFERATION OF CO-STIMULATION BLOCKADE RESISTANT-T CELLS REQUIRED EARLY IFNA PATHWAY ACTIVATION

florence herr - Villejuif France

16:57-17:01

INCREASED FREQUENCY OF T CELL-MEDIATED REJECTION ASSOCIATED WITH ANTIBODY MEDIATED REJECTION IN HLA-DSA NEGATIVE TRANSPLANT RECIPIENTS

David Rodriguez Fuentes. - Córdoba Spain

17:03-17:07

DO NOT BLAME THE INNOCENT: Γ T CELLS ARE NOT INVOLVED IN DONOR SPECIFIC ANTIBODY GENERATION AFTER SOLID ORGAN TRANSPLANTATION

Xavier Charmetant - Lyon France

17:09-17:13

IMMUNOLOGICAL BEHAVIOR OF EARLY GRAFT INFILTRATING CELLS UNTIL 3 DAYS AFTER MURINE SKIN TRANSPLANTATION

Ryo Kanazawa - Sapporo Japan

17:15-17:19

GENOME-WIDE MISMATCH AND DELETION ANALYSIS IN KIDNEY TRANSPLANTATION

Salla Markkinen - Helsinki Finland

17:21-17:25

DONOR-RECIPIENT GENETIC MISMATCH IS ASSOCIATED WITH LIVER ALLOGRAFT REJECTION

Lianne Nieuwenhuis - Groningen Netherlands

17:27-17:31

SOLVENT ACCESSIBLE AMINO ACID MISMATCHES CALCULATED BY HLA-EMMA AS INDEPENDENT RISK FACTOR FOR DEATH-CENSORED GRAFT FAILURE IN RENAL TRANSPLANTATION

Suzanne Bezstarosti - Leiden Netherlands

17:33-17:37

LIVING DONOR KIDNEY TRANSPLANTATION IN PATIENTS WITH DONOR-SPECIFIC HLA ANTIBODIES AFTER DESENSITIZATION WITH IMMUNOADSORPTION

Florian Kälble - Heidelberg Germany

17:39-17:43

ANTI-THYMOCYTE GLOBULIN MEDIATED B-CELL ACTIVATION

Moritz Muckenhuber - Vienna Austria

- 17:45-17:49 *MESENCHYMAL STROMAL CELL DERIVED MEMBRANE PARTICLES ARE INTERNALIZED BY MACROPHAGES AND ENDOTHELIAL CELLS AND EXHIBIT IMMUNOMODULATORY EFFECTS*
Martin Hoogduijn - Rotterdam Netherlands
- 17:51-17:55 *DELINEATING THE IMMUNOGENICITY OF GRAFT COMPONENTS IN COMPOSITE TISSUE ALLOTRANSPLANTATION*
Barbara Kern - Berlin Germany
- 17:57-18:01 *LOCAL IMMUNOSUPPRESSION IN VASCULARIZED COMPOSITE ALLOTRANSPLANTATION: PAVING THE WAY FOR A SAFER ALTERNATIVE*
Isabel Arenas Hoyos - Bern Switzerland

Focus Group Session

Tuesday, 31. August 2021

16:45 - 18:15
 Z1 - Edu Zone |
 Room

Clinical Cases: Person-centered approach towards the person subjected to organ transplantation

Chair(s): *Anne Floden - Alingsås Sweden*
Anna Forsberg - Lund Sweden

- 16:45-16:52 *KIDNEY TRANSPLANTATION IN THE TRANSGENDER PATIENT- A CHALLENGE FOR CARE*
Irena Milaniak - Krakow Poland
- 17:00-17:07 *FIRST PERSON CONSENT: CHALLENGES TO APPROACHING FOR DONATION.*
Bethany Hall - London United Kingdom
- 17:15-17:22 *SUICIDE IN THE UK 2020 – ITS IMPACT ON ORGAN DONATION AND STAFF WELL-BEING*
Jennifer Hughes - Barnsley United Kingdom
- 17:30-17:37 *COLLABORATIVE WORKING- KEY TO MAINTAINING NORMAL ORGAN DONATION AND TRANSPLANT SERVICE DURING COVID PANDEMIC IN NORTHERN IRELAND*
Mary Hayes - Belfast United Kingdom
- 17:45-17:52 *THE OPERATIVE ITALIAN NATIONAL TRANSPLANT CENTRE (CNTO): THE ROLE OF NURSES*
Federica Domini - Roma Italy
- 18:00-18:07 *IMPLEMENTING AND EMBEDDING CHANGES IN LEGISLATION FOR ORGAN AND TISSUE DONATION IN ENGLAND*
Sonya Paterson - Newcastle Upon Tyne United Kingdom

Special Session

Tuesday, 31. August 2021

18:30 - 20:00

Room B -
Auditorium

Future Leaders on Stage

Chair(s): *Liset Pengel - Oxford United Kingdom*
Luca Toti - Rome Italy

PART 1:

ESOT Fellowships recipients will discuss their work and career progress.

PART 2:

Experts together with grant recipients will engage into discussion on research and career development. How do you get started on a research project? How do you set up a multicentre research study? How do you get your project funded? These will be some of questions that will be discussed with our panellists.

18:30-18:35

Introduction

Gabriel Oniscu - Edinburgh United Kingdom

18:35-18:47

Ex-vivo lung perfusion as window of opportunity for genetic lung modulation

LJC Laurens Ceulemans - Tremelo Belgium

18:47-18:59

Biliary cell response to ischemia reperfusion injury; biological pathways involved in post-transplant biliary injury and repair

Hannah Esser - Edinburgh United Kingdom

18:59-19:11

Desensitization and immunization balance: Immunological landscape after kidney transplantation

TJ Thomas Jouve - Grenoble France

19:11-19:23

The pathway from animal models to clinical trial for tackling ischemia reperfusion injury in lung transplantation

Ilker Iskender - Leuven Belgium

19:23-19:53

Panel discussion on research and career development with grant winners and invited experts

Anna Forsberg - Lund Sweden

Ina Jochmans - Leuven Belgium

Giuseppe Remuzzi - Bergamo Italy

19:53-20:00

Closing

-

Special Session

Tuesday, 31. August 2021

18:30 - 20:00
Room K - Red

Cytomegalovirus infection in organ transplantation: new strategies for an old problem

Chair(s): Maddalena Giannella - Bologna Italy
Jens Gottlieb - Hannover Germany

18:30-18:45

ESOT & Takeda Joint Educational Session

CMV management practices across Europe: Results of an ESOT survey
Nassim Kamar - Saubens France

18:45-19:00

Patients at high risk for CMV syndrome/disease: Not only D+/R-
Atul Humar - Toronto Canada

19:00-19:15

Unmet needs for prevention of CMV infection in transplantation: challenges in management of drug toxicities and viral resistances
Maddalena Giannella - Bologna Italy

19:15-19:30

The real high risk patient: when the graft is the site of infection
Paolo Solidoro - Torino Italy

19:30-19:45

What's on the pipeline and what can we expect from upcoming anti-CMV drugs
Oliver Witzke - Essen Germany

19:45-20:00

Discussion and questions
-

Full Oral Session

Wednesday, 1. September 2021

08:00 - 09:30
Room A - Silver

Late Breaking (Full Oral)

Chair(s): -

- 08:00-08:09 *MULTI-OMICS DATA INTEGRATION IN KIDNEY TRANSPLANTATION: THE HIDDEN PATHWAYS OF ANTIBODY-MEDIATED REJECTION*
Claire Tinel - LEUVEN Belgium
- 08:11-08:20 *DEEP PHENOTYPING OF HUMAN KIDNEY TRANSPLANT REJECTION USING SINGLE-CELL TRANSCRIPTOMICS*
Baptiste Lamarthée - Leuven Belgium
- 08:22-08:31 *REAL WORLD USE AND CLINICAL IMPACT OF EXTRACORPOREAL PHOTOPHERESIS IN HEART TRANSPLANT PATIENTS – RESULTS FROM A EUROPEAN MULTICENTER STUDY*
Markus J. Barten - Hamburg Germany
- 08:33-08:42 *EPLETS INCOMPATIBILITY AS A DETERMINANT IN EXPOSURE TO TACROLIMUS*
CCH Christian Córdoba Herrera - Barcelona Spain
- 08:44-08:53 *CREATING A MODEL FOR KIDNEY-VASCULATURE INTERACTION USING AN ORGAN-ON-CHIP DEVICE.*
Amanda Bas-Cristóbal Menéndez - Rotterdam Netherlands
- 08:55-09:04 *A SINGLE-CELL REFERENCE ATLAS OF THE HUMAN KIDNEY TRANSPLANT UNRAVELS CELLULAR HETEROGENEITY IN BULK ALLOGRAFT TISSUE*
Jasper Callemeyn - Korbeek-Lo Belgium
- 09:06-09:15 *PROSPECTIVE EVALUATION OF DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) IN KIDNEY TRANSPLANT RECIPIENTS WITH INDICATION BIOPSY*
Louise Benning - Heidelberg Germany
- 09:17-09:26 *REGIONAL DIFFERENCES IN PRIMARY GRAFT DYSFUNCTION IN HEART TRANSPLANTATION: A REPORT FROM THE INTERNATIONAL CONSORTIUM ON PRIMARY GRAFT DYSFUNCTION*
Jiho Han -

Focus Group Session

Wednesday, 1. September 2021

08:00 - 09:30
Room J - Blue

Diabetes and viral infections after transplantation: Out of the frying pan and into the fire

Chair(s): Valeria Sordi - Milan Italy
Gianluigi Zaza - Verona Italy

08:00-08:07

THE PRESENCE OF METABOLIC SYNDROME BEFORE TRANSPLANTATION INCREASE THE RISK OF CARDIOVASCULAR EVENTS FOLLOWING LIVER TRANSPLANTATION

Julia Herreras - Valencia Spain

08:15-08:22

TREAT-TO-TARGET TRIAL OF CONTINUOUS SUBCUTANEOUS INSULIN-PUMP THERAPY IN NEW-ONSET DIABETES AFTER TRANSPLANTATION (SAPT-NODAT)

Amelie Kurnikowski - Vienna Austria

08:30-08:37

SODIUM/GLUCOSE COTRANSPORTER 2 INHIBITORS IN RENAL TRANSPLANT DIABETIC PATIENTS. SINGLE CENTER PILOT STUDY.

Claudia Muñoz Martínez - CÓRDOBA Spain

08:45-08:52

RISK FACTORS OF EPSTEIN-BARR VIRUS REACTIVATION AFTER RENAL TRANSPLANTATION: RESULTS OF A LARGE, MULTI-CENTRE STUDY

Arturo Blázquez Navarro - Berlin Germany

09:00-09:07

BKV-SPECIFIC IFN- γ ELISPOT ASSAY IN KIDNEY TRANSPLANTATION: A META-ANALYSIS AND SYSTEMATIC REVIEW

Suwasin Udomkarnjananun - Rotterdam Netherlands

09:15-09:22

IMPACT OF COVID-19 IN PATIENTS AWAITING LIVER TRANSPLANTATION

Ilias Kounis - Paris France

Focus Group Session

Wednesday, 1. September 2021

08:00 - 09:30
Room K - Red

From primary to chronic lung allograft dysfunction: The devil is not as black as he is painted

Chair(s): Robin Vos - Leuven Belgium

08:00-08:07

HEMODYNAMIC EFFECTS OF INTEGRATING COMPLIANCE IN THE DESIGN OF AN ARTIFICIAL LUNG: ASSESSMENT WITH A HYBRID SIMULATOR

Tom Verbelen - Leuven Belgium

08:15-08:22

CYTOKINE FILTRATION REGENERATED PULMONARY FUNCTION IN ARDS DAMAGED LUNGS AND REDUCE PRIMARY GRAFT DYSFUNCTION

SL Sandra Lindstedt - Lund Sweden

08:30-08:37

PROPHYLACTIC DESENSITIZATION IN LUNG TRANSPLANT CANDIDATES WITH PRE-FORMED DONOR-SPECIFIC ANTIBODIES: 3-YEAR POST-TRANSPLANTATION OUTCOME.

Olivier Brugière - Suresnes France

08:45-08:52

LUNG TRANSPLANT RECIPIENTS DEVELOPING EARLY DSA WITHIN THE FIRST MONTH EXHIBIT A HIGHER FREQUENCY OF NAÏVE AND A LOWER FREQUENCY OF MEMORY B CELLS

Stella Christoph - Hannover Germany

09:00-09:07

ALTERATION OF T LYMPHOCYTE SUBPOPULATIONS IN LUNG TRANSPLANTED PATIENT RECEIVING PROPHYLACTIC EXTRACORPOREAL PHOTOPHERESIS

Ara Cho - Vienna Austria

09:15-09:22

PARTICLE FLOW RATE FROM THE AIRWAYS AS A MARKER FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD)

Embla Bodén - Lund Sweden

Think Tank

Wednesday, 1. September 2021

08:00 - 09:30
Room C - Yellow

Repo Men: Who will 'own' transplantation in 10 years?

Chair(s): Gabriel Oniscu - Edinburgh United Kingdom
Dominique Martin - Geelong Australia

If in 10 years from now, organs are taken from the organ bank, genetically modified to enhance the function and fit the recipients' immune genotype, then who is owning the field? Is such an intervention financially sustainable? Should it be performed in spin-off clinics or at academic centres? Can organs become a commercial product? If there are profit margins, should the next-of-kin receive a share? Would this replace all other options for organ function replacement (such as dialysis), or will they be xenografts and serve to bridge the gap...or replace human organs?

08:00-08:10

Organs for everybody. The world without organ shortage...but at what price?
Gabriel Oniscu - Edinburgh United Kingdom

08:10-08:25

We cannot do it alone: The role of the private sector in transplantation and organ replacement
-

08:25-08:40

How are we going to do this? A view from the shopfloor
John Forsythe - Bristol United Kingdom

08:40-08:55

Repo men: The moral and ethical issues
Dominique Martin - Geelong Australia

08:55-09:25

Discussion
-

09:25-09:30

Audience voting results
-

Real-life clinical decision making

Wednesday, 1. September 2021

08:00 - 09:30
Room D - Green

Present and future role of HLA and antibodies

Chair(s): *Jacopo Romagnoli - Rome Italy*
Dave Roelen - Leiden Netherlands

Human leukocyte antigen (HLA) testing is reviewed with the understanding that donor-specific HLA antibodies play a significant role in long-term allograft survival. We will discuss the added value of HLA-epitope matching and the importance of virtual crossmatching in kidney transplantation as well as recent developments in lung transplantations.

08:00-08:07

Case presentation: Crossmatching and epitope matching in kidney transplantation

Carla Rosser - London United Kingdom

08:07-08:22

Virtual crossmatching in kidney transplantation: The wait is over

David Turner - Edinburgh United Kingdom

08:22-08:37

The road towards epitope matching

Frans Claas - Leiden Netherlands

08:37-08:44

Case presentation: Epitope Matching for a highly immunized lung patient - sense or nonsense?

Teresa Kauke - Munich Germany

08:44-08:59

What can we learn from abdominal experience?

Antoine Roux - Suresnes France

08:59-09:14

Predicting immunogenicity

Vasilis Kosmoliaptsis - Cambridge United Kingdom

09:14-09:30

Discussion

-

Education Track

Wednesday, 1. September 2021

08:00 - 09:30

Room E - Orange

The cell and me: Single-cell profiling in transplantation

Chair(s): Rikke Norregaard - Aarhus Denmark
Christine Falk - Hannover Germany

Single-cell transcriptomes and spatial single-cell sequencing are accelerating our current understanding of organs and cells in their interaction with the microenvironment and immune cells. Since these single-cell techniques require extensive bioinformatics – which can also be used for defining the cell – the next generation of transplant professionals need to learn about them as a priority.

08:00-08:20

Human cell atlas for the kidney
Menna Clatworthy - Cambridge United Kingdom

08:20-08:40

Cell regeneration: From embryo to transplant
Igor Adameyko - Vienna Austria

08:40-09:00

From single cells to composite tissue transplantation
Gerald Brandacher - Baltimore United States

09:00-09:20

If transplant is not working – the bionic alternative
Oskar Aszmann - Vienna Austria

09:20-09:30

Discussion
-

Real-life clinical decision making

Wednesday, 1. September 2021

08:00 - 09:30

Room F - Turquoise
1

Stretching a small blanket: allocation strategies in heart transplantation

Chair(s): Cristiano Amarelli - Naples Italy
Maria Rosa Costanzo - Naperville United States

No evidence-based data may encompass all the donor and recipient clinical factors when faced with the complex tasks regulating organ allocation in Heart Transplantation. Clinical urgency, chance of survival and matching variables must be weighted to obtain a fair allocation. Many international healthcare systems have redesigned allocation rules and the session will address the outcomes of these recent changes and the possible future solutions.

08:00-08:05

Introduction

-

08:05-08:20

The framework of allocation in the United States
Kiran Khush - Stanford United States

08:20-08:35

The feasibility of a score: the French solution
Christian Jacquelinet - Paris France

08:35-08:50

The new allocation criteria in Italy: The effects of proactive allocation in Level 2 urgency
Maria Frigerio - Milano Italy

08:50-09:05

Allocation of the heart on ECMO recipient: The rescue score
Gino Gerosa - Padova Italy

09:05-09:30

Discussion

-

Focus Group Session

Wednesday, 1. September 2021

08:00 - 09:30

Room G - Turquoise
2

Learning from each other to improve organ donation

Chair(s): Chloe Balleste - Barcelona Spain
Massimo Cardillo - Rome Italy

08:00-08:07

OVERVIEW OF COLLABORATIVE APPROACH TO HELP THE DEVELOPMENT OF ORGAN AND TISSUE DONATION AND TRANSPLANTATION AT EUROPEAN LEVEL.

Martí Manyalich - Barcelona Spain

08:15-08:22

INCREASE ORGANS PROCURED AND TRANSPLANTED VIA A COMPREHENSIVE, INTEROPERABLE, AND SECURE DIGITAL DONOR AND TRANSPLANT MANAGEMENT PLATFORM

John Piano - Los Angeles United States

08:30-08:37

IMPACT ON DONOR DETECTION AFTER THE IMPLEMENTATION OF QUALITY INDICATORS AND TPM TRAINING PROGRAM IN THE KINGDOM OF SAUDI ARABIA

Estephan Arredondo - Barcelona Spain

08:45-08:52

THE DONOR ACTION PROGRAM IN THE EMILIA-ROMAGNA REGION FROM 1998 TO 2019: RESULTS

Carlo De Cillia - BOLOGNA Italy

09:00-09:07

ORGAN DONATION AND TRANSPLANT IN THE ENGLISH-SPEAKING CARIBBEAN REGION: 10 YEARS OF INTERNATIONAL COOPERATION

Maria Gomez - Barcelona Spain

09:15-09:22

QUALITY MANAGEMENT SYSTEM APPLIED TO ORGAN DONATION: UNITED ARAB EMIRATES EXPERIENCE

Maria Gomez - Barcelona Spain

Brief Oral Session

Wednesday, 1. September 2021

08:00 - 09:30
Room H - White 1

Biomolecular tools to predict, monitor and interpret: Elementary, my dear Watson

Chair(s): Carla Baan - Rotterdam Netherlands
Giuseppe Grandaliano - Roma Italy

- 08:00-08:04 SOLUBLE UROKINASE RECEPTOR AND MORTALITY IN KIDNEY TRANSPLANT RECIPIENTS
Christian Morath - Heidelberg Germany
- 08:06-08:10 COMPARATIVE TRANSCRIPTOME ANALYSIS REVEALS A POTENTIAL ROLE OF C1QB IN CHRONIC ANTIBODY-MEDIATED REJECTION OF KIDNEY ALLOGRAFTS.
Mattia Rossi - Verona Italy
- 08:12-08:16 VALIDATION OF FLAVIN MONONUCLEOTIDE TO MONITOR QUALITY OF DONOR KIDNEYS DURING HYPOTHERMIC (OXYGENATED) MACHINE PERFUSION IN KIDNEY TRANSPLANTATION
Fenna van de Leemkolk - Amsterdam Netherlands
- 08:18-08:22 MONITORING OF MOLECULAR PROFILING OF REGULATORY T CELL BIOMARKERS BY USING NON-INVASIVE STRATEGIES TO PREDICT OUTCOME IN RENAL TRANSPLANTATION.
ANGELICA CANOSSI -
- 08:24-08:28 URINARY EXTRACELLULAR VESICLES AND VESICULAR CELL-FREE DNA AS POTENTIAL BIOMARKERS FOR KIDNEY ALLOGRAFT INJURY
Ivana Sedej - Ljubljana Slovenia
- 08:30-08:34 NUCLEAR FACTOR OF ACTIVATED T CELLS AS POTENTIAL PHARMACODYNAMIC BIOMARKER FOR THE RISK OF ACUTE AND SUBCLINICAL REJECTION IN LIVER RECIPIENTS
OLGA MILLAN - Barcelona Spain
- 08:36-08:40 CONNECTION OF BANK1, TOLERANCE, REGULATORY B CELLS, AND APOPTOSIS: PERSPECTIVES OF A REDUCTIONIST INVESTIGATION.
Ludmilla LE BERRE - Nantes France
- 08:42-08:46 IMPACT OF STEATOSIS AND COLD ISCHEMIA TIME ON MITOCHONDRIAL RESPIRATION IN HUMAN LIVER ALLOGRAFTS
Andras T. Meszaros - Innsbruck Austria
- 08:48-08:52 APPLICATION OF THIN-FILM SOLID-PHASE MICROEXTRACTION TO BILE ANALYSIS - BILE FINGERPRINT AS A PROGNOSTIC MARKER DURING LIVER TRANSPLANTATION
Kamil Łuczykowski - Bydgoszcz Poland
- 08:54-08:58SIX VIABILITY ASSESSMENT USING THE "SIX GENE SIGNATURE" DURING LIVER PERFUSION
Rodrigo Figuerido - Newcastle upon Tyne United Kingdom

- 09:00-09:04 *ADVANTAGES OF PLASMATIC CXCL10 AS A PROGNOSTIC & DIAGNOSTIC BIOMARKER FOR THE RISK OF REJECTION AND SUBCLINICAL REJECTION IN KIDNEY TRANSPLANTATION.*
OLGA MILLAN - Barcelona Spain
- 09:06-09:10 *MONITORING KIDNEY GRAFT INJURY BY MEASURING DONOR-DERIVED CELL FREE DNA (DD-CFDNA)*
Emilio Rodrigo - Santander Spain
- 09:12-09:16 *HUMAN CD81 EXTRACELLULAR VESICLES ARE RELEASED DURING NORMOTHERMIC MACHINE PERFUSION*
Wouter Woud - Rotterdam Netherlands
- 09:18-09:22 *TRANSFORMING GROWTH FACTOR-B1 EXPRESSION IN RENAL TRANSPLANT URETER TISSUE AND POST-TRANSPLANT URETERAL STRICTURE*
Emmy Hartog - Groningen Netherlands

Focus Group Session

Wednesday, 1. September 2021

08:00 - 09:30
Room I - White 2

Clinical Cases: Challenges in paediatric liver transplantation

Chair(s): Ulrich Baumann - Hannover Germany

- 08:00-08:07 *NEW FRONTIER FOR BILIARY RECONSTRUCTION IN PEDIATRIC LIVER TRANSPLANTATION: BIODEGRADABLE STENTS*
Sara Maritato - Rome Italy
- 08:15-08:22 *KAPOSÍ'S SARCOMA (KS) IN PEDIATRIC LIVER TRANSPLANTATION (LT) – 3 CLINICAL CASES*
Catarina Cordeiro - Coimbra Portugal
- 08:30-08:37 *SPLENIC STEAL SYNDROME AS A CAUSE OF UNEXPLAINED REFRACTORY ASCITES AFTER PEDIATRIC LIVER TRANSPLANTATION*
Mara Cananzi - Gastroenterologia, Endoscopia Digestiva, Epatologia e Cura del Bambino con Trapianto di Fegato, Dpt. per la Salute della Donna e del Bambino Italy
- 08:45-08:52 *EX SITU LIVER SPLITTING DURING HYPOTHERMIC OXYGENATED MACHINE PERFUSION*
Marco Spada - Rome Italy
- 09:00-09:07 *LONG TERM SURVIVAL AFTER CHORIOCARCINOMA TRANSMITTED BY LIVER GRAFT: A SUCCESSFUL REPORT IN PAEDIATRIC TRANSPLANTATION*
Inês Pessanha - Coimbra. Portugal
- 09:15-09:22 *BILE CAST NEPHROPATHY CAUSING ACUTE KIDNEY INJURY AFTER LIVER TRANSPLANTATION AND PROGRESSION TO CHRONIC KIDNEY DISEASE*
Francesca Tinti - Castelnuovo di Porto (RM) Italy

Brief Oral Session

Wednesday, 1. September 2021

08:00 - 09:30
Studio - ESOT Live
Studio

Late Breaking (Brief Oral)

Chair(s): -

- 08:00-08:04 *POST-VACCINE IMMUNITY TO COVID-19 VACCINE IN END-STAGE RENAL DISEASE PATIENTS AND KIDNEY TRANSPLANT RECIPIENT*
Magdalena Piotrowska - Gdansk Poland
- 08:06-08:10 *EARLY SAFETY OF SARS-COV-2 MRNA VACCINES IN SOLID ORGAN TRANSPLANT RECIPIENTS*
Michael Ou - Baltimore United States
- 08:12-08:16 *IDOTCOVID- INTERNATIONAL DATABASE ON ORGAN DONATION AND TRANSPLANTATION - COVID 19*
Pedro Ventura-Aguiar - Barcelona Spain
- 08:18-08:22 *LIMITED IMMUNOGENICITY OF A SINGLE DOSE OF SARS-COV-2 MRNA VACCINE IN SOLID ORGAN TRANSPLANT RECIPIENTS*
Brian Boyarsky - Baltimore United States
- 08:24-08:28 *SARS-COV 2 VACCINATION AND EARLY SPECIFIC IMMUNE RESPONSE IN SOLID ORGAN TRANSPLANT RECIPIENTS*
Renato Pascale - Bologna Italy
- 08:30-08:34 *PROSPECTIVE EVALUATION OF HEALTH-RELATED QUALITY OF LIFE, UNCERTAINTY AND COPING STRATEGIES IN ORGAN TRANSPLANT RECIPIENTS DURING THE COVID PANDEMIC*
Angus Hann - Birmingham United Kingdom
- 08:36-08:40 *MOTIVATION, EXPERIENCES, AND MENTAL HEALTH OUTCOMES OF UNSPECIFIED KIDNEY DONORS IN THE NETHERLANDS: A QUALITATIVE STUDY*
Mathilde Pronk - Rotterdam Netherlands
- 08:42-08:46 *FIVE YEAR HEPATOCELLULAR CARCINOMA RECURRENCE WITH EVEROLIMUS PLUS REDUCED TACROLIMUS VS STANDARD TACROLIMUS AFTER LIVING-DONOR LIVER TRANSPLANTATION*
Gonzalo Sapisochin - Toronto Canada
- 08:48-08:52 *PREEMPTIVE KIDNEY TRANSPLANTATION VERSUS NON-PREEMPTIVE KIDNEY TRANSPLANTATION IN ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS.*
Reshma Rana Magar - Kidlington, Oxfordshire United Kingdom
- 08:54-08:58 *ACUTE KIDNEY INJURY AFTER HEART TRANSPLANTATION: ROLE OF INTRAOPERATIVE MANAGEMENT*
Veronica Moriconi - Bologna Italy

- 09:00-09:04 *METABOLIC OUTCOMES AFTER PANCREAS TRANSPLANTATION FROM DONORS AFTER CIRCULATORY DEATH - THE UK REGISTRY ANALYSIS*
Jeevan Gopal - London United Kingdom
- 09:06-09:10 *PORTABLE GAMMA-CAMERA AS A USEFUL TOOL FOR BRAIN DEATH DIAGNOSIS*
José Moya Sánchez - MURCIA Spain
- 09:12-09:16 *SPECIFIC URINARY METABOLOMIC PROFILE IN SPONTANEOUS TOLERANT KIDNEY TRANSPLANTED RECIPIENTS*
LC Luc Colas - Nantes France
- 09:18-09:22 *DESIGN OF STEADFAST STUDY EVALUATING TX200-TR101, A CHIMERIC ANTIGEN RECEPTOR T REGULATORY CELL THERAPY FOR LIVING DONOR RENAL TRANSPLANT RECIPIENTS*
Emily Culme-Seymour - London United Kingdom

State of the Art

Wednesday, 1. September 2021

10:00 - 11:30
Room A - Silver

Organ perfusion: Quo Vadis?

Chair(s): Sandra Lindstedt - Lund Sweden
Amelia Hessheimer - Barcelona Spain

Organ perfusion strategies have emerged in our field, with randomised controlled trials ongoing and increasing experience being built. Major 'firsts' in organ perfusion have happened over the past few years, and many more are likely to materialise over the coming 18 months. As an example, recruitment has completed for COMPARE and PUMP studies in kidney preservation as well as HOPE and DHOPE studies, and outcome data will be available by ESOT 2021. Likewise, for lung, heart and normothermic regional perfusion, there are a lot of new data emerging. This backdrop provides the ideal setting for a state-of-the-art session, focused on organ perfusion strategies, aimed at the expert as well as the novice.

10:00-10:20

What is state-of-the-art in machine perfusion?
Gabriel Oniscu - Edinburgh United Kingdom

10:20-10:35

Machine perfusion endpoints achieved in randomised clinical trials: abdominal
Stefan Schneeberger - Innsbruck Austria

10:35-10:50

Machine perfusion endpoints achieved in randomised clinical trials: cardiothoracic
Dirk Van Raemdonck - Leuven Belgium

10:50-11:10

Biomarkers 2021: Have we made progress in predicting organ viability? A multiorgan perspective
Ina Jochmans - Leuven Belgium

11:10-11:30

Discussion
-

Focus Group Session

Wednesday, 1. September 2021

10:00 - 11:30
Room J - Blue

Enhanced recovery in kidney and liver transplantation: make it fast and make it right

Chair(s): -

- 10:00-10:07 *ENHANCED RECOVERY AFTER LIVER TRANSPLANTATION OUTSIDE A STRICT FAST TRACK PROTOCOL: A SINGLE CENTER FEASIBILITY STUDY*
Konstantina Eleni Karakasi - Thessaloniki Greece
- 10:15-10:22 *A NATIONAL SURVEY ON ENHANCED RECOVERY FOR RENAL TRANSPLANT RECIPIENTS: CURRENT PRACTICES AND TRENDS IN THE UNITED KINGDOM*
Carrie Scuffell - Newcastle upon Tyne United Kingdom
- 10:30-10:37 *ENHANCED RECOVERY AFTER SURGERY (ERAS) FOR RENAL TRANSPLANT RECIPIENTS: THE EARLY NEWCASTLE EXPERIENCE*
Carrie Scuffell - Newcastle upon Tyne United Kingdom
- 10:45-10:52 *POSITIVE IMPACT OF ERAS PROGRAMME ON LIVING AND DECEASED DONOR RENAL TRANSPLANT RECIPIENTS DURING COVID PANDEMIC*
Rachel Thomas - Edinburgh United Kingdom
- 11:00-11:07 *FACTORS ASSOCIATED WITH PROLONGED LENGTH OF STAY FOLLOWING RENAL TRANSPLANTATION: A NURSE LED AUDIT*
Leigh Whinham - Newcastle upon Tyne United Kingdom
- 11:15-11:22 *PHYSICAL FUNCTION IMPAIRMENT AMONG KIDNEY TRANSPLANT RECIPIENTS AND PATIENTS ON DIALYSIS*
Wajiha Ghazi - Toronto Canada

Focus Group Session

Wednesday, 1. September 2021

10:00 - 11:30
Room K - Red

Induction and more

Chair(s): *Lucrezia Furian - Padova Italy*
Luuk Hilbrands - Nijmegen Netherlands

- 10:00-10:10 *RABBIT ANTI-THYMOCYTE GLOBULIN AS INDUCTION THERAPY FOLLOWING DESENSITIZATION WITH IMLIFIDASE*
Anna Runström - Lund Sweden
- 10:18-10:28 *TACROLIMUS MONOTHERAPY IN IMMUNOLOGICALLY LOW-RISK KIDNEY TRANSPLANT RECIPIENTS: A RANDOMIZED-CONTROLLED TRIAL.*
Annelies de Weerd - Rotterdam Netherlands
- 10:36-10:46 *COMBINATION OF EXTENDED-RELEASE TACROLIMUS PLUS EVEROLIMUS ONCE-DAILY IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: ER-TAC VS LCPT.*
Gionata Spagnoletti - Rome Italy
- 10:54-11:04 *OUTCOMES OF IL2-RA INDUCTION THERAPY IN STANDARD-RISK RENAL TRANSPLANT RECIPIENTS MAINTAINED ON TACROLIMUS - A META-ANALYSIS*
Hatem Ali - Coventry United Kingdom
- 11:12-11:22 *IMPACT OF TYPE OF CALCINEURIN INHIBITOR ON OUTCOME IN EUROPEAN KIDNEY TRANSPLANT RECIPIENTS AGED ≥60 YEARS – A COLLABORATIVE TRANSPLANT STUDY REPORT*
Fabian Echterdiak - Stuttgart Germany

Real-life clinical decision making

Wednesday, 1. September 2021

10:00 - 11:30
Room C - Yellow

Managing 'sarco-frailty' in the real world: How to prepare our patients

Chair(s): *Patrizia Burra - Padova Italy*
Krzysztof Zieniewicz - Warsaw Poland

In patients with cirrhosis evaluated for liver transplantation, sarcopenia and frailty are increasingly recognized as independent predictors of clinical outcomes including wait-list mortality and reduced survival after surgery. Interestingly, it has been shown that sarcopenia is very common also in patients with NASH cirrhosis and normal to increased BMI, which underscores the lack of correlation between excessive body weight and loss of muscle mass ("sarcopenic obesity"). Evaluation of body mass composition and assessment of frailty are becoming increasingly important in the management of liver transplant candidates and recipients and their proactive treatment may improve outcomes. By using a multidisciplinary approach, this session will therefore cover the most recent advances regarding definition, assessment, and treatment of both sarcopenia and frailty before and after liver transplantation.

10:00-10:20

Definition of sarcopenia and frailty in liver transplant recipients
Alberto Zanetto - Padova Italy

10:20-10:40

Tools for measuring sarcopenia and frailty
Aldo Montano-Loza - Edmonton Canada

10:40-11:00

Treatment of sarcopenia before transplantation
Shira Zelberg-Sagi - Tel Aviv Israel

11:00-11:20

The frail and the fat: Implications of sarcopenic obesity in liver transplant recipients
Constantino Fondevila - Madrid Spain

11:20-11:30

Discussion
-

Education Track

Wednesday, 1. September 2021

10:00 - 11:30
Room D - Green

How to set up an ABO incompatibility programme

Chair(s): Emanuele Cozzi - Padua Italy
David Turner - Edinburgh United Kingdom

ABO-incompatible transplantations are increasingly performed, especially in emergency situations, in living-related transplantations, and for disadvantaged recipients. To establish an ABO incompatibility transplant programme, it is important to define a pre- and post-operative multidisciplinary immunosuppressive therapy protocol. For each recipient, it is essential to plan the immunosuppression regimens both pre- and post- transplantation and the post-operative follow-up using regular immunological panel assessments.

- | | |
|-------------|---|
| 10:00-10:05 | <i>Decision-making, pre-transplant management and candidate selection (kidney)</i>
Nizam Mamode - London United Kingdom |
| 10:05-10:10 | <i>Decision-making, pre-transplant management and candidate selection (liver)</i>
Arvinder Singh Soin - Gurgaon India |
| 10:10-10:15 | <i>Decision-making, pre-transplant management and candidate selection (cardiothoracic)</i>
LJW Lori West - Edmonton Canada |
| 10:15-10:20 | <i>Post-operative management (kidney)</i>
Nizam Mamode - London United Kingdom |
| 10:20-10:25 | <i>Post-operative management (liver)</i>
Arvinder Singh Soin - Gurgaon India |
| 10:25-10:30 | <i>Post-operative management (cardiothoracic)</i>
LJW Lori West - Edmonton Canada |
| 10:30-10:35 | <i>Immunosuppressive treatment protocol pre- and post-transplantation (kidney)</i>
Nizam Mamode - London United Kingdom |
| 10:35-10:40 | <i>Immunosuppressive treatment protocol pre- and post-transplantation (liver)</i>
Arvinder Singh Soin - Gurgaon India |

- 10:40-10:45 *Immunosuppressive treatment protocol pre- and post-transplantation
(cardiothoracic)*
LJW Lori West - Edmonton Canada
- 10:45-11:00 *Environment management when starting an ABO compatibility programme:
Logistical considerations*
Marta Crespo - Barcelona Spain
- 11:00-11:15 *Collaborative Transplant Study: Registry perspective*
Caner Süsal - Heidelberg Germany
- 11:15-11:30 *Discussion*
-

Full Oral Session

Wednesday, 1. September 2021

10:00 - 11:30
Room E - Orange

Late Breaking (Full Oral)

Chair(s):

- 10:00-10:09 *RANDOMIZED TRIAL ON HYPOTHERMIC OXYGENATED PERFUSION VS STATIC COLD STORAGE IN LIVER TRANSPLANTATION FROM EXTENDED CRITERIA DONORS: INTERIM ANALYSIS*
Matteo Ravaioli - Bologna Italy
- 10:11-10:20 *SET UP OF A DCD PIG MODEL OF NORMOTHERMIC MACHINE PERFUSION ASSOCIATED TO A MESENCHYMAL STROMAL CELL COATED BIOREACTOR TO IMPROVE ORGAN PRESERVATION*
Alessandra Bertacco - Padua Italy
- 10:22-10:31 *ESTABLISHING AN IN VITRO 3D MODEL OF FUNCTIONAL HUMAN LIVER ORGANOID*
Aiste Gulla - Vilnius Lithuania
- 10:33-10:42 *MITOCHONDRIAL PERFORMANCE DURING NORMOTHERMIC MACHINE PERFUSION OF THE LIVER PREDICTS CLINICAL OUTCOME AFTER TRANSPLANTATION*
Andras T. Meszaros - Innsbruck Austria
- 10:44-10:53 *THE IMPACT OF NORMOTHERMIC REGIONAL PERFUSION ON SIMULTANEOUS KIDNEY AND PANCREAS TRANSPLANTATION*
James Richards - Edinburgh United Kingdom
- 10:55-11:04 *DONATION AFTER CIRCULATORY DEATH (DCD) DONORS IN THE EMILIA-ROMAGNA REGION (ERR): OUR FIRST FORTY CASES*
Carlo De Cillia - BOLOGNA Italy
- 11:06-11:15 *EARLY IN VITRO DEVELOPMENT OF MESENCHYMAL STROMAL CELLS EXPANDED IN A BIOREACTOR FOR EX-SITU ORGAN PERFUSION*
Caterina Lonati - Milan Italy
- 11:17-11:26 *NORMOTHERMIC MACHINE PERFUSION RECONSTITUTES PORCINE KIDNEY TISSUE METABOLISM BUT STIMULATES INFLAMMATION WHICH IS PARTLY COMPLEMENT DEPENDENT.*
Eline de Boer - Oslo Norway

State of the Art

Wednesday, 1. September 2021

10:00 - 11:30

Room F - Turquoise
 1

OMICS revisited for transplantation

Chair(s): *Maria Kaisar - Oxford United Kingdom*
Gianluigi Zaza - Verona Italy

OMICS are innovative techniques and represent powerful tools to uncover biological processes in SOT. However, due to the unbiased approach in most OMICS methods, they require a lot of bioinformatics and 'big data' tools. The challenge is to understand what OMICS provide for the patient and how OMICS can be more than just an academic exercise

10:00-10:15

The Microbiome from the OMICS perspective
Marisa Alegre - Chicago United States

10:15-10:30

The OMICS place to be: gut microbiome
Till Strowig - Braunschweig Germany

10:30-10:45omic

Cell-free DNA: a new "omic" in transplantation
Kiran Khush - Stanford United States

10:45-11:00

From SNPs to non-HLA alloimmunity
Roman Reindl-Schwaighofer - Vienna Austria

11:00-11:30

Discussion
 -

Full Oral Session

Wednesday, 1. September 2021

10:00 - 11:30

Room G - Turquoise
2

The non-self responses and its consequences

Chair(s): Oriol Bestard - Barcelona Spain
Marlies Reinders - Rotterdam Netherlands

10:00-10:09

DIAGNOSTIC VALUE OF DONOR-DERIVED CELL-FREE DNA TO PREDICT ANTIBODY-MEDIATED REJECTION IN DONOR-SPECIFIC ANTIBODY-POSITIVE RENAL ALLOGRAFT RECIPIENTS

Katharina Mayer - Vienna Austria

10:11-10:20

DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING BASED VIRTUAL BIOPSY SYSTEM IN KIDNEY TRANSPLANT PATIENTS

Daniel Yoo - Paris France

10:22-10:31

DEVELOPMENT OF A COMPREHENSIVE BANFF AUTOMATION SYSTEM FOR KIDNEY ALLOGRAFT PRECISION DIAGNOSTICS

Daniel Yoo - Paris France

10:33-10:42

ASSESSMENT OF THE IBOX PREDICTION SYSTEM IN REAL LIFE SETTING AND DIFFERENT MEDICO-ECONOMIC TRANSPLANT SYSTEMS: THE IBOXEXT TRIAL

Olivier Aubert - Paris France

10:44-10:53

EARLY INFLAMMATION AFTER KIDNEY TRANSPLANTATION IS ASSOCIATED WITH LONG-TERM ALL-CAUSE MORTALITY

Torbjørn Heldal - Oslo Norway

10:55-11:04

LOSS OF CD24^{HI}CD38^{HI} TRANSITIONAL B CELLS IN ANTIBODY-MEDIATED REJECTION OF KIDNEY TRANSPLANTS

Kevin Louis - Paris France

11:06-11:15

CIRCULATING AND INTRAGRAFT DONOR(HLA)-SPECIFIC B CELLS DRIVE ANTIBODY-MEDIATED REJECTION IN HEART AND KIDNEY TRANSPLANT PATIENTS

Alba Torija - Hospitalet de Llobregat Spain

11:17-11:26

ANTIBODY-MEDIATED REJECTION OF KIDNEY ALLOGRAFT IS ASSOCIATED WITH AN INCREASE IN DIFFERENTIATED CD28-CD8⁺ T CELLS IN THE PERIPHERAL BLOOD

Hoa Mai - Nantes France

Brief Oral Session

Wednesday, 1. September 2021

10:00 - 11:30

Room H - White 1

Bugs in transplantation: News and perspectives

Chair(s): *Murat Akova - Ankara Turkey*
Aiko De Vries - Amsterdam Netherlands

- 10:00-10:04 *CIRCULATORY FOLLICULAR HELPER T LYMPHOCYTES PROTECT AGAINST CMV INFECTION IN KIDNEY TRANSPLANT RECIPIENTS*
Patricia Suárez Fernández - Madrid Spain
- 10:06-10:10 *ANTIVIRAL TREATMENT PATTERNS FOR CYTOMEGALOVIRUS PREVENTION AMONG ADULT KIDNEY TRANSPLANT RECIPIENTS: A USRDS-MEDICARE LINKED DATABASE STUDY*
Amit Raval - Kenilworth NJ United States
- 10:12-10:16 *DONOR CYTOMEGALOVIRUS SEROPOSITIVITY CLUSTERS WITH RISK FACTORS FOR DELAYED GRAFT FUNCTION IN RENAL TRANSPLANTATION, BUT DOES NOT DIRECTLY CONTRIBUTE*
Richard Dumbill - Oxford United Kingdom
- 10:18-10:22 *PREVENTION OF CYTOMEGALOVIRUS INFECTION BY EVEROLIMUS IN SEROPOSITIVE KIDNEY TRANSPLANT RECIPIENTS*
Lionel Couzi - Bordeaux France
- 10:24-10:28 *VALGANCICLOVIR PROPHYLAXIS VERSUS PREEMPTIVE THERAPY FOR PREVENTION OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS: A RANDOMIZED CONTROLLED TRIAL*
Tomas Reischig - Pilsen Czech Republic
- 10:30-10:34 *INFECTION PATTERN IN EVEROLIMUS VERSUS MYCOPHENOLATE-BASED REGIMENS IN KIDNEY TRANSPLANT RECIPIENTS: 24-MONTH RESULTS FROM THE TRANSFORM STUDY*
Mario Carmellini - Siena Italy
- 10:36-10:40 *OUTCOME OF EBV NEGATIVE RECIPIENTS OF EBV POSITIVE DONOR ORGAN TRANSPLANT IN A SINGLE CENTRE*
Caroline Dudreuilh - London United Kingdom
- 10:42-10:46 *TACROLIMUS METABOLISM RATE AND BK INFECTION IN RENAL TRANSPLANT PATIENTS*
Dalvir Kular - London, United Kingdom
- 10:48-10:52 *RELATIONSHIP BETWEEN CARBAPENEM-RESISTANT ENTEROBACTERIALES CARRIAGE AND GUT MICROBIOME AFTER LIVER TRANSPLANTATION: A PROSPECTIVE COHORT STUDY*
Matteo Rinaldi - Bologna Italy
- 10:54-10:58 *ASSOCIATION BETWEEN ACUTE GRAFT PYELONEPHRITIS AND KIDNEY GRAFT LOSS: A SINGLE-CENTER OBSERVATIONAL STUDY*
Mehdi Maanaoui - Lille France

- 11:00-11:04 *BACTERIAL AND FUNGAL BLOODSTREAM INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS: RESULT FROM A DANISH COHORT WITH NATIONWIDE FOLLOW-UP*
Dina Leth Møller - Copenhagen Denmark
- 11:06-11:10 *ENTEROCOCCAL INFECTIONS IN THE FIRST YEAR AFTER LIVER TRANSPLANTATION*
Daniel Bräuner Rasmussen - København Ø Denmark
- 11:12-11:16 *SUPERFICIAL SURGICAL SITE INFECTION AT HAND-PORT SITE AFTER HAND ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMY FOR LIVING DONOR KIDNEY TRANSPLANTATION*
Takahisa Hiramitsu -
- 11:18-11:22 *CONTROLLED DONATION AFTER CIRCULATORY DEATH: IS THERE A RISK FACTOR OF CULTURE-POSITIVE PRESERVATION FLUID ON SOLID ORGANS FOR TRANSPLANTATION?*
María Figueras - Barcelona Spain

Focus Group Session

Wednesday, 1. September 2021

10:00 - 11:30
Room I - White 2

Introducing cells for immune regulation

Chair(s): Elke Eggenhofer - Ihrlenstein Germany
Fadi Issa - Oxford United Kingdom

- 10:00-10:07 *MESENCHYMAL STROMAL CELLS COMBINED WITH EVEROLIMUS PROMOTE T REG EXPANSION BUT DO NOT SYNERGIZE IN A RAT LIVER TRANSPLANT REJECTION MODEL*
Morgan Vandermeulen - Liege Belgium
- 10:15-10:22 *EFFICIENT EXPANSION OF HUMAN GRANZYME B-EXPRESSING B CELLS WITH POTENT REGULATORY PROPERTIES*
Hoa Mai - Nantes France
- 10:30-10:37 *GAMMA-DELTA T CELL THERAPY FOR THE TREATMENT OF POST-TRANSPLANT CMV INFECTION: PROOF OF CONCEPT*
gabriel Marseres - Bordeaux France
- 10:45-10:52 *MESENCHYMAL STEM CELLS LOCAL THERAPY FOR INDUCTION OF IMMUNOSUPPRESSION IN LIVER TRANSPLANTATION: RESULTS OF PILOT STUDY.*
Sergey Korotkov - Minsk Belarus
- 11:00-11:07 *CREATION OF BIOENGINEERED VASCULARIZED SPLEEN MATRIX AS AN ENDOCRINE CELL SUPPORT*
Louis Maistriaux - Brussels Belgium
- 11:15-11:22 *CHARACTERIZATION OF MESENCHYMAL STEM CELL INDUCED REGULATORY B CELLS (MSC-INDUCED BREG)*
Sergio Garcia Garcia - Badalona Spain

Brief Oral Session

Wednesday, 1. September 2021

10:00 - 11:30

Studio - ESOT Live
Studio

Building resilience in organ donation

Chair(s): Corinne Antoine - Saint Denis France

- 10:00-10:04 CRITICAL THE "CRITICAL PATHWAY" FOR TISSUE DONATION: NEW DEFINITIONS FOR A COMMON AND SYSTEMATIC EUROPEAN APPROACH TO DECEASED DONOR TISSUE DONATION.
Alberto Sandiumenge - Sitges Spain
- 10:06-10:10 HOW DO SPANISH TRANSPLANT COORDINATORS APPROACH RELATIVES FOR CONSENT TO INTENSIVE CARE FOR ORGAN DONATION? RESULTS OF AN EMPIRICAL STUDY
Rubén García-Sánchez - Madrid Spain
- 10:12-10:16 ITALIAN SURVEY ON THE OPINIONS OF PROFESSIONALS FROM TRANSPLANT AND INTENSIVE CARE AREAS ABOUT COVID-19 AND SOLID ORGAN TRANSPLANTATION ACTIVITY
federica galiandro - roma Italy
- 10:18-10:22 APPLICATION OF THEORY OF PLANNED BEHAVIOR ON ORGAN DONATION BEHAVIOR: A SYSTEMATIC REVIEW
marzieh latifi - Tehran Iran
- 10:24-10:28 EUDONORGAN: A SUCCESSFUL TRAINING PROGRAM TO IMPROVE ORGAN DONATION KNOWLEDGE IN THE EUROPEAN UNION AND NEIGHBOURING COUNTRIES.
Patricia Peralta Lasso - Barcelona Spain
- 10:30-10:34 CONDITIONS THAT INFLUENCE FAMILY CONSENT FOR INTENSIVE CARE FOR ORGAN DONATION: THE PERSPECTIVE OF SPANISH TRANSPLANT COORDINATORS
Jorge S. López - Pamplona Spain
- 10:36-10:40 ENLIGHTENING YOUNG MINDS: A SMALL STEP IN THE CURRICULUM, A GIANT LEAP IN ORGAN DONATION - A SURVEY OF 996 RESPONDENTS ON ORGAN DONATION
Abdul Rahman Hakeem - Leeds United Kingdom
- 10:42-10:46 SEIZING THE POTENTIAL RISK OF TRANSMISSION OF OLIGODENDROGLIOMA TO RECIPIENTS
Serena Ammendola - Verona Italy
- 10:48-10:52 OUT-OF-HOSPITAL DONORS WITH IRREVERSIBLE CARDIAC ARREST IN RUSSIA: ONE OF THE PROMISING RECOURSE ACCORDING THE FIRST ST PETERSBURG EXPERIENCE
Andrey Skvortsov - Saint-Petersburg Russian Federation
- 10:54-10:58 WHAT HAPPENS TO UNSPECIFIED KIDNEY DONOR CANDIDATES WHO CANNOT PROCEED TO DONATE: AN INDUCTIVE THEMATIC ANALYSIS FROM THE BOUND STUDY
Mira Zuchowski - London United Kingdom

- 11:00-11:04 *DECEASED DONOR TRANSPLANTATION DURING COVID TIMES -
SUCCESS STORY FROM STATE IN INDIA.
Maria Gomez - Barcelona Spain*
- 11:06-11:10 *NEW TECHNOLOGIES APPLIED TO MASTER EDUCATION IN THE TIME OF
COVID-19
Alba Coll - Barcelona Spain*
- 11:12-11:16 *IMPACT OF THE SARS-COV-2 PANDEMIC ON TISSUE DONATION IN
CATALONIA
Belen Garcés Jimeno - Barcelona Spain*
- 11:18-11:22 *EFFECTS OF THE SARS-COV2 PANDEMIC ON ORGAN OFFERS IN EUROPE
Federica Domini - Roma Italy*

Plenary

Wednesday, 1. September 2021

11:45 - 13:15
 Room A - Silver

From candlelight to rocket science: The journey of transplantation

Chair(s): *Stefan Schneeberger - Innsbruck Austria*
Vassilios Papalois - London United Kingdom

The 'race' between biological and mechanical replacement of organs remains a key factor and a moving target in our field that deserves a spotlight. The key aspect for artificial organs in this context is the availability and long-term outcome. While the mechanical function of an organ (heart) can be easily replaced with artificial organs, replacing the biological functions is rather more difficult to achieve. Biological organ replacement is limited by organ availability and the other hope for the future is rapid development in repairing of damaged organs. In this session, we focus on the current and future options for implantable artificial organs, as well as applying organ regeneration into clinical practice.

11:45-11:50 *Session introduction: 700 days of ESOT Congress 2021 Milan journey*
Umberto Cillo - Padova Italy

11:50-12:00 *Achievements in transplantation*
Maria Rosa Costanzo - Naperville United States

12:00-12:25 *At our best in Europe: Leonardo da Vinci Award winners*
 -

12:25-12:45 *No transplant as we know it*
William Fissell - Nashville, Tennessee United States

12:45-13:05 *Organoids to model human disease*
J.C. Hans Clevers - Utrecht Netherlands

13:05-13:15 *Presidential Address & Closing*
Luciano Potena - Bologna Italy

INDUSTRY SATELLITE SYMPOSIA

Satellite Plenary Symposium

Sunday, 29. August 2021

18:00 - 19:30
Room K - Red

CAREDX SYMPOSIUM: Changing the Transplant Care Paradigm: Advanced Strategies for Allograft Surveillance

Chair(s): Olivier Aubert - Paris France

18:00-18:10

Introduction

-

18:10-18:25

Non-invasive renal allograft surveillance with dd-cfDNA blood testing

Fritz Diekmann - Esplugues de Llobregat Spain

18:25-18:40

Circulating dd-cfDNA levels risk-stratify kidney allograft injury at for cause biopsy

Ioannis N. Boletis - Athens Greece

18:40-18:55

Measuring dd-cfDNA in lung transplantation: enlightening graft injury

Berta Saez Gimenez - Barcelona Spain

18:55-19:10

Personal and Practical Experience with Donor-Derived Cell-Free DNA Testing for Heart Transplant Surveillance

Kiran Khush - Stanford United States

19:10-19:25

Q&A

-

19:25-19:30

Closing remarks

-

Satellite Parallel Symposium

Monday, 30. August 2021

13:15 - 14:45

Room B -

Auditorium

MALLINCKRODT SYMPOSIUM: ECP Immunomodulation in SOT: A Role for Early Intervention?

Chair(s): *Lionel Rostaing - Grenoble France*

13:15-13:35

ECP Immunomodulation – New Mechanistic Insights and Utility in Solid Organ Transplantation

James Hutchinson - Regensburg Germany

13:35-13:55

ECP as Induction Therapy Post Lung Transplant : Results from a Pilot Study

Ilaria Righi - Paullo Italy

13:55-14:15

ECP Immediately after Heart Transplantation in High Risk Patients

Johannes Goekler - Vienna Austria

14:15-14:35

ECP as an Immunosuppression Sparing Approach in Kidney Transplantation

Jean-François Augusto - Angers France

14:35-14:45

Q&A

-

Satellite Parallel Symposium

Monday, 30. August 2021

13:15 - 14:15
Room J - Blue

**NATERA SYMPOSIUM: Fresh Perspectives on Rejection Assessment:
Integrating Absolute DNA Levels in Monitoring Toolkit**

Chair(s): -

13:15-13:25

Welcome and Introduction
Philippe Gauthier -

13:25-13:45

Two-threshold caller
Suphamai Bunnapradist - California United States

13:45-14:05

Trifecta Study
Philip F. Halloran - Canada

14:05-14:15

Open for questions & answers
-

Satellite Parallel Symposium

Monday, 30. August 2021

13:15 - 14:45
Room K - Red

EUROFINS SYMPOSIUM: dd-cfDNA and GEP in Kidney Transplantation – Redundant or Complimentary?

Chair(s): Steve Kleiboeker - Lee's Summit United States
Patty West-Thielke - Framingham United States

13:15-13:20

Welcome and Introduction

-

13:20-13:45

Review impact, diagnosis, and prognosis of subclinical rejection
Dany Anglicheau - Paris France

13:45-14:10

Discuss potential uses of biomarkers in the management of kidney transplant recipients
Oriol Bestard - Barcelona Spain

14:10-14:35

Review the data on the combined use of dd-cfDNA and gene expression profiling
John Friedewald - Chicago United States

14:35-14:45

Q&A

-

Satellite Parallel Symposium

Monday, 30. August 2021

13:15 - 14:45
Room C - Yellow

XVIVO SYMPOSIUM: Extending horizons in organ transplantation

*Chair(s): Stefan Schneeberger - Innsbruck Austria
Rutger Ploeg - Oxford United Kingdom*

13:15-13:20

*Welcome message
Dag Andersson - Gothenburg Sweden*

13:20-13:37

*The importance of oxygen during hypothermic kidney perfusion – results of the COPE-COMPARE trial
Ina Jochmans - Leuven Belgium*

13:37-13:54

*HOPE for human livers
Philipp Dutkowski -*

13:54-14:11

*Cost effectiveness of HOPE in human liver transplantation. Experiences from the HOPE ECD-DBD trial.
Georg Lurje - Berlin Germany*

14:11-14:28

*Combined hypothermic and normothermic machine perfusion of high-risk donor livers
Robert J. Porte - Groningen Netherlands*

14:28-14:30

Panel discussions
-

Satellite Parallel Symposium

Monday, 30. August 2021

16:45 - 18:15

Room B -
Auditorium

NOVARTIS SYMPOSIUM: How can we improve graft survival and patient outcomes with current and future diagnostic, monitoring and predictive tools?

Chair(s): Franco Citterio - Rome Italy

16:45-16:55

Today's challenges for improving graft survival
Franco Citterio - Rome Italy

16:55-17:05

Optimizing patient management – the benefits and limitations of the renal biopsy
Kerstin Amann - Erlangen Germany

17:05-17:15

Algorithms, AI and machine learning: new horizons for predicting long-term outcomes
Olivier Aubert - Paris France

17:15-17:35

Patient case studies: biopsies and the iBox predictive algorithm in clinical practice
David Wojciechowski - Dallas United States

17:35-17:50

Q&A and closing remarks
-

Satellite Plenary Symposium

Monday, 30. August 2021

18:30 - 20:00
Room A - Silver

HANSA SYMPOSIUM: Roadmap to Transplant for the Highly Sensitized Patient

Chair(s): *Lucrezia Furian - Padova Italy*

18:30-18:32

*Welcome and Opening
Lucrezia Furian - Padova Italy*

18:32-18:52

*Stuck in the Garage - Patients Who Are Unlikely to be Transplanted
Oriol Bestard - Barcelona Spain*

18:52-19:12

*Avoiding the Crash and Burn – AMR Management Strategies
Denis Glotz - Paris France*

19:12-19:32

*Getting to the Destination - ESOT Desensitization TLJ 2.0
Nizam Mamode - London United Kingdom*

19:32-19:52

*Hitting the Accelerator - Idefirix – A Paradigm Shift in Desensitization
Stanley Jordan - Los Angeles United States*

19:52-20:00

Q&A - Discussion

-

Satellite Parallel Symposium

Tuesday, 31. August 2021

08:00 - 09:00
Room J - Blue

ORGANOX SYMPOSIUM: Normothermic Perfusion: New Horizons

Chair(s): Peter Friend - Oxford United Kingdom

08:00-08:03

Opening introduction: the clinical experience and scientific investigations.
Peter Friend - Oxford United Kingdom

08:03-08:18

Making a Difference: Working with High Risk Donors.
Jens Brockmann - Munster Germany

08:18-08:33

The NAPLES Study: Working with High Risk Recipients
Thamara Perera - Birmingham United Kingdom

08:33-08:48

Defatting Livers & Deep Genomic Phenotyping of Perfused Livers to Develop RNA Therapies
Carlo Ceresa - Oxford United Kingdom
Quin Wills - Oxford United Kingdom

08:48-09:00

Q&A session chaired by Prof Peter Friend

-

Satellite Parallel Symposium

Tuesday, 31. August 2021

08:00 - 09:00
Room K - Red

EUROFINS SYMPOSIUM: Blazing the Pathway of Precision Medicine for Liver Transplantation

Chair(s): *Michael Abecassis - Tucson United States*
Steve Kleiboeker - Lee's Summit United States
Patty West-Thielke - Framingham United States

08:00-08:05

Welcome and Introduction

-

08:05-08:20

Overview of clinical data and current practice challenges with immunosuppression minimization strategies in liver transplant recipients
Marina Berenguer - Valencia Spain

08:20-08:35

Review of biomarkers of graft injury and rejection in monitoring the liver allograft focusing on GEP and dd-cfDNA data
Josh Levitsky - Chicago United States

08:35-08:50

Examine the state of precision medicine in liver transplantation and the potential for biomarkers to fill the unmet need
Francois Durand - Clichy France

08:50-09:00

Q&A

-

Satellite Parallel Symposium

Tuesday, 31. August 2021

13:15 - 14:15
Room A - Silver

THERMOFISHER SYMPOSIUM: Clinical Applications for Gene Expression Profiling in Transplant Biopsies

Chair(s): Christopher Lawrence - London United Kingdom

13:15-14:00

Clinical Applications for MMDx®: Gene Expression Profiling in Transplant Biopsies

Georg Böhmig - Vienna Austria

Satellite Parallel Symposium

Tuesday, 31. August 2021

13:15 - 14:15
Room J - Blue

BIOTEST SYMPOSIUM: The Incredibles 2 – Immunoglobulins in Transplantation

Chair(s): *Martina Sester - Homburg Germany*

13:15-13:20

Welcome and Introductions

-

13:20-13:35

Mission Impossible? How CMV Immunoglobulins may tip the Balance towards Patient's Benefit

Martina Sester - Homburg Germany

13:35-13:50

The Transplantation is not enough: Fighting viral Reactivations post Liver Transplantation

Quirino Lai - Rome Italy

13:50-14:05

Resident Evil: Tackling viral Pathogens post Lung Transplantation

Paolo Solidoro - Torino Italy

14:05-14:15

Q&A and Discussion

-

Satellite Parallel Symposium

Tuesday, 31. August 2021

13:15 - 14:15
Room K - Red

CHIESI SYMPOSIUM: Can the choice of tacrolimus formulation and personalization of therapy help achieving treatment stability?

Chair(s): Rainer Oberbauer - Vienna Austria

13:15-13:30

Patient needs and treatment choices as a step towards improving personalization therapy

Rainer Oberbauer - Vienna Austria

13:30-13:45

Achieving treatment stability in kidney transplant recipients: is this more relevant than ever?

Gianluigi Zaza - Verona Italy

13:45-14:00

Patient characteristics and personalization of tacrolimus therapy in liver transplant recipients

Hans Schlitt - Regensburg Germany

14:00-14:15

Q&A

-

Satellite Parallel Symposium

Tuesday, 31. August 2021

13:15 - 14:15 Room F - Turquoise 1	AFERETICA SYMPOSIUM: From Organ Preservation to Organ Regeneration <i>Chair(s): Luciano De Carlis - Milan Italy</i> <i>Frank D'Ovidio - New York United States</i>
13:15-13:20	<i>Introduction</i> -
13:20-13:35	<i>Expanding the organ transplant pool: the role of ex vivo perfusion</i> <i>Giuseppe Remuzzi - Bergamo Italy</i>
13:35-13:45	<i>The inflammatory Mediators and graft function: the kidneys</i> <i>Sarah Hosgood - Cambridge United Kingdom</i>
13:45-13:55	<i>Cytokines, Trapiantability, PGD, Survival: the lungs</i> <i>Massimo Boffini - Torino Italy</i> <i>Mauro Rinaldi – Torino Italy</i>
13:55-14:05	<i>Mesenchymali stromal cells: should they be integrated in machine perfusion devices?</i> <i>Francesco Dazzi - London United Kingdom</i>
14:05-14:15	<i>Discussion</i> -

Satellite Parallel Symposium

Tuesday, 31. August 2021

13:30 - 14:30
Room C - Yellow

ORGAN RECOVERY SYSTEMS: Oxygenated Hypothermic Machine Perfusion to Improve Liver Outcomes in Transplantation

Chair(s): -

13:30-13:55

Results from the first US-based Multi-Center Randomized Trial using Oxygenated Hypothermic Machine Perfusion of the Liver
James Guarrera - Newark United States

13:55-14:20

What can Molecular Biomarkers and Fluid Dynamics teach us when using Oxygenated Hypothermic Machine Perfusion?
Flavio Paterno - Newark United States

14:20-14:30

Q&A

-